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Background: Tobacco use remains the leading risk factor for preventable disease in Canada. 
Although tobacco smoke is the direct cause of smoking-induced diseases, nicotine addiction 
sustains the use of tobacco. Electronic cigarettes (e-cigarettes) are battery-powered devices that 
deliver nicotine in an aerosol form. Despite a restriction on the sale of nicotine-containing e-
cigarettes in Canada, products with and without nicotine are accessible to Canadians. Although 
e-cigarettes are likely to be much less harmful than tobacco cigarettes, empirical evidence of 
potential reduced risk at the individual level is limited. To date, behavioural switching studies 
involving tobacco cigarettes and e-cigarettes are limited by restrictions placed on e-cigarette user 
and product characteristics, and few have examined biomarkers of exposure among concurrent 
(dual) users of these products. Furthermore, although dual users constitute the majority of e-
cigarette users in Canada, little is known about their behaviour. The current study seeks to fill 
several critical evidence gaps regarding dual users’ patterns of use and exposure to nicotine and 
tobacco smoke constituents in the Canadian context.  
Objectives: The study examined: 1) Patterns of use and perceptions of tobacco cigarettes and e-
cigarettes among dual users. In the context of product switching, the study examined: 2) 
Exposure to nicotine and compensatory behaviour; 3) Exposure to tobacco smoke constituents; 
4) Symptoms of nicotine withdrawal for tobacco cigarettes and e-cigarettes, respectively; 5) Self-
efficacy for abstaining from smoking tobacco cigarettes and using e-cigarettes, respectively; and 
6) Perceived respiratory health.  
Methods: An un-blinded within-subjects experiment was conducted with a sample of adult daily 
dual users (n=48) in Kitchener-Waterloo and Toronto, Ontario. Participants completed three 
consecutive seven-day periods in which the use of tobacco cigarettes and e-cigarettes was 
experimentally manipulated, resulting in four study conditions: dual use, exclusive use of 
tobacco cigarettes, exclusive use of e-cigarettes, and use of neither product. To control for order 
effects, the order in which participants experienced the study conditions was randomized. 
Participants’ behaviours and exposure to nicotine and tobacco smoke constituents were assessed 
following each study condition. Patterns of use and product perceptions were examined at 
baseline using descriptive statistics. Repeated measures models were used to examine the 
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following outcomes: compensatory behaviour for nicotine, exposure to tobacco smoke 
constituents, symptoms of nicotine withdrawal, self-efficacy, and perceived respiratory health.  
Results: Dual users were 36 years of age, mostly male (71%), and exhibited low to moderate 
nicotine dependence (FTCD: 4.7 (SD=1.9)). Study participants had smoked and vaped daily for 
17.4 (SD=12.2) and 1.2 (SD=0.9) years, respectively, and all reported initiating use of tobacco 
cigarettes prior to e-cigarettes. Although dual users reported similar daily consumption of 
tobacco cigarettes and e-cigarettes (13.7 (SD=5.6) tobacco cigarettes per day vs. 10.9 (SD=11.4) 
bouts of e-cigarette use, p=0.09), a greater proportion reported smoking tobacco cigarettes within 
the first hour of waking (98% vs. 59% for e-cigarettes; p<0.001). Virtually all dual users reported 
using tank systems (92%) and e-cigarettes with nicotine (94%). The most commonly reported 
reasons for using e-cigarettes included: to smoke fewer tobacco cigarettes (79%), to help with 
cravings for tobacco cigarettes (71%), and because of the belief that e-cigarettes are less harmful 
than tobacco cigarettes (71%). Compared to tobacco cigarettes, dual users considered e-
cigarettes as more socially acceptable (65%), less satisfying (67%), less pleasurable (64%), less 
harmful (87%), and less expensive (81%).  
Findings from the product-switching experiment indicated that compared to dual use, levels of 
urinary cotinine were stable when participants exclusively smoked (p=0.524), but significantly 
decreased when they exclusively vaped (p=0.027), despite significant increases in e-cigarette 
consumption (p=0.001). Biomarkers of exposure, including exhaled carbon monoxide (CO), 
urinary 1-hydroxypyrene (1-HOP), and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL), were significantly lower when participants exclusively vaped, as compared to when 
they engaged in dual use (CO: -41%, p<0.001; 1-HOP: -31%, p=0.025; NNAL: -30%, p=0.017). 
A similar trend was observed among participants abstaining from both tobacco cigarettes and e-
cigarettes, as compared to dual use (CO: -26%, p<0.001; 1-HOP: -14% (ns); NNAL: -35%, 
p=0.016). In addition, biomarkers of exposure showed an increasing trend among participants 
when they exclusively smoked as compared to dual use (CO: +21%, p=0.029; 1-HOP: +23%, 
p=0.048; NNAL: +8% (ns)). Study participants experienced significantly greater urges to smoke 
tobacco cigarettes when they were not permitted to do so (p=0.001). Although changes in 
participants’ self-efficacy for abstaining from tobacco cigarettes depended on the order in which 
they experienced study conditions, the self-efficacy of all participants at the end of the product-
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switching experiment did not differ significantly from their baseline values. In contrast, 
participants reported no significant changes in urges to use e-cigarettes (p=0.460) or in their self-
efficacy to abstain from using e-cigarettes (p=0.150) across study conditions. Dual users reported 
significant improvements in various domains of respiratory health when they abstained from 
smoking tobacco cigarettes, including improvement in experiencing shortness of breath, cough, 
cough with phlegm, sounds emanating from the chest, and in perceived lung function (p<0.001 
for all).   
Conclusions: The findings suggest that dual use behaviour is similar to that in other 
jurisdictions, despite Canada’s restrictive regulatory framework for these products. Tobacco 
cigarettes appear superior to e-cigarettes in their ability to deliver nicotine. Although abstaining 
from smoking tobacco cigarettes elicits cravings, it is also associated with significant 
improvements in perceived respiratory health. Consistent with other research, results from the 
current study demonstrate that abstaining from tobacco cigarettes is the most important factor in 
reducing exposure to tobacco smoke constituents. Therefore, dual use is likely to have public 
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In 1941, a young girl was forced to leave her beloved Ukrainian village behind and work in war-
torn Germany. In the post-war years, she and her family would move several more times, across 
three continents, in search of a better life. That young girl was my grandmother, whose simple 
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1.1 Tobacco use in Canada 
Tobacco use represents an immense public health challenge, given its role as one of the most 
important risk factors for non-communicable disease, including cardiovascular disease, 
respiratory diseases, and cancer (U.S. Department of Health and Human Services [USDHHS], 
2014). The World Health Organization (WHO) (2013) attributes approximately six million 
deaths and half a trillion dollars of economic damage to the use of tobacco annually. Left 
unhindered, tobacco will kill as many as one billion people by the end of the century (WHO, 
2013). In Canada, despite substantial declines in smoking prevalence over several decades, 
tobacco use remains the leading risk factor for preventable disease (Krueger, Turner, Krueger, & 
Ready, 2014). In addition, tobacco use places a significant burden on the economy. For instance, 
the annual costs associated with tobacco use amounted to approximately $21.3 billion in 2012 
(Krueger et al., 2014).  
1.1.1 Product design and market 
Cigarettes are tobacco products that deliver various chemical compounds to the user via tobacco 
smoke, which is the product of combustion. Tobacco smoke is a complex aerosol mixture 
consisting of more than 7,000 chemical compounds, which forms as the vapors generated by 
combustion cool and condense upon delivery to the user (USDHHS, 2010; WHO International 
Agency for Research on Cancer [IARC], 2004). The main components (by weight) of tobacco 
smoke include nitrogen, oxygen, carbon dioxide, carbon monoxide, nitrogen oxides, and various 
sulfur-containing gaseous compounds. Carbon monoxide and carbon dioxide result from the 
combustion of tobacco and represent nearly 15% of the weight of the gas phase of tobacco 
smoke (USDHHS, 2010).  
Nicotine is a key constituent of tobacco, with most commercial tobacco products carrying 
concentrations from six to 18 mg/g (0.6-1.8% by weight) (USDHHS, 2010). Nicotine in tobacco 
smoke exists in either a protonated or un-protonated (“free”) form, the levels of which depend 
upon various factors. Over the last century, the design of cigarettes has evolved to ensure that 
tobacco smoke has enough free nicotine for rapid transfer and delivery to the user, but not so 
much as to make smoking overly harsh (USDHHS, 2010).  
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Tobacco-specific nitrosamines (TSNAs) are a family of potent carcinogens, including NNK [4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone], NNN [N’-nitrosonornicotine], NAB [N’-
nitrosoanabasine], and NAT [N’-nitrosoanatabine]. As the name of this family of compounds 
suggests, TSNAs are specific to tobacco and tobacco smoke, due to their presence at high levels 
in these sources as compared with other consumer products (USDHHS, 2010). TSNAs are 
predominantly formed during the curing and processing of tobacco as well as through 
combustion (IARC, 2004); as a result, levels of TSNAs in tobacco and tobacco smoke can vary 
widely both between and within brands across markets (USDHHS, 2010).   
Polycyclic aromatic hydrocarbons (PAHs) are chemical compounds formed by incomplete 
combustion of natural organic matter, such as wood, petroleum, and tobacco. Due to the fact that 
PAHs are found throughout the environment, exposure to these chemicals may have various and 
multiple sources (USDHHS, 2010). At least 500 PAHs have been found in tobacco smoke, of 
which 16 have been identified as causing or having the potential to cause cancer. Levels of PAHs 
in tobacco smoke have been shown to vary by the type of tobacco and the nitrate content of 
tobacco products (USDHHS, 2010).  
1.1.2 Health effects 
Tobacco smoke is the key medium through which a host of chemicals are delivered to smokers, 
resulting in various health effects. Smoking causes cancers of the lung, larynx, oral cavity, 
pharynx, esophagus, pancreas, bladder, kidney, cervix, and stomach, as well as acute myeloid 
leukemia; furthermore, there is evidence that suggests a causal relationship between smoking and 
colorectal and liver cancers (USDHHS, 2010). In addition to being a major cause of 
cardiovascular disease, cigarette smoking appears to have a multiplicative interaction effect with 
other major risk factors for coronary heart disease, including hyperlipidemia, hypertension, and 
diabetes mellitus (USDHHS, 2010). Tobacco smoke also causes various non-malignant 
respiratory diseases, including chronic obstructive pulmonary disease (COPD), emphysema, 
chronic bronchitis, and asthma, and further increases the risk of death from pneumonia 
(USDHHS, 2010).  
Several classes of carcinogens, including TSNAs, PAHs, aromatic amines, aldehydes, volatile 
organic hydrocarbons, and metals, are present in tobacco smoke and have been implicated in 
various cancer-causing mechanisms. Extensive research has demonstrated the uptake of these 
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carcinogens by smokers, who have higher levels of carcinogen metabolites in their urine than do 
non-smokers (IARC, 2004; USDHHS, 2010). Many of the carcinogens noted above cause cancer 
via the production of DNA adducts, which, if left unrepaired, can cause various permanent 
mutations and damage to critical genes involved in the control of cellular growth (IARC, 2004). 
In particular, research has demonstrated the potency of NNK as a pulmonary carcinogen in both 
rat models and human smokers (IARC, 2004). The key constituents of tobacco smoke 
responsible for cardiovascular disease include oxidizing chemicals, nicotine, carbon monoxide, 
and particulate matter (USDHHS, 2010). Finally, various components of tobacco smoke, 
including acrolein, formaldehyde, nitrogen oxides, cadmium, and hydrogen cyanide, have the 
potential to injure the lungs, resulting in respiratory diseases (USDHHS, 2010).  
Although tobacco smoke is the direct cause of smoking-induced diseases, nicotine addiction 
sustains the use of tobacco: among individuals who have ever tried smoking, approximately one-
third become daily smokers; furthermore, among smokers who try to quit, less than five percent 
are successful at any one time (Benowitz, 2010; USDHHS, 2010). Nicotine is an addictive drug 
whose psychoactive impact depends upon the dose of nicotine delivered and the mode of its 
delivery to the human brain (USDHHS, 2014). The inhalation of tobacco smoke delivers nicotine 
rapidly into the bloodstream and to the brain, which promotes dependence and high levels of 
smoke exposure (IARC, 2004). This feature distinguishes tobacco cigarettes as highly appealing 
and addictive when compared to other tobacco and nicotine products (Zeller & Hatsukami, 
2009).  
Nicotine is a highly bioactive compound with a wide range of effects. Although relatively benign 
among adult populations, nicotine has been linked with diverse adverse health outcomes for the 
developing fetus and for adolescents, particularly with respect to brain development (USDHHS, 
2014; England, Bunnell, Pechacek, Tong, & McAfee, 2015). In addition, nicotine poses risk of 
acute toxicity or poisoning from ingestion at high-enough doses (USDHHS, 2014).   
Research evidence indicates that cigarette design features, such as tobacco blend, filter type and 
length, paper type and porosity, ventilation, and chemical additives, influence the yield of 
tobacco smoke constituents (USDHHS, 2010). Furthermore, smoking characteristics influence 
the delivery of these constituents to smokers. These include puff topography characteristics (puff 
number, duration, volume, flow rate, and inter-puff interval), cigarette length smoked, and 
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blockage of ventilation holes, and exhibit considerable variability across smokers (USDHHS, 
2010). The size of constituent particles also plays an important role in their deposition and 
retention in the respiratory system, which influences risks for health (USDHHS, 2010). In sum, 
many factors may play a role in determining the exposure of smokers to toxic constituents found 
in tobacco smoke and the implications of such exposure for health.  
1.1.3 Prevalence and patterns of use 
According to the Canadian Tobacco, Alcohol and Drugs Survey (CTADS), as of 2015, 13.0% of 
the Canadian population aged 15 years and older were current smokers (Reid, Hammond, 
Rynard, Madill, & Burkhalter, 2017).  Among current smokers, a majority reported smoking 
daily, with an average daily cigarette consumption of 13.8 cigarettes per day. Smoking 
prevalence varies by age, with the highest rates of prevalence among young adults aged 20-24 
years (18.5%). Smoking prevalence also varies by sex, with higher prevalence among males 
(15.6%) than females (10.4%). In addition, male daily smokers consume nearly three cigarettes 
more per day than females (15.2 and 11.9, respectively) (Reid et al., 2017). 
1.2 E-cigarette use in Canada 
1.2.1 Product design and market 
Hon Lik, a Chinese pharmacist, is credited with inventing the modern electronic cigarette (e-
cigarette), a type of electronic nicotine delivery system. E-cigarettes use battery power to heat a 
solution, producing an aerosol that is inhaled by users (Besaratinia & Tommasi, 2014). E-
cigarette solutions typically contain nicotine dissolved in propylene glycol and/or glycerin, and 
may contain various additives and flavours (Bertholon, Becquemin, Annesi-Maesano, & 
Dautzenberg, 2013). E-cigarettes have evolved to produce three distinct “generations” or classes 
of products: 1) disposable products; 2) products that use pre-filled cartridges that can be replaced 
by the user; and 3) products that are re-chargeable and have an open tank or reservoir that may 
be filled with liquid by the user (Grana, Benowitz, & Glantz, 2014). Disposable products and 
those that use pre-filled cartridges are “closed” systems (meaning they are not intended to be re-
filled with liquid or for their component parts to be replaced by the user), and tend to be similar 
in appearance to tobacco cigarettes. In contrast, re-chargeable products (commonly referred to as 
“tank” systems), are typically bulkier, heavier, and visually distinct from tobacco cigarettes. 
These products are considered “open” systems, meaning they are intended to be re-filled with 
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liquid. Furthermore, these products allow users to modify product components, such as battery 
capacity and voltage, which subsequently influences users’ vaping experiences (Breland, Soule, 
Lopez, Ramoa, El-Hellani, & Eissenberg, 2016; Grana, Benowitz & Glantz, 2014). Images of the 
variety of available e-cigarette products are shown in Figure 1.  
Figure 1: Variety of available e-cigarette products 
 
Notes: 
Figure adapted from Breland et al, 2016. 
 
Over the last decade, e-cigarettes have spread from China to the rest of the world, with rapid 
growth in the number of brands, models, and flavours available to consumers (Zhu, Sun, 
Bonnevie, Cummins, Gamst, Yin, & Lee, 2014). Although independent e-cigarette 
manufacturers were the only stakeholders in the global e-cigarette market in its early years, the 
tobacco industry has since entered by either acquiring independent companies or developing its 
own products (Kamerow, 2013). Consistent with other markets, e-cigarettes in Canada are 
available in both brick-and-mortar and online retail outlets, in a variety of types, flavours, and 
nicotine concentrations (Hammond, White, Czoli, Martin, Maggenis, & Shiplo, 2015). However, 
when compared to the United States (US), the Canadian market is distinct in its relative 
availability of nicotine-free products and in its dominant e-cigarette brands (Hammond et al., 
2015), likely as a result of its current regulatory framework (discussed further below). In general, 
e-cigarettes are commonly marketed to smokers as potential cessation aids and/or as substitutes 
to use in situations that prohibit smoking (National Cancer Institute [NCI] & Centers for Disease 




1.2.2 Health effects 
To date, available evidence regarding the health effects of e-cigarettes indicates that they are 
likely to be much less harmful than tobacco cigarettes, given that they do not contain tobacco, do 
not rely on combustion, and thus do not produce smoke (Hajek, Etter, Benowitz, Eissenberg, & 
McRobbie, 2014). However, other constituents of e-cigarette liquids and aerosols may pose 
health risks to users.  
First, nicotine – which may or may not be present in e-cigarettes – poses the same health risks as 
it does in tobacco cigarettes. Second, propylene glycol and/or vegetable glycerin are typical 
solvents used in e-liquids. Propylene glycol is an alcohol that is commonly used as: an additive 
in foods and cosmetics, a solvent in pharmaceuticals, an antifreeze, and as a key ingredient in 
theatrical mist or fog (Bertholon et al., 2013). Studies examining the health effects of theatrical 
staff exposed to such mist concluded that massive and prolonged exposure results in irritation of 
the airways (Bertholon et al., 2013). Vegetable glycerin is a non-toxic additive that is widely 
used in the food and chemical industry. However, it may pose a risk as used in e-cigarettes due to 
the fact that it can generate toxic acrolein at high temperatures (Bertholon et al., 2013). Next, 
flavouring agents are commonly added to e-cigarette liquids. Although most of these are 
commonly used in foods and indoor fragrances, data regarding the health effects related to their 
inhalation are not available (Bertholon et al., 2013; Breland et al., 2016). Finally, various 
contaminants, such as TSNAs, volatile organic compounds, polycyclic aromatic hydrocarbons, 
metals, carbonyls, glycols, and aldehydes have been identified in some samples of e-liquids, at 
variable amounts, although typically at levels far below those found in cigarettes (Bertholon et 
al., 2013; Breland et al., 2016; Fernandez, Ballbe, Sureda, Fu, Salto, & Martinez-Sanchez, 2015). 
Furthermore, the presence of several specific contaminants and irritants may be associated with 
specific flavours and/or as a result of excessive heating during product use (Behar, Davis, Wang, 
Bahl, Lin & Talbot, 2014; Farsalinos, Kistler, Gillman & Voudris, 2015; Farsalinos, Voudris & 
Poulas, 2015). In sum, although limited, available evidence indicates that e-cigarette aerosol 
exposure can result in short-term respiratory effects, such as irritation and cough, as well as 
nausea and vomiting; however, the long-term health effects of these products remain unknown 
(Grana, Benowitz & Glantz, 2014).  
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1.2.3 Prevalence and patterns of use 
As of 2015, 13.2% of Canadian adults had ever tried an e-cigarette, while 3.2% reported using 
these products in the past 30 days, and 1.0% reported daily use (Reid, Hammond, Rynard, 
Madill, & Burkhalter, 2017). These findings represent significant increases in use of e-cigarettes 
from 2013 (Czoli, Reid, Rynard & Hammond, 2015). Prevalence of e-cigarette use varied by 
age, with the highest rates of ever use among youth aged 15-19 (25.7%) and young adults aged 
20-24 (30.5%); these groups also had the highest prevalence of current use (6.3%). In addition, 
ever use of e-cigarettes was higher among males (16.1%) compared to females (10.5%) (Reid et 
al., 2017).  
Prevalence of e-cigarette use was also found to vary greatly by smoking status, with greater rates 
of use among smokers compared to non-smokers. Rates of e-cigarette ever use were 51.0% 
among current smokers compared to 7.6% among non-smokers. Similarly, current use of e-
cigarettes was 15.5% among current smokers and 1.4% among non-smokers. Although e-
cigarette ever and current use did not differ by sex among smokers and non-smokers, differences 
in use rates were seen by age. With respect to ever use of e-cigarettes, use was highest among 
youth aged 15-19 (82.5% and 19.6%) and young adults aged 20-24 (80.0% and 19.4%), and 
declined with age, among both smokers and non-smokers, respectively. Prevalence of e-cigarette 
current use followed a similar pattern, with the highest rates of use among youth aged 15-19 
(36.9% among smokers, and 3.0% among non-smokers) (Reid et al., 2017). Thus, data indicate 
that in the Canadian context, e-cigarette use is most common among young people and among 
smokers, and rates of use are increasing over time (Czoli, Reid, Rynard & Hammond, 2015; Reid 
et al., 2017).  
1.3 E-cigarettes and public health 
The presentation of e-cigarettes as modern, potentially acceptable alternatives to tobacco in 
today’s market creates many new challenges for public health. Despite the fact that e-cigarettes 
appear to be risk-reducing for an individual’s health (as compared to tobacco cigarettes), their 
use may not be harm-reducing for the overall population; this is because the public health impact 
of such products depends on users’ behavior (Stratton, Shetty, Wallace, & Bondurant, 2001), 
which may differ in important respects across different subpopulations, with the potential to 
yield both positive and negative effects.  
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1.3.1 Potential to reduce tobacco use 
E-cigarettes may present a potential public health benefit to the extent that they decrease 
smoking rates, thereby reducing smokers’ exposure to harmful chemicals found in tobacco and 
tobacco smoke. The benefits of quitting smoking have been shown for smokers of all ages: the 
lifetime risk of premature death of smokers who quit completely and permanently early in life is 
very similar to that of non-smokers (Doll, Peto, Boreham & Sutherland, 2004; USDHHS, 2010). 
Although this evidence holds for two of the three main fatal conditions caused by smoking – 
cardiovascular disease and COPD – former smokers carry a persistent elevated risk for lung 
cancer, as compared to non-smokers of the same age (Doll et al., 2004; USDHHS, 2010). 
Nevertheless, in the face of an addictive habit that will claim the lives of one-half of all long-
term smokers (Doll et al., 2004), and in light of the fact that less than two percent of smokers 
successfully quit smoking each year (Giovino, 2002), a potential decrease in the tobacco-related 
health burden could indeed be substantial.  
The efficacy of e-cigarettes in smoking cessation is presently unclear. Many smokers report 
using e-cigarettes to quit smoking; indeed, quitting or cutting down smoking are the most 
commonly reported reasons for using e-cigarettes (Grana, Benowitz & Glantz, 2014; Carroll 
Chapman & Wu, 2014). To date, two randomized control trials have examined the use of e-
cigarettes as a quit aid. One trial failed to find consistent differences across three e-cigarette 
conditions (Caponnetto, Campagna, Cibella, Morjaria, Caruso, Russo, & Polosa, 2013), while 
the other reported similar abstinence rates among participants assigned e-cigarettes as those 
assigned nicotine patches (Bullen, Howe, Laugesen, McRobbie, Parag, Williman, & Walker, 
2013). However, it should be noted that these studies were limited by inadequate statistical 
power, and by their employment of early model e-cigarettes with uncertain or poor nicotine 
delivery profiles. A recent Cochrane review of these studies concluded that use of nicotine-
containing e-cigarettes in these trials led to increased long-term cessation and a reduction in the 
number of cigarettes smoked, as compared to placebo e-cigarettes (McRobbie, Bullen, 
Hartmann-Boyce & Hajek, 2014; Hartmann-Boyce et al., 2016). Further research involving 
novel products is needed to evaluate the cessation potential of these devices (Lopez & 




1.3.2 Potential negative effects 
E-cigarettes also have the potential to undermine public health in several ways. First, there is the 
possibility that smokers will take up these products, but use them in places or at times where or 
when smoking is prohibited. In essence, smokers may use these products as an aid to continue, 
rather than to quit, smoking. In the event that smokers do not achieve complete cessation (i.e., do 
not change their cigarette consumption or reduce their cigarette consumption, while taking up e-
cigarettes), they are unlikely to experience any significant health benefits (Bjartveit & Tverdal, 
2009; USDHHS, 2010).  
A second concern is the potential of e-cigarettes to attract novel users and/or to reclaim former 
users. Of particular concern is the appeal of e-cigarettes to youth, who, according to the gateway 
hypothesis, may initiate nicotine use with e-cigarettes and, once addicted, progress to smoking 
cigarettes, exposing them to significant health risks (WHO, 2014). Advertising and promotion of 
e-cigarettes, as well as the vast availability of flavours of these products, have been cited with 
concern as potentially appealing to youth (Standing Committee on Health, 2015). Although not 
yet empirically examined, e-cigarettes may also pose a risk for relapse among former smokers, 
given the potential reduced harm profile they pose to individual users (Rass, Pacek, Johnson, & 
Johnson, 2015).  
Third, e-cigarettes have the potential to weaken existing tobacco control policies. Public health 
professionals have expressed concern over the similarity of e-cigarettes to tobacco cigarettes, 
with respect to both product design and behavioural use (Standing Committee on Health, 2015). 
Due to this similarity, e-cigarettes may erode the social unacceptability of smoking that currently 
prevails (WHO, 2014). Given the successes of tobacco control policies in reducing smoking 
prevalence – by encouraging quit attempts by smokers and by preventing uptake by youth – the 
risk of renormalization may have a significant impact on public health (CDC, 2014; Holford et 
al, 2014).   
Although some or all of these potential positive and negative effects may occur with respect to 
the ‘disruptive technology’ of e-cigarettes (Fagerström, Etter & Unger, 2015), the public health 
impact of these products will result from the net effect of these consequences on the smoking 
rate of the population (Benowitz & Goniewciz, 2013; Czoli et al., 2015; Zeller, 2012). The 
behavior of dual use, meaning the regular current use of both tobacco cigarettes and e-cigarettes, 
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is a particular issue that warrants public health attention because of its potential to yield both 
positive (i.e., smoking reduction/cessation) and negative (i.e., delay of cessation) impacts 
(Benowitz & Goniewicz, 2013; Rass et al., 2015).  
1.4 Dual use of cigarettes and e-cigarettes 
1.4.1 Dual use in Canada 
Data from the 2015 CTADS describe prevalence of dual use in the Canadian context. Dual use 
appears to be common, given that the majority (63%) of current users of e-cigarettes also 
reported currently smoking tobacco cigarettes (Reid et al., 2017). The proportion of e-cigarette 
current users who were current smokers was lower among youth aged 15-19 (56%), as well as 
among adults aged 25-44 (56%), and greater among young adults aged 20-24 (68%), as well as 
among adults aged 45+ (70%) (Reid et al., 2017). Despite the high prevalence of dual use in 
Canada, evidence regarding dual use behaviours and dual users’ exposure to specific chemical 
compounds is scarce. In addition to CTADS, several population surveys have been conducted 
examining e-cigarette use among Canadians (Czoli, Hammond, & White, 2014; Czoli, 
Hammond, Reid, Cole, & Leatherdale, 2015; Hamilton, Ferrence, Boak, Schwartz, Mann, 
O’Connor, & Adlaf, 2015; Shiplo, Czoli, & Hammond, 2015), although these studies did not 
examine behaviours among dual users as a distinct subpopulation. While findings from the 
International Tobacco Control Four-Country Survey from 2010-2011 reported rates of and 
reasons for use of e-cigarettes among former and current smokers, data are limited with respect 
to their outdated collection period, and by the fact that they are pooled across Canada, the US, 
the United Kingdom, and Australia (Adkison et al., 2013). Consequently, the current evidence 
base regarding dual use is drawn mainly from studies conducted in other contexts.  
1.4.2 Patterns of dual use 
Research evidence regarding the behaviour of dual use stems from six sources:  
 An online survey of adult e-cigarette users (n=2807), of which 20% were currently 
smoking cigarettes (n=553), recruited via online e-cigarette forums between 2012 and 
2014 (Etter, 2015); 




 A national panel survey of current adult smokers in the US (n=2254), of which 24% were 
currently using e-cigarettes (n=582), conducted in April-May 2014 (Rutten et al., 2015); 
 A case-control study of dual users (n=3530) matched for age and gender with formerly-
smoking vapers (n=3530), recruited via online e-cigarette forums in April-July 2013 
(Farsalinos, Romagna, & Voudris, 2015); 
 A survey of 319 adult smokers and vapers in Munich, Germany, of which 30% were dual 
users, recruited using various methods in 2012 (Rüther et al., 2016);  
 An online survey of young adults in the US, of which 31% were dual users, recruited 
online in August 2014 (Berg, 2016).  
Rass and colleagues’ (2015) survey data provide a detailed profile of dual users’ patterns of use. 
In this study, dual use was defined as: use of e-cigarettes and tobacco cigarettes for at least three 
months each, use of e-cigarettes and tobacco cigarettes in the past week, and use of a nicotine-
containing e-cigarette. Overall, dual users used tobacco cigarettes more than e-cigarettes, 
smoking tobacco cigarettes more times per day and more days per week, as compared to e-
cigarettes. Furthermore, dual users appeared to be more dependent upon their tobacco cigarettes 
versus their e-cigarettes, as evidenced by: higher scores of nicotine dependence, less time to first 
use of the day, greater reluctance to give up the first use of the day, greater likelihood of daily 
use, and stronger cravings. With respect to the temporality of dual use behaviours, initiation of 
tobacco cigarette use after e-cigarette use was observed in only one of 350 study participants 
(Rass et al., 2015).  
Etter (2015) reported a significant decrease in dual users’ self-reported number of tobacco 
cigarettes smoked per day (CPD) since the initiation of e-cigarette use, from a mean of 23 to a 
mean of nine. Similarly, dual users from both US-based surveys reported changes in CPD since 
the initiation of e-cigarette use: in both studies (by Rass et al., 2015, and Rutten et al, 2015, 
respectively), slightly over half the sample reported reductions in CPD (50% and 54%); slightly 
less than half reported no change in CPD (45% and 41%); while very few dual users reported an 
increase in CPD (5% and 2%) (Rass et al., 2015; Rutten et al, 2015). Rass and colleagues (2015) 
provided some further detail on reduction of cigarette smoking among their sample of dual users: 
since initiation of e-cigarette use, the median CPD decreased significantly from 10 to seven, 
corresponding to a 30% reduction. Furthermore, among dual users in this sample, those who 
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used e-cigarettes daily had significantly greater reduction in CPD compared to non-daily users 
(Rass et al., 2015). Dual users in the case-control study by Farsalinos, Romagna, & Voudris, 
(2015) all reported a reduction in their consumption of tobacco cigarettes since taking up e-
cigarettes: approximately two-thirds of dual users were smoking tobacco cigarettes daily (with a 
reduction in median CPD from 20 to four), while one-third were smoking tobacco cigarettes 
occasionally.  
In an examination of dual users’ past quit attempts and intentions to quit by Rass et al. (2015), 
68% of dual users reported a past serious quit attempt for tobacco cigarettes, and 41% reported a 
serious quit attempt for tobacco cigarettes in the past year. Further, 68% reported having used 
nicotine replacement therapy (NRT), cessation medications, or other methods to assist in quitting 
tobacco cigarettes. Finally, a comparison of quit intentions for tobacco cigarettes and e-cigarettes 
showed that twice as many dual users were planning to quit using tobacco cigarettes (73%) 
versus e-cigarettes (36%) in the next year (Rass et al., 2015).  
Rass et al. (2015) also found differences in the settings in which dual users used their products. 
Overall, dual users reported more commonly using e-cigarettes versus tobacco cigarettes indoors 
and in situations in which they were concerned about the health of others; in contrast, dual users 
reported a greater likelihood of using tobacco cigarettes versus e-cigarettes in hedonic situations 
or when feeling stressed or anxious (Rass et al., 2015).   
Findings from Farsalinos, Romagna, & Voudris (2015) provide data regarding e-cigarette 
product characteristics used by dual users. Dual users commonly used second-generation (52%) 
or third-generation (41%) products, with very few using first-generation devices (6%). This 
finding appears to be supported by the survey of German dual users by Rüther and colleagues 
(2016), in which one-half (50.0%) of dual users reported using tank systems. Further, a majority 
of dual users used ready-to-use liquids (64%), as opposed to pre-filled cartomizers (3%) or do-it-
yourself liquids (33%). Among a sample of German dual users, approximately one-half (51.2%) 
reported using only e-liquid with nicotine, while just 3.1% reported using only e-liquid without 
nicotine, and 37.4% reported using both types of e-liquid (Rüther et al., 2016). In addition, a 
study of young adult dual users in the US by Berg (2016) found that a large majority (94.3%) 
used e-liquids with nicotine. Dual users in the study by Farsalinos and colleagues (2015) also 
reported a reduction in nicotine levels of their e-liquids, from a median level of 17 mg/mL at 
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initiation of use to 12 mg/mL at the time of the survey. The most commonly used e-cigarette 
flavour reported by a sample of young adult dual users in the US was fruit (60.9%), followed by 
sweet flavours (e.g., vanilla, candy) (56.2%), menthol/mint (34.7%), and tobacco (27.4%) (Berg, 
2016).  
1.4.3 Perceptions of and reasons for dual use 
Evidence regarding perceptions of products and behaviours among dual users is also limited. The 
perception of e-cigarettes as less harmful than tobacco cigarettes appears common, with a 
majority of participants supporting this belief: 87% in the study by Rass et al. (2015), and 90% in 
the study by Farsalinos, Romagna, & Voudris (2015). In addition, Rass et al. (2015) reported that 
a majority of dual users stated that e-cigarettes were less enjoyable (63%) and less addictive 
(57%) than tobacco cigarettes.  
Several studies have examined dual users’ reasons for using e-cigarettes. The most frequently 
reported reasons for e-cigarette use were to reduce or quit smoking, to reduce the health risks of 
smoking (either to the user or to others), or to deal with situations or places where smoking is 
prohibited (Berg, 2016; Etter, 2015; Patel et al., 2016; Rass et al., 2015; Rutten et al., 2015). 
Rass et al. (2015) further examined dual users’ most important reason for e-cigarette use, for 
which the belief that e-cigarettes were less harmful to health than tobacco cigarettes (25%), and 
the wish to cut down smoking in preparation for a quit attempt (21%), were most frequently 
endorsed. Dual users in the case-control study by Farsalinos, Romagna, & Voudris (2015) 
similarly viewed using e-cigarettes to reduce or quit smoking and to reduce others’ exposure to 
secondhand smoke as very important reasons for use, while economic considerations and 
avoiding smoking restrictions were acknowledged as less important reasons.   
1.4.4 Exposure to nicotine and compensatory behaviour 
Research in the tobacco domain has demonstrated that individuals smoke to achieve a particular 
dose of nicotine needed to sustain their addiction (Benowitz, 2001). This is evidenced by 
population-level data showing considerable variability in nicotine intake between smokers 
(following adjustment for daily cigarette consumption and consideration of cigarette brand 
smoked) (Jarvis, Boreham, Primatesta, Feyerabend & Bryant, 2001), yet remarkable stability 
with respect to levels of nicotine exposure among smokers over time (Hammond, Fong, 
Cummings & Hyland, 2005; Jarvis, Giovino, O’Connor, Kozlowski & Bernert, 2014). Self-
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titration of nicotine is also evidenced in “switching” studies, wherein smokers adjust their 
smoking behaviour to maintain their desired dose across different tobacco products. For instance, 
smokers switching from ‘regular yield’ cigarettes to ‘low yield’ cigarettes may smoke more 
cigarettes per day, may take more and deeper puffs, may puff with a faster draw rate, and/or may 
block ventilation holes in the cigarette in order to acquire the nicotine they desire (Benowitz, 
2001; Hammond et al., 2005). As a result of such compensatory behavioural changes, smokers of 
‘low yield’ cigarettes are not likely to have a lower risk of disease, as compared to their ‘regular 
yield’ cigarette-smoking counterparts (Benowitz, 2001).  
Currently, evidence regarding the delivery of nicotine via e-cigarettes is limited. In a review of 
eight studies of acute e-cigarette administration, Marsot & Simon (2015) reported that regular e-
cigarette users showed measurable, yet highly variable, levels of plasma nicotine and cotinine (a 
key nicotine metabolite), although nicotine was delivered more slowly by e-cigarettes as 
compared to tobacco cigarettes. In addition, studies comparing levels of cotinine between e-
cigarette users and tobacco cigarette smokers revealed that although cotinine levels among users 
of these different products can be similar, they are not always so (Adriaens, Van Gucht, 
Declerck, & Baeyens, 2014; Hecht et al., 2015; Göney, Çok, Tamer, Burgaz, & Şengezer, 2016; 
Wagener et al., 2016). Variability in these findings has been attributed to: user characteristics, 
including users’ experience with particular devices, patterns of use (e.g., occasional versus 
regular use), and puff topography (e.g., more puffs, greater puff volume); as well as factors 
related to e-cigarette design, including the generation or class of product, and liquid nicotine 
content and concentration (Farsalinos, Spyrou, Stefopoulos, Tsimopoulou, Kourkoveli, Tsiapras, 
Kyrzopoulos, Poulas, & Voudris, 2015; Lopez & Eissenberg, 2015; Marsot & Simon, 2015; 
Wagener et al., 2016).  
To date, published switching studies involving tobacco cigarettes and e-cigarettes have reported 
mixed results. In a within-subjects study by van Staden, Groenewald, Engelbrecht, Becker, & 
Hazelhurst (2013), the cotinine levels of 13 smokers decreased significantly over a 2-week 
period following adoption of a first-generation e-cigarette device. A similar study by McRobbie, 
Phillips, Goniewicz, Myers Smith, Knight-West, Przulj, & Hajek (2015) examined cotinine 
levels in a group of 33 smokers following use of a first-generation product for 1 month. 
Although cotinine levels among the full sample decreased significantly over the study period, 
15 
 
subgroup analyses comparing those participants who did not manage to stop smoking at follow-
up (dual users) to those participants who were able to stop smoking at follow-up (abstainers) 
revealed important differences. Specifically, cotinine levels decreased among dual users, who 
had significantly higher baseline cotinine levels compared to abstainers, whereas cotinine levels 
remained stable among abstainers (McRobbie et al., 2015). Findings from two industry-
sponsored studies similarly reported significant decreases in levels of cotinine and nicotine 
equivalents among smokers who switched to use of a Fontem Ventures first-generation device 
for 5 days (O’Connell, Graff, & D’Ruiz, 2016) and for 12 weeks (Cravo et al., 2016). In contrast, 
in a within-subjects study by Berg, Barr, Stratton, Escoffery, & Kegler (2014), 72 smokers using 
variable products over an 8-week period showed no marked changes in cotinine levels. Similarly, 
switching studies assessing dual use behaviour of smokers who adopted e-cigarettes have 
reported stable cotinine levels after 1 week of use (Meier, Wahlquist, Heckman, Cummings, 
Froeliger, & Carpenter, 2017) and after 8 months of use (Pacifici, Pichini, Graziano, Pellegrini, 
Massaro, & Beatrice, 2015). Finally, in a within-subjects study, 20 Polish smokers who adopted 
a pen-style M201 e-cigarette also showed stable levels of various nicotine metabolites (with the 
exception of nornicotine), following 2 weeks of use (Goniewicz et al., 2016). Taken together, 
these findings show that some smokers were able to successfully switch from tobacco cigarettes 
to e-cigarettes, compensating for nicotine via a new nicotine delivery product. In addition, it 
appears that baseline cotinine levels and the type of e-cigarette product used may partly 
determine whether this switch can be successfully completed.  
1.4.5 Exposure to tobacco smoke constituents 
Several studies examining the use of e-cigarettes in short, controlled sessions in the laboratory 
have shown that e-cigarettes do not deliver carbon monoxide to the user (Adriaens et al., 2014; 
Flouris et al., 2013; Vansickel, Cobb, Weaver, & Eissenberg, 2010; Wagener et al., 2016). 
Furthermore, it has been shown that exhaled carbon monoxide decreases over time, both among 
individuals who switch from use of tobacco cigarettes to use of e-cigarettes (Adriaens et al., 
2014; Caponnetto et al., 2013; McRobbie et al., 2015; Pacifici et al., 2015; Polosa et al., 2014; 
van Staden et al., 2013; Goniewicz et al., 2016; Litt, Duffy, & Oncken, 2016), and among 
individuals who switch from use of tobacco cigarettes to dual use of tobacco cigarettes and e-
cigarettes (McRobbie et al., 2015; Pacifici et al., 2015). Similar findings have been reported by 
industry-sponsored studies (Cravo et al., 2016; O’Connell et al., 2016).  
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Few studies have examined exposure to tobacco smoke constituents other than carbon monoxide. 
A study by Hecht and colleagues (2015) examined exposure to PAHs in exclusive e-cigarette 
users versus two samples of tobacco cigarette users. Comparisons showed that levels of a PAH 
biomarker, 1-hydroxypyrene (1-HOP), were significantly lower in e-cigarette users than in both 
samples of tobacco cigarette smokers, and furthermore, were similar to levels found in non-
smokers (Hecht et al., 2015). To date, two studies examining smokers’ switch to use of e-
cigarettes have examined levels of 1-HOP. In an industry-sponsored study, O’Connell and 
colleagues (2016) reported significant decreases in levels of 1-HOP among clinically-confined 
subjects who switched to exclusive use of e-cigarettes, dual use, or who gave up tobacco and 
nicotine products entirely. Finally, Goniewicz and colleagues (2016) examined eight PAH 
biomarkers among smokers who used e-cigarettes for two weeks. The authors reported mixed 
findings, with some PAH biomarkers showing a significant decline, and others – including 1-
HOP – showing no significant change. Goniewicz and colleagues (2016) note that these observed 
trends may have differed between participants who continued to smoke tobacco cigarettes and 
those who quit entirely, although their ability to formally examine such differences was limited 
by the small number of study participants.  
Another key constituent of tobacco smoke that has been studied is NNAL [4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol], a metabolite of the TSNA NNK [4-
(metylnitrosamino)-1-(3-pyridyl)-1-butanone]. Comparative analyses have shown significantly 
lower levels of NNAL in samples of e-cigarette users as compared to samples of tobacco 
cigarette smokers (Hecht et al., 2015; Shahab et al., 2017), as well as compared to samples of 
dual users of tobacco cigarettes and e-cigarettes (Shahab et al., 2017). Similar findings were 
reported for comparisons between a group of exclusive tobacco cigarette smokers and two 
groups of e-cigarette users, with no difference in NNAL levels between the two groups of e-
cigarette users (Wagener et al., 2016). In addition, both independent and industry-sponsored 
switching studies have shown that levels of NNAL declined significantly following abstinence 
from tobacco cigarettes (Cravo et al., 2016; Goniewicz et al., 2016; O’Connell et al., 2016).  
1.4.6 Nicotine withdrawal  
Studies examining use of e-cigarettes among smokers in short, controlled sessions in the 
laboratory have shown that e-cigarettes effectively reduce cravings for cigarettes (Adriaens et al., 
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2014; Bullen, McRobbie, Thornley, Glover, Lin, & Laugesen, 2010; D’Ruiz, Graff, & Robinson, 
2016; Vansickel et al., 2010; Walele, Sharma, Savioz, Martin, & Williams, 2016). Interestingly, 
these studies have used various e-cigarette products, including first- and second-generation 
devices, suggesting that these products’ ability to reduce cravings may only partly depend on 
their ability to deliver nicotine.  
In contrast, findings from real-world studies of the effects of e-cigarettes on nicotine withdrawal 
have been mixed. Switching studies involving smokers taking up first-generation (Meier et al., 
2017) and second-generation (Wagener et al., 2014) e-cigarettes reported no significant changes 
in nicotine withdrawal symptoms following ad libitum use for one week. In contrast, in a 
switching study involving a sample of Polish smokers adopting an e-cigarette, Goniewicz and 
colleagues (2016) observed a statistically significant decline in nicotine withdrawal scores over a 
two-week period. Similarly, in an industry-sponsored parallel group study comparing smokers 
who switched to e-cigarettes with smokers who continued smoking their usual brand of tobacco 
cigarettes, subjects in both groups showed a steady decrease in cravings throughout the 12-week 
study, with no significant differences between the two groups (Cravo et al., 2016). 
Unfortunately, although the two randomized controlled trials of e-cigarettes (Bullen et al., 2013; 
Caponnetto et al., 2013), as well as the observational study of smokers adopting e-cigarettes by 
McRobbie and colleagues (2015), examined symptoms of nicotine withdrawal among 
participants, these results have not been published.  
1.4.7 Self-efficacy  
To date, evidence regarding the effects of e-cigarettes on smokers’ self-efficacy to quit smoking 
is limited to two studies in which smokers switched to use of e-cigarettes for one week periods 
(Meier et al., 2017; Wagener et al., 2014). In the study by Meier and colleagues (2017), no 
significant change in smokers’ confidence to quit smoking was reported. The authors speculate 
that this may be due to limited substitution of e-cigarettes for tobacco cigarettes, as evidenced by 
the lack of apparent change in smoking behaviours among their study participants following 
adoption of a first-generation e-cigarette, either with or without nicotine (Meier et al., 2017). In 
the study by Wagener and colleagues (2014), participants reported a significant increase in 




1.4.8 Perceived health and subjective effects  
To date, the use of e-cigarettes has been associated with few adverse events. Following acute 
exposure, only mild adverse events have been reported, the most common of which included 
mouth and throat irritation, as well as cough (Bullen et al., 2010; O’Connell et al., 2016; Walele 
et al., 2016). In studies examining exposure over longer periods of time, and in observational 
studies reporting on regular use in real-life settings, reporting of adverse events has been 
similarly low, with no reports of serious adverse events related to e-cigarette use (Adriaens et al., 
2014; Caponnetto et al., 2013; Cravo et al., 2016; McRobbie et al., 2015). Furthermore, studies 
of smokers switching to use of e-cigarettes have showed progressive decreases in the occurrence 
of negative effects commonly reported by smokers, including cough, dry mouth, chest tightness, 
shortness of breath, throat irritation, and headache (Caponnetto et al., 2013; Cibella et al., 2016; 
Polosa et al., 2014; van Staden et al., 2013; Goniewicz et al., 2016). Positive effects reported by 
users of e-cigarettes include: less cough and phlegm, improved breathing, improved taste and 
smell, increased appetite, and improved ability to exercise (Adriaens et al., 2014; Berg et al., 
2014; van Staden et al., 2013).  
1.5 Policy context  
In Canada, e-cigarettes containing nicotine are regulated as drug delivery devices under the 
federal Food and Drugs Act (Health Canada, 2009a). E-cigarettes containing nicotine, with or 
without a health claim, require market authorization from Health Canada before they can be 
imported, marketed, or sold. To date, no such product has received market approval; therefore, e-
cigarettes containing nicotine are prohibited in Canada. In contrast, e-cigarettes that do not 
contain nicotine and do not make health claims can be legally bought and sold. Health Canada 
has issued public advisories against the use of e-cigarettes, as these products “may pose health 
risks and have not been fully evaluated for safety, quality, and efficacy” (Health Canada, 2009b).  
Despite restrictions on the sale of nicotine, evidence has shown that nicotine-containing e-
cigarettes are accessible to Canadians. Although Health Canada has overseen seizures of such 
products at the border and has sent letters to retailers in violation of these regulations (Standing 
Committee on Health, 2015), the overall enforcement of these regulations appear weak. Research 
evidence shows that in addition to accessible online retail outlets, consumers may purchase 
nicotine-containing e-cigarettes in specialty ‘vape’ shops, which are operating openly in several 
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cities across the country (Hammond et al., 2015). Furthermore, population surveys have shown 
that Canadians of various ages use nicotine-containing e-cigarettes. For instance, among the 15% 
of Ontario high school students who reported ever using e-cigarettes in the 2013 Ontario Student 
Drug Use and Health Survey, approximately one-third (28%) had used e-cigarettes with nicotine 
(Hamilton et al., 2015). In addition, according to national CTADS data, nearly one-half (48%) of 
respondents who had used an e-cigarette reported that the last one they used contained nicotine 
(Reid et al., 2017).  
In light of this situation and growing debate concerning these products (Miller, 2014), the 
Canadian House of Commons Standing Committee on Health held hearings on the subject. In 
March 2015, the Committee released a report highlighting recommendations for the regulation of 
e-cigarettes under a new, unique legislative framework that would include both e-cigarettes with 
and without nicotine, requiring various safety standards, prohibiting the use of e-cigarettes in 
public spaces, and restricting the promotion and accessibility of e-cigarettes to youth. In addition, 
the Committee recommended continued support for independent research regarding these 
products and their use among the Canadian population (Standing Committee on Health, 2015). 
Furthermore, several provinces, including British Columbia, Manitoba, Newfoundland and 
Labrador, New Brunswick, Nova Scotia, Ontario, Prince Edward Island, and Quebec, have 
developed policies for the sale, marketing and use of both nicotine- and non-nicotine-containing 
e-cigarettes (Province of British Columbia, 2015; Province of Manitoba, 2015; Province of 
Newfoundland and Labrador, 2016; Province of New Brunswick, 2015; Province of Nova 
Scotia, 2014; Province of Ontario, 2015; Province of Prince Edward Island, 2015; Province of 
Quebec, 2015). In addition, in response to the Standing Committee’s report, federal legislation 
has been introduced in the Senate to amend the Tobacco Act and the Non-smokers’ Health Act in 
order to regulate the manufacture, sale, labelling, promotion, and use of vaping products 
(Parliament of Canada, 2016).  
1.6 Study rationale and research questions 
The current study seeks to fill several critical evidence gaps regarding dual users’ behaviours and 
exposure to nicotine and tobacco smoke constituents. Despite the fact that a majority of the e-
cigarette-using population in Canada are dual users (Reid et al., 2017), scarcely anything is 
known about the way in which dual users use both tobacco cigarettes and e-cigarettes. The 
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current study will be the first to examine detailed patterns of use and perceptions of tobacco 
cigarettes and e-cigarettes among Canadian dual users, including frequency and consumption of 
product use, types of products used, product perceptions, reasons for product use, and settings in 
which products are used. Due to the fact that Canada has a distinct regulatory framework on e-
cigarettes as well as a unique e-cigarette market, context-specific evidence regarding the 
behaviour of individuals who use such products is needed to inform policy.  
The current study will also contribute to the evidence base regarding dual users’ exposure to 
nicotine and tobacco smoke constituents, while addressing some of the limitations of published 
switching studies in the literature. First, many published studies have examined outdated devices 
suspected of poorly delivering nicotine (McRobbie et al., 2015; van Staden et al., 2013). Second, 
most study participants have been completely or partially naïve to e-cigarette use (Berg et al., 
2014; McRobbie et al., 2015; Pacifici et al., 2015; Goniewicz et al., 2016), which may have 
implications for uptake and proper use of e-cigarettes, given the ‘learning curve’ that is at times 
needed to adjust to these devices (McQueen, Tower, & Sumner, 2011). Furthermore, in only one 
study were participants allowed to select their e-cigarette flavour and nicotine concentration 
(Pacifici et al., 2015), despite evidence supporting the selection of such product characteristics 
by e-cigarette users as highly important (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, Spyrou & 
Voudris, 2013; Farsalinos et al., 2015b). Although placing restrictions on e-cigarette user and/or 
product characteristics may enhance the internal validity of study designs, such designs fail to 
capture realistic interactions between e-cigarette users and their devices, and as a result, are 
limited in their generalizability to user populations and products in today’s market. Finally, 
published switching studies have been limited in their examination of a single product change, 
reflecting the potential risk of participants in two distinct states; of these, just two studies have 
explicitly examined the potential risks of dual users (McRobbie et al., 2015; Pacifici et al., 2015). 
Thus, a critical evidence gap involves examination of biomarkers of exposure across all 
conditions of use relating to tobacco cigarettes and e-cigarettes.  
Finally, the current study will provide evidence to inform the debate regarding the public health 
impact of e-cigarettes. Given the critical role played by smoking topography in determining 
nicotine uptake and risk exposure, compensatory behaviour in the context of e-cigarette use 
carries important implications for public health. First, whether or not individuals exhibit 
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compensatory behaviour when using e-cigarettes may shed light on the potential of e-cigarettes 
to serve as an effective substitute for tobacco cigarettes. In other words, if individuals are able to 
compensate for nicotine by using e-cigarettes, these products may have the potential to replace 
tobacco cigarettes as a ‘cleaner’ source of nicotine. Second, the extent to which individuals using 
e-cigarettes exhibit compensatory behaviour will impact their exposure to constituents present in 
tobacco smoke. Thus, by examining dual users’ product use behaviours and exposure to nicotine 
and tobacco smoke constituents, the current study will provide evidence to delineate some of the 
potential negative and positive effects e-cigarettes may have on public health.   
The current study will examine the following specific research questions:  
Research question 1: What patterns of use and perceptions of tobacco cigarettes and e-
cigarettes are exhibited or held by dual users? 
Research question 2: Is compensatory behaviour for nicotine exhibited among dual users when 
they switch from dual use to exclusive use of either tobacco cigarettes or e-cigarettes?  
Research question 3: Is exposure to tobacco smoke constituents reduced among dual users 
when they switch from dual use to: exclusive use of tobacco cigarettes, exclusive use of e-
cigarettes, or use of neither product? 
Research question 4: Do cravings or self-efficacy change among dual users when they switch 
from dual use to: exclusive use of tobacco cigarettes, exclusive use of e-cigarettes, or use of 
neither product? 
Research question 5: Does perceived health change among dual users when they switch from 






2.1 Study design 
An un-blinded within-subjects experiment was conducted with a sample of adult (18+ years) 
dual users of tobacco cigarettes and e-cigarettes in Kitchener-Waterloo and Toronto, Ontario. 
Participants completed three consecutive seven-day periods in which the use of tobacco 
cigarettes and e-cigarettes was experimentally manipulated.   
2.2 Study protocol 
2.2.1 Recruitment 
Study participants were recruited from September 2015 through March 2016 via advertisements 
using various media channels. Vape shops located in Kitchener-Waterloo, Guelph, Cambridge, 
and Toronto, were identified and contacted for assistance with recruitment. Shops that agreed to 
assist with recruitment were asked to do one or more of the following: post flyers in their stores; 
distribute flyers to their customers; post flyers online on their websites and/or blogs; and share 
flyers online via their email distribution list. Research staff also recruited potential participants 
by approaching vape shop customers as they exited the shops. Study advertisements were placed 
in local newspapers, including ‘The Chronicle’ and ‘The Record’ in Kitchener-Waterloo, as well 
as ‘24 Hours’ and ‘Metro’ in Toronto. Online advertisements were also posted on Kijiji, Craig’s 
List, Facebook, and Reddit. A sample recruitment flyer and advertisement are included in 
Appendix A.  
2.2.2 Eligibility  
A brief telephone screener was used to assess the eligibility of potential participants. In order to 
participate in the study, potential participants must have met the following criteria:  
 Be 18 years of age or older 
 Be able to read and understand English 
 Have access to the internet on a daily basis 
 Be a current cigarette daily smoker and smoke a minimum of five cigarettes per day 
 Not have serious intentions to quit smoking in the next six months 
 Be a current daily e-cigarette user 
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 Not have used other tobacco products, such as kreteks, bidis, cigars, pipe tobacco, 
smokeless tobacco or hookah/waterpipe in the past seven days 
 Not have used any nicotine replacement therapy products, such as the patch, gum, inhaler 
or lozenges in the past seven days 
 Not have used any medications, such as ‘Zyban’, ‘Wellbutrin’, or ‘Champix’ to help 
them quit smoking in the past seven days 
 Not have participated in any group or individual counselling programs to help them quit 
smoking in the past seven days 
 Not have ever experienced serious cardiac arrhythmias (tachycardia) or severe or 
worsening angina pectoris (chest pain) 
 Not have had a heart attack or stroke within the last three months 
 Not have had cancer within the last year 
 Not have asthma, chronic obstructive pulmonary disease (COPD), a seizure disorder, or 
any life-threatening medical conditions with a prognosis of less than a year 
 Not have a history of psychosis, schizophrenia, bipolar disorder, or suicidal thoughts, and 
 Be available for four weekly visits over a three-week period. 
Research staff provided eligible participants with an overview of the study protocol and 
answered any questions. Eligible participants who indicated they were interested in participating 
in the study were asked for their contact information and had their study visits scheduled in 
either Kitchener-Waterloo or Toronto.  
2.2.3 Study conditions and experimental groups 
A depiction of the study design is presented in Figure 2. Participants completed three 
consecutive seven-day periods in which the use of tobacco cigarettes and e-cigarettes was 
experimentally manipulated:   
 Condition 1: Baseline behaviour of dual use of tobacco cigarettes and e-cigarettes;  
 Condition 2: Exclusive use of tobacco cigarettes;  
 Condition 3: Exclusive use of e-cigarettes; and 




Week 1 Week 2 Week 3 
To control for order effects, the order in which participants experienced the study conditions was 
randomized. Participants were randomly assigned to one of two condition orders, consisting of 
pre-defined sequences of product use:  
 Group A: Participants were permitted to use e-cigarettes in Week 1, and tobacco 
cigarettes in Week 2; or  
 Group B: Participants were permitted to use tobacco cigarettes in Week 1, and e-
cigarettes in Week 2.  
 





















* Study participants were randomized to one of two condition orders (Group A or Group B). 
 
Seven-day study periods were used to ensure sufficient time for any changes in smoking and 
vaping behaviours to stabilize following a switch to a new behaviour (Hammond et al., 2005) 
and to account for the half-life and clearance rates of the most of the assessed biomarkers 
(described below). During each of the first two weeks of the study, participants were instructed 
to use the permitted product as desired, but to abstain from using the alternate product. During 
the final week of the study, all participants were asked to abstain from using both tobacco 
cigarettes and e-cigarettes. In order to assist participants in abstaining from both products in the 
final week of the study, they were provided with links to online smoking cessation resources 
developed by Health Canada and the Ontario Ministry of Health and Long-Term Care. For the 
Visit 1 Visit 2 Visit 3 Visit 4 
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duration of the study, participants were also asked not to use alternative tobacco products (such 
as kreteks, bidis, cigars, pipe tobacco, smokeless tobacco or hookah/waterpipe), nicotine 
replacement therapy products (such as the patch, gum, inhaler or lozenges), smoking cessation 
medications (such as ‘Zyban’, ‘Wellbutrin’, or ‘Champix’), or participate in individual or group 
counseling for smoking cessation. For the duration of the study, participants were not ‘blinded’ 
to the products they used, and were permitted to use any types of tobacco cigarettes and/or e-
cigarettes they wished.  
2.2.4 Study visits 
Eligible participants were asked to attend four one-hour visits in Kitchener-Waterloo or Toronto: 
at baseline and after each of the three 7-day periods. At each study visit, participants were asked 
to complete a questionnaire regarding their smoking and vaping behaviours, and provide samples 
of exhaled breath and urine. Visit questionnaires were approximately 20 minutes in length and 
were completed using an iPad. Participants were asked to provide a ‘spot’ urine sample, which 
was frozen at -20°C immediately afterwards. Participants were also asked to provide two exhaled 
breath samples, which were measured using Bedfont Micro 4 Smokerlyzer and piCO+ 
Smokerlyzer machines (Bedfont Scientific Ltd.). Additional items and procedures at Visit 1 
included: review of a study information sheet, and provision of informed consent. At Visits 1-3, 
participants were provided with instructions for the subsequent week, corresponding to their 
assigned group. Finally, at Visit 4, participants were provided with a study feedback letter, and 
thanked for participating in the study.  
2.2.5 Daily diaries 
Participants were asked to complete a 5-minute online daily diary about their consumption of 
tobacco cigarettes and e-cigarettes at the end of each day of the study. Links to the online daily 
diaries were emailed to each participant on the morning of each day by research staff. 
2.2.6 Remuneration 
In appreciation of their participation in the study, participants received a total of $295: $50 after 
Visit 1, $70 after Visit 2, $75 after Visit 3, and $100 after Visit 4.  
2.2.7 Ethics clearance 
This study was reviewed by and received clearance from the University of Waterloo Office of 
Research Ethics (ORE #20735). At Visit 1, research staff provided all potential participants with 
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an information letter about the study, reviewed all study activities, and answered any questions. 
Potential participants were then asked to provide written informed consent to acknowledge their 
agreement to participate in the study. Participant confidentiality was maintained by assigning 
each participant a unique identification number and keeping all collected data in a secure 
database. A copy of the study information letter and informed consent form are included in 
Appendix B.  
2.3 Study measures  
Sample copies of the study questionnaires are included in Appendix C. Measures drawn and/or 
adapted from the literature were used whenever possible. In some instances, the research team 
developed questionnaire items for several dimensions of vaping behaviour, due to the fact that 
there are few standardized behavioural assessments for this emerging behaviour.  
2.3.1 Eligibility criteria and sociodemographic characteristics 
Current daily smokers of tobacco cigarettes were defined as individuals who had smoked at least 
100 tobacco cigarettes in their lifetime, had smoked a tobacco cigarette in the past 30 days, and 
reported smoking tobacco cigarettes every day. Current daily users of e-cigarettes were defined 
as individuals who had used an e-cigarette in the past 30 days, had used an e-cigarette at least 
once a day for each of the past seven days, and reported using e-cigarettes every day. Participants 
who qualified as current daily tobacco cigarette smokers and current daily e-cigarette users were 
termed dual users for the purposes of this study. Sociodemographic information included self-
reported age, gender, education, and ethnicity.   
2.3.2 Smoking behaviours  
Participants’ smoking history was evaluated by asking how long they had been smoking tobacco 
cigarettes daily. Validated measures of participants’ daily consumption of tobacco cigarettes and 
time to first tobacco cigarette were collected on the basis of each day as well as for each study 
week. In addition, participants’ time since last tobacco cigarette was collected for each day in 
the study. Data regarding participants’ usual brand of tobacco cigarettes was also collected.  
Participants were asked to indicate where they smoked tobacco cigarettes for each study week (at 
home, at school or work, at a restaurant or bar, in a vehicle, while walking on the street, in a park 
or other outdoor venue, or some other place). Those who indicated that they had smoked tobacco 
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cigarettes at home, at school or work, or at a restaurant or bar, were asked a follow-up question 
as to whether they had smoked tobacco cigarettes indoors, outdoors, or both indoors and 
outdoors for each of these designated places.  
Validated measures were used to examine participants’ intentions to quit smoking, as well as the 
number of past quit attempts and length of time since their most recent quit attempt (for tobacco 
cigarettes). Participants who indicated that they had any intentions to quit were asked whether 
they would use a quit aid, including a nicotine patch, gum, or lozenge; an e-cigarette; or 
prescription medication (e.g., ‘Zyban’, ‘Champix’).  
2.3.3 Vaping behaviours 
Participants’ vaping history was evaluated by asking how long they had been using e-cigarettes 
daily. Validated measures of cigarette consumption were adapted to the behaviour of e-cigarette 
use, including: number of times participants used an e-cigarette (bouts), average number of puffs 
taken per bout, and average duration of use per bout. In addition, participants’ time to first e-
cigarette and time since last e-cigarette were collected, mirroring measures for tobacco 
cigarettes. Measures of e-cigarette consumption and time to first e-cigarette were collected on the 
basis of each day as well as for each week in the study, while participants’ time since last e-
cigarette was collected for each study day.   
Several measures were used to collect information regarding characteristics of e-cigarette 
products used for each week in the study, including: flavours of e-cigarettes/e-liquids used 
(tobacco, menthol/mint, spice, candy, fruit, coffee/drinks/alcohol, other); type of e-cigarette(s) 
used (a disposable e-cigarette, an e-cigarette that uses replaceable pre-filled cartridges, or an e-
cigarette that is re-chargeable and has a tank or reservoir that you fill with liquid); and the 
brand(s) of e-cigarettes/e-liquids used. To assess the nicotine content of e-cigarettes/e-liquids, 
participants were asked to indicate whether they had used only e-cigarettes with nicotine, only 
nicotine-free / non-nicotine e-cigarettes, or some e-cigarettes with nicotine and some nicotine-
free / non-nicotine e-cigarettes. Participants who indicated that they had used e-cigarettes 
containing nicotine were asked to indicate the concentration/strength of nicotine in their e-
cigarettes/e-liquids.  
Participants were asked to indicate where they used e-cigarettes for each week in the study (at 
home, at school or work, at a restaurant or bar, in a vehicle, while walking on the street, in a park 
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or other outdoor venue, or some other place). For those who indicated that they had used e-
cigarettes at home, at school or work, or at a restaurant or bar, they were asked a follow-up 
question as to whether they had used e-cigarettes indoors, outdoors, or both indoors and 
outdoors for each of these designated places.  
Participants’ reasons for use of e-cigarettes were examined with respect to the reason(s) they 
began to use e-cigarettes daily, and the reason(s) they currently use e-cigarettes. For each of 
these measures, participants were asked to indicate all reasons that applied to them from a list, as 
well as to select one reason as the most important reason for their decisions.  
Validated measures for quitting smoking were adapted to the behaviour of e-cigarette use, 
including: intentions to quit using e-cigarettes, as well as the number of past quit attempts and 
length of time since their most recent quit attempt (for e-cigarettes). 
2.3.4 Nicotine dependence 
Nicotine dependence or addiction has been characterized as a cluster of several symptoms, 
including the following primary criteria: highly controlled or compulsive use, psychoactive 
effects, and drug-reinforced behavior. Additional criteria include: addictive behavior, often 
involving stereotypic patterns of use, use despite harmful effects, relapse following abstinence, 
and recurrent drug cravings; and the observation that dependence-producing drugs often produce 
tolerance, physical dependence, and pleasant effects (USDHHS, 2010).  
Nicotine dependence was measured using the Fagerström Test for Cigarette Dependence (FTCD) 
and the Nicotine Dependence Syndrome Scale (NDSS). The FTCD is a validated six-item 
instrument used to measure behavioral and physiological aspects of addiction. The FTCD is a 
unidimensional measure that shows limited internal consistency, adequate test-retest reliability, 
modestly correlates with key biomarkers (including levels of carbon monoxide, nicotine, and 
cotinine), and is a predictor of withdrawal symptoms and successful smoking cessation 
(Heatherton, Kozlowski, Frecker & Fagerström, 1991; USDHHS, 2010; Fagerström, 2012). The 
FTCD’s first item – time to first cigarette – is a strong predictor of smoking cessation 
(USDHHS, 2010; Fagerström, 2012).  
The NDSS is a valid 19-item instrument used to provide a multidimensional measure of nicotine 
dependence (Shiffman, Waters, & Hickcox, 2004). The NDSS provides an overall score of 
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nicotine dependence, as well as five subscale scores relating to: drive (craving and withdrawal, 
withdrawal avoidance, and subjective compulsion to smoke), priority (preference for smoking 
over other reinforcers), tolerance (reduced sensitivity to the effects of smoking), continuity 
(regularity of smoking rate), and stereotypy (invariance of smoking or rigid patterns of tobacco 
use). The NDSS shows moderate to strong internal consistency, and modest to strong test-retest 
reliability. In addition, NDSS scores have been associated with number of cigarettes smoked, 
difficulty in abstaining, and severity of past withdrawal symptoms among smokers who have not 
quit, while among treatment-seeking smokers, NDSS scores have predicted urges during 
smoking and during abstinence, acute withdrawal symptoms, and cessation outcome (Shiffman, 
Waters, & Hickcox, 2004; USDHHS, 2010).  
Both measures of nicotine dependence were adapted for e-cigarette use (E-FTCD and E-NDSS, 
respectively), by substituting the words/phrase ‘smoke cigarettes’ with ‘use e-cigarettes’. All 
four instruments were used to assess participants’ nicotine dependence at baseline. Similar 
measures for e-cigarettes have been used previously in studies of e-cigarette users (Etter & 
Eissenberg, 2015; Rass et al., 2015).  
2.3.5 Nicotine withdrawal 
The brief, 10-item version of the Questionnaire of Smoking Urges (QSU-Brief) is a valid 
measure of urges and cravings to smoke (Cox, Tiffany, & Christen, 2001). The QSU-Brief 
provides an overall score reflecting cravings to smoke, as well as scores for two factors that 
represent distinct expressions of craving: one represents a desire and intention to smoke with 
smoking perceived as rewarding (Factor 1), while the other represents an anticipation of relief 
from negative affect with an urgent desire to smoke (Factor 2) (Cox, Tiffany, & Christen, 2001). 
The QSU-Brief was also adapted to the behaviour of e-cigarette use (E-QSU-Brief), by 
substituting the words/phrase ‘smoke cigarettes’ with ‘use e-cigarettes’. Given the centrality of 
cravings to continued cigarette use and relapse (USDHHS, 2010), the QSU-Brief and the E-
QSU-Brief were used to evaluate participants’ cravings for tobacco cigarettes and e-cigarettes at 
baseline and following each week in the study.  
2.3.6 Self-efficacy 
The Smoking Self-Efficacy Questionnaire (SEQ-12) is a valid and reliable 12-item scale used to 
measure current and former smokers’ confidence in their ability to abstain from smoking when 
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facing internal and external stimuli or barriers (Etter, Bergman, Humair, & Perneger, 2000). 
Participants are asked to state how sure they are that they could refrain from smoking in various 
situations. The SEQ-12 consists of two six-item factors, representing internal stimuli (e.g., 
feeling depressed) and external stimuli (e.g., being with other smokers). The SEQ-12 was also 
adapted to the behaviour of e-cigarette use (E-SEQ-12), by substituting the words/phrase ‘smoke 
cigarettes’ with ‘use e-cigarettes’. Both the SEQ-12 and the E-SEQ-12 scales were be applied at 
baseline and following each week in the study.  
2.3.7 Dual use behaviours 
Several additional measures were constructed in order to acquire more detail regarding dual use 
behaviours. First, in order to ascertain the temporality of dual use behaviours, participants were 
asked to indicate which behaviour they began first: smoking cigarettes or using e-cigarettes. 
Next, dual users were asked which behaviour (smoking cigarettes or using e-cigarettes) they 
identify with more, as a way of eliciting their perceived identity with respect to dual use 
behaviours. Among those who indicated that they began smoking cigarettes before using e-
cigarettes, change in their daily cigarette consumption was inferred by asking, “Since you started 
using e-cigarettes daily, have you changed the amount you use per day?”, with response options 
‘I smoke fewer cigarettes’, ‘I smoke the same amount of cigarettes’, or ‘I smoke more 
cigarettes’.  
In addition, change in participants’ daily consumption of e-cigarettes and change in the strength 
of nicotine most commonly used by participants were examined using the following questions: 
“Since you started using e-cigarettes daily, have you changed the amount you use per day?”, 
with response options on a bipolar five-step Likert scale ranging from “I use much more” to “I 
use much less”; and “Since you started using e-cigarettes daily, have you changed the strength of 
nicotine that you use most?”, with response options ‘I increased the strength’, ‘no change in 
strength’, or ‘I decreased the strength’. Participants’ perceived addiction to each product were 
evaluated using the question: “Do you consider yourself addicted to regular tobacco cigarettes / 
e-cigarettes?”, with response options ‘not at all’, ‘somewhat addicted’, or ‘very addicted’. 
Finally, in order to measure participants’ perceived smoking cessation efficacy of e-cigarettes, 
participants were asked to indicate whether they thought using e-cigarettes would make it easier 
to quit smoking cigarettes, with response options ‘not at all’, ‘a little’, or ‘a lot’.  
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2.3.8 Perceptions of e-cigarettes  
Several questions elicited participants’ attitudes of e-cigarettes relative to tobacco cigarettes. The 
measures used the question stem “Compared to smoking regular tobacco cigarettes, using e-
cigarettes is…”, and required participants to evaluate the relative social acceptability, 
satisfaction, pleasure, harm, and affordability of e-cigarettes compared to tobacco cigarettes, 
using bipolar five-step Likert scales (e.g., ‘... a lot less socially acceptable’, ‘a little less socially 
acceptable’, ‘equally as socially acceptable’, ‘a little more socially acceptable’, or ‘a lot more 
socially acceptable’).  
2.3.9 Perceived health and subjective effects 
Several measures about lung function and breathing were included in the questionnaires. The 
measures asked participants to reflect on any changes they may have experienced in the past 
seven days, answering with the responses ‘worse than usual’, ‘no difference’, or ‘better than 
usual’. Respiratory health measures asked about any changes in: experiencing shortness of 
breath, frequency of experiencing cough, frequency of experiencing cough with phlegm, sounds 
emanating from the chest, and an overall description of lung function.   
Participants were asked a few additional questions about their perceived overall health following 
each study condition. First, in order to assess participants’ perceived overall health, they were 
asked, “In the past seven days, have you noticed any change in your overall health status as a 
result of not [smoking cigarettes / using e-cigarettes]?”, with the following response options: 
‘worse than usual’, ‘no difference’, ‘better than usual’. Second, participants’ negative or positive 
effects were examined by asking those who indicated ‘worse than usual’ or ‘better than usual’ to 
explain any negative or positive effects they had experienced in the past week, respectively 
(open-ended response).  
Participants were asked a few questions that prompted them to think about their experiences 
following each study condition. First, participants’ perceived addiction was evaluated for each 
product by asking “Do you consider yourself addicted to [tobacco cigarettes / e-cigarettes]?”, 
with the following response options: ‘not at all’, ‘somewhat addicted’, and ‘very addicted’. 
Second, in order to evaluate participants’ perceived difficulty in abstaining from using a 
particular product, participants were asked, “Over the past seven days, how easy or difficult was 
32 
 
it to go without [smoking cigarettes / using e-cigarettes]?”, indicating their response using a 




An overview of the measures included in each of the study questionnaires is provided in Table 1. Sample copies of the study 
questionnaires are included in Appendix C. 











Eligibility criteria and sociodemographic 
information 
X     
Smoking and vaping behaviours X X X X X1 
Nicotine dependence [(E-)FTCD; (E-)NDSS] X     
Nicotine withdrawal [(E-)QSU] X X X X  
Self-efficacy [(E-)SEQ-12] X X X X  
Perceptions of e-cigarettes X X X X  
Perceived health and subjective effects X X X X  
Notes:  




2.3.10 Biomarkers of exposure 
Biomarkers of exposure measure the presence of a tobacco or tobacco smoke constituent or their 
metabolites in the body. Measurement of biomarkers in bodily fluids can be used to quantify 
exposure to specific substances in various settings, with greater accuracy than can be achieved 
by self-reported data (WHO, 2007). Several biomarkers of exposure were examined in the 
current study, as described below.  
Carbon monoxide was measured in participants’ exhaled breath samples to provide an indication 
of uptake of tobacco smoke constituents. Given its elimination half-life of approximately four 
hours, carbon monoxide is a short-term measure of exposure (WHO, 2007). Carbon monoxide is 
widely used in tobacco research to distinguish smokers from non-smokers: exhaled air carbon 
monoxide levels of ≥ 8-10 parts per million (ppm) are typically used to identify smokers (SRNT 
Subcommittee on Biochemical Verification, 2002).  
Urinary concentration of cotinine, a major proximate metabolite of nicotine, was measured to 
provide an indication of exposure to nicotine from tobacco smoke. The elimination half-life of 
urinary cotinine among smokers has been estimated as 16 hours upon smoking cessation (Haley, 
Sepkovic, & Hofmann, 1989; WHO, 2007). Cotinine is the most widely used biomarker of 
exposure to nicotine from tobacco smoke, and can also be used to distinguish smokers from non-
smokers: urinary cotinine levels of ≥ 50 ng/mL are typically used to identify smokers (SRNT 
Subcommittee on Biochemical Verification, 2002).  
Urinary concentration of 1-hydroxypyrene (1-HOP) was measured to provide an indication of 
carcinogen exposure, specifically with respect to exposure to polycyclic aromatic hydrocarbons 
(PAHs). 1-HOP is the major urinary metabolite of pyrene, a non-carcinogenic component of all 
PAH mixtures (Hecht, 2002). 1-HOP has a half-life of approximately 19 hours, although 
estimates vary between 4 and 48 hours (Brandt & Watson, 2003). 1-HOP was examined as a 
complementary biomarker of tobacco smoke exposure, given that levels of PAHs may not 
change in similar proportion to levels of other tobacco smoke constituents, and because 
individuals may be exposed to PAHs from other environmental sources, such as grilled meats 
(WHO, 2007). Non-smokers are characterized by low levels of PAH exposure, typically at or 
below 1.4 μmol/mol creatinine, while levels among smokers are approximately 5 times higher 
(Brandt & Watson, 2003).  
35 
 
Urinary concentration of NNAL [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol] was measured 
at baseline to provide an indication of exposure to the tobacco-specific carcinogen NNK. NNAL 
(and its glucuronides) are metabolites of NNK, and can be readily detected in human urine 
(Hecht, 2002). NNAL is only slowly released from the human body after smoking cessation, 
with a half-life of approximately 40-45 days (Hecht et al., 1999). NNAL can be used to 
distinguish between smokers and non-smokers, given its high specificity with regard to smoking 
– detectable levels of NNAL are usually only found in the urine of non-smokers who have been 
exposed to environmental tobacco smoke. In the literature, levels of total NNAL less than 1 
pmol/mL are rarely seen among smokers, whereas the highest levels in non-smokers exposed to 
environmental tobacco smoke are rarely greater than 0.4 pmol/mL (Hecht, 2002).     
Creatinine is a waste product of muscle metabolism. Urinary creatinine measures are often used 
to adjust or correct for variability in the volume and concentration of urine in spot samples when 
measuring urinary concentrations of environmental and workplace chemicals or their metabolites 
(Barr et al, 2005). In the current study, levels of urinary biomarkers (cotinine, 1-HOP, NNAL) 
were adjusted for creatinine by dividing the analyte concentration by the creatinine 
concentration.  
Validated methods were used by Roswell Park Cancer Institute (Buffalo, US) to analyze levels 
of urinary cotinine (Liang, 2015), urinary 1-HOP (Lankova, Urbancova, Sram, Hajslova & 
Pulkrabova, 2016), and urinary NNAL (Jacob et al., 2008).   
2.3.11 Cognitive testing 
A pilot test involving two individuals with a history of dual use was conducted at the University 
of Waterloo in July 2015. A brief protocol involving two visits to the laboratory and completion 
of three online questionnaires was used to test core components of the study protocol, including 
study questionnaires and collection of biological samples. Cognitive interviews were conducted 
to ensure that study questionnaires had clear instructions and measures. The two pilot 






2.4.1 Sample characteristics 
Characteristics of dual users were examined using descriptive statistics with respect to: age, sex, 
ethnicity, education, daily cigarette consumption, and nicotine dependence (using both measures 
of the FTCD and the NDSS, applied to both tobacco cigarettes and e-cigarettes).  
2.4.2 Baseline patterns and perceptions of dual use 
Baseline patterns of use of tobacco cigarettes and e-cigarettes, as well as perceptions of e-
cigarettes, were examined using exploratory descriptive statistics, without formulation of specific 
a priori hypotheses.  
2.4.3 Testing changes in continuous outcomes across study conditions 
Changes in several key continuous outcomes were examined across study conditions. The 
distributions of each continuous outcome were visually examined for any violations from 
normality, and appropriate transformations were applied, as necessary. Previous research 
suggests that log transformations may be required for cotinine, 1-HOP, and NNAL values (e.g., 
Benowitz et al., 2012; Hammond & O’Connor, 2014). For each key outcome, means were 
computed at baseline and for each study condition. Repeated measures models (using the Linear 
Mixed Model function in SPSS) were constructed to examine mean differences for each key 
outcome across study conditions, while accounting for correlated measurements within subjects. 
Analyses were conducted using SPSS v.24 (Illinois, US) and p-values < 0.05 were considered 
statistically significant.  
2.4.3.1 Exposure to nicotine and compensatory behaviour 
Hypothesis 1a: Compared to baseline, consumption of tobacco cigarettes will be significantly 
higher in the study condition of exclusive use of tobacco cigarettes.   
Changes in consumption of tobacco cigarettes were examined by examining changes in mean 
levels of reported tobacco cigarettes consumed per day in the condition of exclusive use of 
tobacco cigarettes and dual use at baseline. A repeated measures model was constructed with 
daily tobacco cigarette consumption as the outcome (Model 1). The model was examined with 
the following covariates: assigned condition order, and baseline nicotine dependence. 
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Hypothesis 1b: Compared to baseline, consumption of e-cigarettes will be significantly higher 
in the study condition of exclusive use of e-cigarettes.  
Changes in consumption of e-cigarettes were examined by examining changes in mean levels of 
reported e-cigarettes consumed per day in the condition of exclusive use of e-cigarettes and dual 
use at baseline. A repeated measures model was constructed with daily e-cigarette consumption 
as the outcome (Model 2). The model was examined with the following covariates: assigned 
condition order, and baseline nicotine dependence. 
Hypothesis 1c: Compared to baseline, levels of urinary cotinine will be significantly lower in 
the study condition of no product use.  
Compensatory behaviour was evaluated by examining changes in mean levels of urinary cotinine 
between each study condition and dual use at baseline. A repeated measures model was 
constructed with urinary cotinine as the outcome (Model 3). The model was examined with the 
following covariates: assigned condition order, baseline nicotine dependence, e-cigarette product 
type, and e-cigarette nicotine content.  
2.4.3.2 Exposure to tobacco smoke constituents 
Hypothesis 2a: Compared to baseline, levels of exhaled carbon monoxide will be significantly 
lower in study conditions of exclusive use of e-cigarettes, and of no product use.  
Changes in biomarkers of tobacco smoke exposure were examined by comparing differences in 
mean levels of exhaled carbon monoxide between each study condition and dual use at baseline. 
A repeated measures model was constructed with exhaled carbon monoxide as the outcome 
(Model 4). The model was examined with the following covariates: assigned condition order. 
Hypothesis 2b: Compared to baseline, levels of urinary 1-HOP will be significantly lower in 
study conditions of exclusive use of e-cigarettes, and of no product use.  
Changes in biomarkers of tobacco smoke exposure were examined by comparing differences in 
mean levels of urinary 1-HOP (adjusted for urinary creatinine) between each study condition and 
dual use at baseline. A repeated measures model was constructed with urinary 1-HOP as the 
outcome (Model 5). The model was examined with the following covariates: assigned condition 
order, baseline nicotine dependence, e-cigarette product type, and e-cigarette nicotine content. 
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Hypothesis 2c: Compared to baseline, levels of urinary NNAL will be significantly lower in 
study conditions of exclusive use of e-cigarettes, and of no product use.  
Changes in biomarkers of tobacco smoke exposure were examined by comparing differences in 
mean levels of urinary NNAL (adjusted for urinary creatinine) between each study condition and 
dual use at baseline. A repeated measures model was constructed with urinary NNAL as the 
outcome (Model 6). The model was examined with the following covariates: assigned condition 
order, baseline nicotine dependence, e-cigarette product type, and e-cigarette nicotine content. 
2.4.3.3 Nicotine withdrawal  
Hypothesis 3a: Compared to baseline, measures of nicotine withdrawal for tobacco cigarettes 
will be significantly higher in study conditions of exclusive use of e-cigarettes, and of no product 
use.  
Changes in measures of nicotine withdrawal for tobacco cigarettes were examined by comparing 
differences in scores for the QSU between each study condition and dual use at baseline. A 
repeated measures model was constructed with QSU score as the outcome (Model 7). The model 
was examined with the following covariates: assigned condition order, baseline nicotine 
dependence. 
Hypothesis 3b: Compared to baseline, measures of nicotine withdrawal for e-cigarettes will be 
significantly higher in study conditions of exclusive use of tobacco cigarettes.  
Changes in measures of nicotine withdrawal for e-cigarettes were examined by comparing 
differences in scores for the E-QSU between each study condition and dual use at baseline. A 
repeated measures model was constructed with E-QSU score as the outcome (Model 8). The 
model was examined with the following covariates: assigned condition order, baseline nicotine 
dependence. 
2.4.3.4 Self-efficacy 
Hypothesis 4a: Changes in measures of self-efficacy for tobacco cigarettes will depend upon 
participants’ condition order. Compared to baseline, measures of self-efficacy for tobacco 
cigarettes will be significantly higher in study conditions of exclusive use of e-cigarettes, and of 
no product use, among participants assigned to Group A; and measures of self-efficacy for 
tobacco cigarettes will be significantly higher in study conditions of exclusive use of tobacco 
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cigarettes, of exclusive use of e-cigarettes, and of no product use, among participants assigned to 
Group B. 
Changes in measures of self-efficacy for tobacco cigarettes were examined by comparing 
differences in scores for the SEQ between each study condition and dual use at baseline. A 
repeated measures model was constructed with SEQ score as the outcome (Model 9). The model 
was examined with the following covariates: assigned condition order, baseline nicotine 
dependence. 
Hypothesis 4b: Compared to baseline, measures of self-efficacy for e-cigarettes will be 
significantly higher in study conditions of exclusive use of tobacco cigarettes, and of no product 
use.  
Changes in self-efficacy for e-cigarettes were examined by comparing differences in scores for 
the E-SEQ between each study condition and dual use at baseline. A repeated measures model 
was constructed with E-SEQ score as the outcome (Model 10). The model was examined with 
the following covariates: assigned condition order, baseline nicotine dependence.  
2.4.4 Testing changes in binary outcomes across experimental conditions 
Changes in several binary outcomes were examined across study conditions, while accounting 
for correlated measurements within subjects. For each key outcome, the proportion of 
participants corresponding to each level of the binary ordinal outcome variables were computed 
at baseline and for each study condition. Repeated measures models (using the Generalized 
Linear Mixed Model function in SPSS) were constructed to examine differences in proportions 
across study conditions. Analyses were conducted using SPSS v.24 (Illinois, US) and p-values < 
0.05 were considered statistically significant.  
2.4.4.1 Perceived health  
Hypothesis 5: Compared to baseline, a significantly greater proportion of participants will report 
better respiratory health (with respect to experiencing shortness of breath, frequency of 
experiencing cough, frequency of experiencing cough with phlegm, sounds emanating from the 
chest, and an overall description of lung function) in study conditions of exclusive use of e-
cigarettes, and of no product use.  
40 
 
Changes in perceived respiratory health were examined with respect to five domains: 
experiencing shortness of breath, frequency of experiencing cough, frequency of experiencing 
cough with phlegm, sounds emanating from the chest, and an overall description of lung 
function. Each outcome was modeled as a binary variable (0=‘worse than usual health’ or ‘no 
difference in health’; 1=‘better than usual health’). Generalized linear mixed models were 
constructed to test for differences in the proportion of participants who reported better than usual 
health (compared to those who did not) between each study condition and dual use at baseline, 
for each of the five domains listed above (Models 11-15). The models were examined with the 
following covariate: assigned condition order.  
2.4.5 Power calculations 
Prior to the study, power calculations were conducted for two representative tests: differences in 
biomarker levels and smoking behaviour across conditions. Data from published studies by 
McRobbie et al. (2015), Pacifici et al. (2015), and Hecht et al. (2015) were used to estimate 
means and standard deviations for each of the outcomes. A range of estimates for the correlation 
between outcome measures across study conditions (0.65, 0.75, and 0.85) were used to estimate 
power. Two-sided power calculations were conducted assuming 20% loss of sample due to 
attrition and/or incomplete data and a final sample size of 50 participants, using G*Power v. 3.1 
(Heinrich-Heine-Universität Düsseldorf), where alpha = 0.05.   
In a within-subjects switching study by McRobbie et al. (2015), exposure to carbon monoxide 
changed from 23 (SD=11) ppm to 11 (SD=8) ppm among a sample of smokers who took up e-
cigarettes but did not quit smoking after a period of four weeks. Using these estimates, the 
current study provided 80% power to detect a small to medium Cohen’s effect size, 
corresponding to a 15%, 13%, and 11% difference in exhaled carbon monoxide with correlation 
estimates of 0.65, 0.75, and 0.85, respectively. In addition, McRobbie and colleagues (2015) 
reported a change in urinary cotinine among this sample of smokers, from 2203 (SD=1734) 
ng/mL to 1227 (SD=679) ng/mL. A power calculation based on these estimates indicates that the 
current study provided 80% power to detect a small to medium Cohen’s effect size, 
corresponding to a 26%, 24%, and 22% difference with correlation estimates of 0.65, 0.75, and 
0.85, respectively, for urinary cotinine. Hecht et al. (2015) reported levels of exposure to various 
constituents in samples of smokers versus a sample of e-cigarette users. A comparison of levels 
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of 1-HOP showed greater exposure among smokers compared to e-cigarette users, at 0.97 
(SD=1.21) pmol/mL and 0.38 (SD=0.39) pmol/mL, respectively. Using these estimates, the 
current study provided 80% power to detect a small to medium Cohen’s effect size, 
corresponding to a 42%, 40%, and 38% difference with correlation estimates of 0.65, 0.75, and 
0.85, respectively, for urinary 1-HOP.  
Finally, data from a within-subjects switching study by Pacifici et al. (2015) were used to 
estimate changes in reported daily cigarette consumption. In the study by Pacifici and colleagues 
(2015), among a subsample of smokers who took up e-cigarettes and were classified as dual 
users one month later, their reported daily cigarette consumption changed from 23.3 (SD=6.1) to 
2.3 (SD=1.5). A power calculation based on these estimates indicates that the current study 
provided 80% power to detect a small to medium Cohen’s effect size, corresponding to a 9% 





3.1 Sample characteristics 
Overall, 293 individuals were screened for eligibility to participate in the study. Of these, 60 
individuals were deemed eligible and recruited for the study. A summary of the methods used to 
recruit participants is presented in Appendix D. Among the 60 individuals recruited for the study, 
three were excluded due to their failure to attend all study visits. In addition, 9 participants were 
excluded due to very low (< 5 ppm) carbon monoxide levels, as measured at baseline. Although 
exhaled carbon monoxide levels of ≥ 8-10 ppm are typically used to identify smokers (SRNT 
Subcommittee on Biochemical Verification, 2002), a slightly more lenient threshold (≥ 5 ppm) 
was used due to the fact that individuals recruited into the study were established dual users, who 
exhibit lower levels of carbon monoxide in their breath (Goniewicz et al., 2016). Thus, a total of 
48 participants were included in the analyses.  
3.1.1 Sociodemographic characteristics  
Sociodemographic characteristics of the final sample of 48 dual users are summarized in Table 2. 
Overall, dual users had a mean age of 35.9 (SD=11.7) years, and a majority were male (70.8%) 
and self-identified as ‘White’ (70.8%). Approximately two-thirds (66.7%) of participants were 
recruited from Toronto, and approximately half of participants were randomized to each of 
Group A (52.1%) and Group B (47.9%). As shown in Table 2, participants in each group did not 














 % (n) or mean (SD)  
Age 
[years] 
Overall 35.9 (11.7) 36.0 (11.4) 35.8 (12.2) 
t=0.039 
(p=0.969) 
18-24 14.6% (7) 20.0% (5) 8.7% (2) 
χ2=6.740 
(p=0.081) 
25-39 56.3% (27) 44.0% (11) 69.6% (16) 
40-54 20.8% (10) 32.0% (8) 8.7% (2) 
55+ 8.3% (4) 4.0% (1) 13.0% (3) 
Sex  
Male 70.8% (34) 64.0% (16) 78.3% (18) χ 2=1.179 
(p=0.278) Female 29.2% (14) 36.0% (9) 21.7% (5) 
Ethnicity 
White 70.8% (34) 64.0% (16) 78.3% (18) χ 2=1.179 
(p=0.278) Other 29.2% (14) 36.0% (9) 21.7% (5) 
Education 





35.4% (17) 32.0% (8) 39.1% (9) 
Any university 37.5% (18) 44.0% (11) 30.4% (7) 
City 
Kitchener-Waterloo 33.3% (16) 24.0% (6) 43.5% (10) χ 2=2.045 
(p=0.153) Toronto 66.7% (32) 76.0% (19) 56.5% (13) 
Notes:  
1 Differences in means were tested using independent t-tests, while differences in proportions were tested using chi-square tests. 
 
3.1.2 Nicotine dependence  
As shown in Table 3, dual users exhibited low to moderate nicotine dependence, with a mean 
FTCD score of 4.7 (SD=1.9). Nicotine dependence for tobacco cigarettes was greater than for e-
cigarettes, at 4.7 (SD=1.9) and 3.0 (SD=2.1), respectively, (t=4.864, p<0.001). This result was 
reflected in specific items of the FTCD: for instance, a greater proportion of dual users reported 
smoking tobacco cigarettes (95.8%) versus e-cigarettes (56.2%) within the first hour of waking.  
With respect to the NDSS measure, dual users exhibited moderate nicotine dependence, with a 
mean NDSS score of -0.48 (SD=0.76). Similarly, dual users exhibited greater nicotine 
dependence for tobacco cigarettes (NDSS -0.48 (SD=0.76)) as compared to e-cigarettes (E-
NDSS -1.22 (SD=0.79)), (t=6.657, p<0.001) (see Table 4). When asked about their perceived 
addiction to each product, almost all dual users indicated they were addicted to tobacco 
cigarettes (97.9%), but not to e-cigarettes (97.9%) (see Table 5). A McNemar-Bowker test was 
used to examine participants’ perceived addiction to each product. The omnibus test yielded a 
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significant difference: χ2=37.000, p<0.001. McNemar post-hoc analyses with Bonferroni 
adjustment indicated that a significantly greater proportion of participants perceived themselves 
as addicted to tobacco cigarettes as compared to e-cigarettes (very addicted vs. not at all 
addicted: χ2=8.000, p=0.024; very addicted vs. somewhat addicted: χ2=19.000, p=0.003; and 
somewhat addicted vs. not addicted: χ2=10.000, p=0.006).  
Table 3: Tobacco cigarette and e-cigarette dependence, as measured by the Fagerström 




% (n) or mean (SD) 
(E-) FTCD  
Overall 4.7 (1.9) 3.0 (2.1) 
0-2 (very low) 9.3% (4) 35.4% (17) 
3-4 (low) 34.9% (15) 34.2% (13) 
5 (moderate) 20.9% (9) 2.6% (1) 
6-7 (high) 27.9% (12) 18.4% (7) 
8-10 (very high) 7.0% (3) 0.0% (0) 
 
(E-) FTCD Q1: How soon after you wake up do 
you smoke (use) your first cigarette (e-
cigarette)? 
Within 5 min 31.3% (15) 6.3% (3) 
6-30 min 50.0% (24) 31.3% (15) 
31-60 min 14.6% (7) 18.8% (9) 
After 60 min 4.2% (2) 43.8% (21) 
 (E-) FTCD Q2: Do you find it difficult to 
refrain from smoking cigarettes (using e-
cigarettes) in places where it is forbidden?  
Yes 27.1% (13) 14.9% (7) 
No 72.9% (35) 85.1% (40) 
 
(E-) FTCD Q3: Which cigarette (e-cigarette) 
would you hate most to give up? 
First in the 
morning 
47.9% (23) 14.6% (6) 
All others 45.8% (22) 85.4% (35) 
 
(E-) FTCD Q4: How many cigarettes/day 
(times do you use e-cigarettes/day) do you 
smoke? 
10 or less 29.2% (14) 58.3% (28) 
11 to 20 47.9% (23) 22.9% (11) 
21 to 30 22.9% (11) 8.3% (4) 
31 or more 0.0% (0) 10.4% (5) 
 (E-) FTCD Q5: Do you smoke (use) more 
frequently during the first hours after waking 
than during the rest of the day? 
Yes 43.8% (21) 10.6% (5) 
No 56.3% (27) 89.4% (42) 
 (E-) FTCD Q6: Do you smoke (use) if you are 
so ill that you are in bed most of the day? 
Yes 47.9% (23) 63.0% (29) 
No 45.8% (22) 37.0% (17) 
Notes:  
Abbreviations: (E-) FTCD=Fagerström Test for Cigarette Dependence (E=version adapted for e-cigarettes). 
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Table 4: Tobacco cigarette and e-cigarette dependence, as measured by the Nicotine 
Dependence Syndrome Scale (NDSS), among dual users (n=48) 
 Tobacco cigarettes E-cigarettes 
Mean (SD) 
(E-) NDSS Overall - 0.48 (0.76) - 1.22 (0.79) 
 (E-) NDSS Drive - 0.19 (0.95) - 1.70 (1.18) 
 (E-) NDSS Stereotypy - 0.16 (0.78) 0.50 (0.98) 
 (E-) NDSS Continuity - 0.66 (1.04) - 1.05 (1.28) 
 (E-) NDSS Priority - 0.68 (0.58) - 0.55 (0.57) 
 (E-) NDSS Tolerance - 0.44 (0.97) - 0.63 (0.92) 
Notes:  
Abbreviations: (E-) NDSS=Nicotine Dependence Syndrome Scale (E=version adapted for e-cigarettes). 
 




 % (n) 
Do you consider yourself addicted to… ? 
Not at all 2.1% (1) 39.6% (19) 
Somewhat addicted 39.6% (19) 58.3% (28) 





3.2 Baseline patterns of use and perceptions among dual users 
3.2.1 Patterns of product use 
Patterns of use of tobacco cigarettes and e-cigarettes are presented in Table 6. With respect to 
smoking and vaping histories, participants had smoked and vaped daily for a mean of 17.4 and 
1.2 years, respectively. Dual users reported similar rates of daily consumption of tobacco 
cigarettes and of e-cigarettes (p=0.09). Specifically, dual users reported smoking a mean of 13.7 
tobacco cigarettes per day and using e-cigarettes 10.9 times (bouts) per day, with a mean of 9.2 
puffs per bout, with each bout lasting approximately 7.7 minutes. A greater proportion of dual 
users reported smoking tobacco cigarettes (97.9%) as compared to e-cigarettes (58.7%) within 
the first hour of waking (p<0.001). In addition, dual users reported a greater number of past quit 
attempts for tobacco cigarettes versus e-cigarettes (p=0.006), and a greater proportion of dual 
users reported intentions to quit smoking tobacco cigarettes (91.5%) versus e-cigarettes (56.5%) 
(p=0.001). Among those intending to quit smoking tobacco cigarettes (n=43), the vast majority 
(90.7%) indicated they would consider using e-cigarettes to help them quit, with fewer saying 










(p-value)1  % (n) or mean (SD) 
Duration of daily use [years] 17.4 (12.2) 1.2 (0.9) 
t=8.978 
(p<0.001) 
Times used (bouts) per day2 13.7 (5.6) 10.9 (11.4) 
t=1.744 
(p=0.09) 
Number of puffs per bout - 9.2 (9.4) - 
Duration of bout [minutes] - 7.7 (9.8) - 
Time to 
first use 
Within 5 min 31.3% (15) 8.7% (4) 
(p<0.001) 
6-30 min 52.1% (25) 23.9% (11) 
31-60 min 14.6% (7) 26.1% (12) 
After 60 min 2.1% (1) 41.3% (19) 





Within the next month 21.3% (10) 8.7% (4) 
(p=0.001) 
Within 6 months 25.5% (12) 13.0% (6) 
Sometime in the future, beyond 6 months 44.7% (21) 34.8% (16) 
Not intending to quit 8.5% (4) 43.5% (20) 
Notes:  
1 Differences in means were tested using paired samples t-tests, while differences in proportions were tested using McNemar tests.    
2 Times used per day=cigarettes per day, in the past 7 days, for tobacco cigarettes; “bouts” per day (defined as an instance of at least one puff) for 
e-cigarettes.  
 
3.2.2 Types of products used  
Brands of tobacco cigarettes smoked by dual users are included in Appendix E. Briefly, 
commonly smoked brands included Belmont (25.0%), Next (20.8%), and First Nations brands 
(10.4%). Characteristics of e-cigarette products used by dual users are summarized in Table 7. A 
large majority of dual users reported using tank systems (91.7%) and e-cigarettes with nicotine 
(93.8%). Common flavours included fruit (50.0%), tobacco (41.7%), and candy (41.7%). As 
shown in Table 8, among those who reported using e-cigarettes with nicotine (n=45), nicotine 
concentrations less than or equal to 14 mg/mL were most commonly used (71.1%). Dual users 




Table 7: Self-reported e-cigarette product characteristics used by dual users (n=48)  
Product characteristic %  (n) 
Product type* 
Disposable  6.3% (3) 
Re-useable 8.3% (4) 
Tank system 91.7% (44) 
Flavour(s)* 
Fruit 50.0% (24) 
Tobacco 41.7% (20) 
Candy 41.7% (20) 
Coffee/drinks/alcohol 20.8% (10) 
Menthol/mint 18.8% (9) 
Spice 10.4% (5) 
Other1 2.0% (1) 
Nicotine 
content 
Only e-cigarettes with nicotine 81.3% (39) 
Only e-cigarettes without nicotine 6.3% (3) 




* Proportions may not sum to 100% due to the fact that participants could select multiple response options. 
1 Other flavours included: neutral.  
 
Table 8: Self-reported product nicotine concentrations used, among those who reported 
using e-cigarettes with nicotine (n=45)  
Nicotine concentration % (n) 
1-8 mg/mL (0.1-0.8%) 40.0% (18) 
9-14 mg/mL (0.9-1.4%) 31.1% (14) 
15-20 mg/mL (1.5-2.0%) 8.9% (4) 
21-24 mg/mL (2.1-2.4%) 6.7% (3) 
25 mg/mL (2.5%) or more  4.4% (2) 





3.2.3 Places of product use 
As shown in Table 9, places where tobacco cigarettes and e-cigarettes were commonly used 
followed a similar pattern, with the greatest rates of use at home, followed by while walking on 
the street, in a vehicle, at school or work, etc. No significant differences were detected between 
rates of use of each product at each place.  
Table 9: Places of tobacco cigarette and e-cigarette use among dual users (n=48)  
Place 
Tobacco cigarettes E-cigarettes Test statistic 
(p-value)1 % (n) % (n) 
At home 93.8% (45) 100.0% (48) 
 (p=0.083) 
 Indoors 20.0% (9) 41.7% (20) 
 Outdoors 44.4% (20) 4.2% (2) 
 Both indoors and outdoors 35.6% (16) 54.2% (26) 
While walking on the street 77.1% (37) 68.8% (33)  (p=0.388) 
In a vehicle 64.6% (31) 64.6% (31)  (p=1.000) 
At school or work 60.4% (29) 54.2% (26) 
 (p=0.375) 
 Indoors 3.4% (1) 15.4% (4) 
 Outdoors 89.7% (26) 42.3% (11) 
 Both indoors and outdoors 6.9% (2) 42.3% (11) 
In a park or other outdoor venue 47.9% (23) 41.7% (20)  (p=0.629) 
At a restaurant or bar 20.8% (10) 35.4% (17) 
 (p=0.065) 
 Indoors 0.0% (0) 11.8% (2) 
 Outdoors 100.0% (10) 41.2% (7) 
 Both indoors and outdoors 0.0% (0) 47.1% (8) 
Other2 2.1% (1) 6.3% (3) (p=0.500) 
Notes:  
* Proportions may not sum to 100% due to the fact that participants could select multiple response options. 
1 Differences in proportions were tested using McNemar tests. 
2 Other places included: friend (1) for tobacco cigarettes; and on public transit (2), at a friend’s house (1), at a doctor’s office (2), at other offices 




3.2.4 Reasons for e-cigarette use 
Dual users were asked to indicate reasons for their initiation and current use of e-cigarettes. As 
shown in Table 10, when asked to select all relevant reasons from a list, the most commonly 
reported reasons for currently using e-cigarettes included: to smoke fewer tobacco cigarettes 
(79.2%), to help with cravings for tobacco cigarettes (70.8%), and because they are less harmful 
than smoking tobacco cigarettes (70.8%). Reasons for initiation of e-cigarette use followed a 
similar pattern. When asked to specify the most important reason for their current use of e-
cigarettes, the most commonly reported reasons included: to smoke fewer tobacco cigarettes 
(25.0%), to quit smoking tobacco cigarettes (20.8%), because they are less harmful than smoking 
tobacco cigarettes (14.6%), because they cost less money (12.5%), and because respondents 
liked their taste or flavour (10.4%) (see Table 11). Once again, the most important reasons for 
initiation of e-cigarette use were generally consistent with those for current use.   
Table 10: Potential reasons for initiation and current use of e-cigarettes reported by dual 




Current use of 
e-cigarettes 
% (n) % (n) 
To help me to smoke fewer cigarettes 75.0% (36) 79.2% (38) 
They are less harmful to me than smoking 72.9% (35) 70.8% (34) 
To help me with cravings for cigarettes 70.8% (34) 70.8% (34) 
I like their taste/flavour 62.5% (30) 66.7% (32) 
They are less harmful to others around me than smoking 56.3% (27) 60.4% (29) 
To help me quit smoking 58.3% (28) 54.2% (26) 
They cost less 50.0% (24) 47.9% (23) 
I can use them in places where smoking is not allowed 56.3% (27) 47.9% (23) 
They were recommended by a family/friend 41.7% (20) 41.7% (20) 
Due to boredom 29.2% (14) 27.1% (13) 
To reduce stress 29.2% (14) 20.8% (10) 
They were recommended by a health professional 6.3% (3) 6.3% (3) 
To control body weight 4.2% (2) 4.2% (2) 
Other1 6.3% (3) 2.1% (1) 
Don’t know 2.1% (1) 0.0% (0) 
* Proportions may not sum to 100% due to the fact that participants could select multiple response options 
1 Other places included: hobby (1), no cigarettes (1), to more easily smoke e-cigarettes inside during the winter (1) for initiation of e-cigarettes; 
and hobby (1) for current use of e-cigarettes.  
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Table 11: The most important reason for initiation and current use of e-cigarettes reported 




Current use of 
e-cigarettes 
% (n) % (n) 
To help me to smoke fewer cigarettes 18.8% (9) 25.0% (12) 
To help me quit smoking 27.1% (13) 20.8% (10) 
They are less harmful to me than smoking 18.8% (9) 14.6% (7) 
They cost less 12.5% (6) 12.5% (6) 
I like their taste/flavour 4.2% (2) 10.4% (5) 
I can use them in places where smoking is not allowed 6.3% (3) 8.3% (4) 
To help me with cravings for cigarettes 2.1% (1) 6.3% (3) 
They are less harmful to others around me than smoking 4.2% (2) 2.1% (1) 
They were recommended by a health professional 0.0% (0) 0.0% (0) 
They were recommended by a family/friend 0.0% (0) 0.0% (0) 
Due to boredom 4.2% (2) 0.0% (0) 
To reduce stress 0.0% (0) 0.0% (0) 
To control body weight 2.1% (1) 0.0% (0) 





3.2.5 Dual use characteristics  
All dual users in the study sample reported that they began smoking tobacco cigarettes before 
using e-cigarettes. As shown in Table 12, when asked which behaviour they identified with more 
– smoking tobacco cigarettes or using e-cigarettes – a majority (60.4%) indicated they identified 
themselves as a tobacco cigarette smoker, while 37.5% identified themselves as both a tobacco 
cigarette smoker and an e-cigarette user. From the time they began vaping daily, 37.5% indicated 
they vape about the same amount, while approximately one-third indicated either vaping more 
(33.3%) or less (29.2%). Further, from the time they began vaping daily, a majority (75.0%) of 
respondents reported smoking fewer tobacco cigarettes. Finally, the vast majority (95.8%) of 
dual users supported the notion that e-cigarettes would make it easier to quit smoking tobacco 
cigarettes.  
Table 12: Dual use characteristics among dual users (n=48)  
Characteristic % (n) 
Which behaviour do you identify yourself with more – smoking or vaping?    
 I identify myself as a smoker 60.4% (29) 
 I identify myself as a vaper 2.1% (1) 
 I identify myself as both a smoker and a vaper 37.5% (18) 
From the time you started vaping daily, have you changed the amount you use per day?  
 I use less 29.2% (14) 
 I use about the same amount 37.5% (18) 
 I use more 33.3% (16) 
From the time you started vaping daily, has the strength of nicotine you use most changed?  
 Strength of nicotine has decreased 25.0% (12) 
 Strength of nicotine has not changed 64.6% (31) 
 Strength of nicotine has increased 10.4% (5) 
From the time you started vaping daily, has the number of tobacco cigarettes you smoke changed?  
 Number of tobacco cigarettes has decreased 75.0% (36) 
 Number of tobacco cigarettes has not changed 20.8% (10) 





3.2.6 Perceptions of e-cigarettes  
As shown in Table 13, compared to tobacco cigarettes, e-cigarettes were considered more 
socially acceptable (64.6%), less satisfying (66.7%), less pleasurable (63.8%), less harmful 
(87.2%), and less expensive (81.3%).  
Table 13: Perceptions of e-cigarettes among dual users (n=48)  
Perception % (n) 
Acceptability: Compared to smoking regular tobacco cigarettes, using e-cigarettes is …  
 … less socially acceptable 12.5% (6) 
 … equally as socially acceptable 22.9% (11) 
 … more socially acceptable 64.6% (31) 
Satisfaction: Compared to smoking regular tobacco cigarettes, using e-cigarettes is …  
 … less satisfying  66.7% (32) 
 … equally as satisfying 22.9% (11) 
 … more satisfying 10.4% (5) 
Pleasure: Compared to smoking regular tobacco cigarettes, using e-cigarettes is …  
 … less pleasurable  63.8% (30) 
 … equally as pleasurable 17.0% (8) 
 … more pleasurable 19.2% (9) 
Harm: Compared to smoking regular tobacco cigarettes, using e-cigarettes is …  
 … less harmful  87.2% (41) 
 … equally as harmful  12.8% (6) 
 … more harmful 0.0% (0) 
Cost: Compared to smoking regular tobacco cigarettes, using e-cigarettes is …  
 … less expensive 81.3% (39) 
 … equally as expensive 14.6% (7) 





3.3 Randomization check 
To test whether randomization of participants was successful, several baseline measures were 
examined by assigned condition order (Group A, Group B). As shown in Table 14, participants 
in each group did not differ on any of the measures.  










(p-value)3 mean (SD) 




13.7 (5.6) 13.9 (6.1) 13.5 (5.1) 
t=0.218 
(p=0.828) 
E-cigarettes  11.1 (11.4) 11.5 (12.1) 10.7 (10.8) 
t=0.237 
(p=0.814) 
Urinary cotinine [ng/mL] 1329.4 (783.6) 1173.6 (773.1) 1498.8 (776.0) 
t=-1.453 
(p=0.153) 
Exhaled carbon monoxide [ppm] 17.4 (11.1) 15.6 (9.2) 19.5 (12.8) 
t=-1.206 
(p=0.234) 
Urinary 1-HOP2  
[pg/mg creatinine] 
3076.6 (2790.9) 3732.3 (3232.2) 2363.8 (2055.0) 
t=1.764 
(p=0.085) 
Urinary NNAL2  
[pg/mg creatinine] 




1 Times used per day=cigarettes per day, in the past 7 days, for tobacco cigarettes; ‘bouts’ per day (defined as an instance of at least one puff) for 
e-cigarettes.  
2 Arithmetic mean. 
3 Differences in means were tested using independent t-tests. 
 
3.4 Patterns of product use across study conditions 
Participants’ patterns of use of tobacco cigarettes and e-cigarettes across study conditions are 
presented in Table 15 (for a detailed daily summary of patterns of product use, see Appendix F). 
Patterns of use of ‘permitted’ tobacco cigarettes and e-cigarettes are shown against a white 
background, while patterns of use of ‘not permitted’ tobacco cigarettes and e-cigarettes are 
shown against a grey background in the table below. On average, participants reported using e-
cigarettes 2.7 times per day in the condition of Exclusive use of tobacco cigarettes and reported 
smoking 1.9 tobacco cigarettes per day in the condition of Exclusive use of e-cigarettes. In the 
condition of No product use, participants reported smoking 2.8 tobacco cigarettes per day and 


















% (n) or mean (SD) 
Tobacco 
cigarette 
Times used (bouts) per day1 13.7 (5.6) 12.3 (6.2) 1.9 (1.8)2 2.8 (1.7)2 
Time to first 
use 
Within 5 min 31.3% 36.4% 15.4% 12.4% 
6-30 min 52.1% 36.7% 5.1% 12.4% 
31-60 min 14.6% 16.3% 10.3% 5.3% 
After 60 min 2.1% 10.5% 69.2% 69.9% 
Mean (SD)3 0.9 (0.7) 1.0 (0.8) 2.6 (0.6) 2.4 (1.0) 
Time since last use [hours] 0.8 (0.6) 4.8 (13.6) 63.7 (37.8) 84.0 (92.5) 
      
E-
cigarette 
Times used (bouts) per day1 11.1 (11.4) 2.7 (1.9)2 17.4 (16.0) 2.7 (2.1)2 
Number of puffs per bout 9.2 (9.4) 4.5 (5.1)2 7.9 (4.8) 3.0 (1.5)2 
Duration of bout [minutes] 7.7 (9.8) 2.1 (1.7)2 6.7 (5.4) 2.7 (3.7)2 
Time to first 
use 
Within 5 min 8.7% 0.0% 27.7% 6.8% 
6-30 min 23.49% 21.7% 37.8% 8.5% 
31-60 min 26.1% 4.3% 20.6% 8.5% 
After 60 min 41.3% 73.9% 13.8% 76.3% 
Mean (SD)3 2.0 (1.0) 2.8 (0.6) 1.1 (0.8) 2.5 (0.9) 
Time since last use [hours] 5.0 (7.0) 78.2 (38.1) 1.5 (2.6) 114.6 (90.6) 
Notes:  
Grey-shaded areas indicate use of ‘not permited’ products, for each study condition. Measures of patterns of use for ‘not permitted’ products were 
obtained through self-reported responses collected from participants’ daily diaries, while those for permitted products (white areas) were obtained 
through self-reported responses collected from scheduled laboratory visits.  
1 Times used per day=cigarettes per day, in the past 7 days, for tobacco cigarettes; ‘bouts’ per day (defined as an instance of at least one puff) for 
e-cigarettes.  
2 Summary statistics presented for subset of participants who reported using a given product.  





3.5 Exposure to nicotine and compensatory behaviour 
3.5.1 Patterns of use of tobacco cigarettes  
To examine whether participants compensated for nicotine by changing their patterns of tobacco 
cigarette use, several patterns of use were compared across conditions of Dual use and of 
Exclusive use of tobacco cigarettes (see Table 16).  
Table 16: Patterns of use of tobacco cigarettes across conditions of Dual use and Exclusive 
use of tobacco cigarettes (n=48) 






Exclusive use of 
tobacco cigarettes 
Mean (95% CI) 
Times used per day1 13.7 (12.1, 15.3) 12.3 (10.5, 14.0) 
F=7.888 
(p=0.008) 




Abbreviations: CI=confidence interval.  
1 Times used per day=cigarettes per day, in the past 7 days, for tobacco cigarettes.  
2 Mean time to first use calculated for recoded variable as a continuous measure ranging from 0 (within 5 minutes) to 3 (after 60 minutes). 
 
 
A repeated measures model was conducted to examine daily tobacco cigarette consumption 
across study conditions, with assigned condition order (Group A, Group B) and baseline nicotine 
dependence (FTCD score) as covariates, and an unstructured variance-covariance structure. The 
repeated measures model yielded a significant effect of condition (F=7.888, p=0.008): daily 
tobacco cigarette consumption was significantly higher in the condition of Dual use compared to 
the condition of Exclusive use of tobacco cigarettes (mean difference=1.4, 95% CI: 0.4 to 2.4, 
p=0.008). Baseline nicotine dependence was also significantly associated with daily tobacco 
cigarette consumption (F=22.941, p<0.001), with higher levels of baseline nicotine dependence 
associated with greater daily consumption of tobacco cigarettes (β=1.8, 95% CI: 1.0 to 2.5, 
p<0.001). No significant effect was detected for the interaction of condition and assigned 
condition order (F=2.999, p=0.091). 
A repeated measures model was also conducted to examine time to first tobacco cigarette across 
study conditions, with assigned condition order (Group A, Group B) and baseline nicotine 
dependence (FTCD score) as covariates, and an unstructured variance-covariance structure. The 
repeated measures model indicated that there were no statistically significant differences in time 
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to first tobacco cigarette across study conditions (F=1.602, p=0.213). However, baseline nicotine 
dependence was significantly associated with time to first tobacco cigarette (F=50.339, p<0.001), 
with higher levels of baseline nicotine dependence associated with a lower value for time to first 
tobacco cigarette (β= -0.3, 95% CI: -0.3 to -0.2, p<0.001).  
A significant interaction between assigned condition order and condition (F=5.291, p=0.027) 
was observed. Stratified analyses indicated that the main (null) effect of condition (described 
above) held for Group B participants (F=0.609, p=0.444). In addition, baseline nicotine 
dependence was significantly associated with time to first tobacco cigarette (F=16.142, p=0.001), 
with higher levels of baseline nicotine dependence associated with a lower value for time to first 
tobacco cigarette (β= -0.2, 95% CI: -0.3 to -0.1, p=0.001). 
In contrast, a significant effect of condition was detected for Group A participants (F=5.072, 
p=0.036): time to first tobacco cigarette was significantly lower in the condition of Dual use as 
compared to the condition of Exclusive use of tobacco cigarettes (mean difference=-0.3, 95% CI: 
-0.6 to -0.1, p=0.036). In addition, baseline nicotine dependence was significantly associated 
with time to first tobacco cigarette (F=31.584, p<0.001), with higher levels of baseline nicotine 
dependence associated with a lower value for time to first tobacco cigarette (β= -0.3, 95% CI: -





3.5.2 Patterns of use of e-cigarettes  
To examine whether participants compensated for nicotine by changing their patterns of e-
cigarette use, several measures of patterns of use were compared across conditions of Dual use 
and of Exclusive use of e-cigarettes (see Table 17). 
Table 17: Patterns of use of e-cigarettes across conditions of Dual use and Exclusive use of 
e-cigarettes (n=48) 





Exclusive use of e-
cigarettes 
Mean (95% CI) 
Times used (bouts) per day1 11.1 (7.8, 14.5) 17.4 (12.8, 22.1) 
F=10.113 
(p=0.003) 
Number of puffs per bout 9.2 (6.5, 12.0) 7.9 (6.5, 9.4) 
F=1.447 
(p=0.236) 
Duration of bout [minutes] 7.7 (4.8, 10.6) 6.7 (5.1, 8.3) 
F=0.782 
(p=0.382) 




Abbreviations: CI=confidence interval.  
1 Times used per day=‘bouts’ per day (defined as an instance of at least one puff) for e-cigarettes.  
2 Mean time to first use calculated for recoded variable as a continuous measure ranging from 0 (within 5 minutes) to 3 (after 60 minutes). 
 
A repeated measures model was conducted to examine daily e-cigarette consumption across 
study conditions, with assigned condition order (Group A, Group B) and baseline nicotine 
dependence (FTCD score) as covariates, and an unstructured variance-covariance structure. The 
repeated measures model yielded a significant effect of condition (F=10.113, p=0.003): daily e-
cigarette consumption was significantly higher in the condition of Exclusive use of e-cigarettes 
compared to the condition of Dual use (mean difference=6.2, 95% CI: 2.3 to 10.1, p=0.003). No 
significant effect was detected for the interaction of condition and assigned condition order 
(F=0.010, p=0.921). 
A repeated measures model was conducted to examine number of puffs per daily e-cigarette bout 
across study conditions, with assigned condition order (Group A, Group B) and baseline nicotine 
dependence (FTCD score) as covariates, and an unstructured variance-covariance structure. The 
model indicated that there were no significant differences in the number of puffs per daily e-
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cigarette bout across study conditions (F=1.447, p=0.236), and no significant effect was detected 
for the interaction of condition and assigned condition order (F=0.746, p=0.393). 
A repeated measures model was conducted to examine the duration of daily e-cigarette bout 
across study conditions, with assigned condition order (Group A, Group B) and baseline nicotine 
dependence (FTCD score) as covariates, and an unstructured variance-covariance structure. The 
model indicated that there were no significant differences in the duration of daily e-cigarette bout 
across study conditions (F=0.782, p=0.382), and no significant effect was detected for the 
interaction of condition and assigned condition order (F=0.826, p=0.369). 
A repeated measures model was also conducted to examine time to first e-cigarette across study 
conditions, with assigned condition order (Group A, Group B) and baseline nicotine dependence 
(FTCD score) as covariates, and an unstructured variance-covariance structure. The repeated 
measures model yielded a significant effect of condition (F=24.004, p<0.001): time to first e-
cigarette was significantly lower in the condition of Exclusive use of e-cigarettes compared to the 
condition of Dual use (mean difference= -0.9, 95% CI: -1.2 to -0.5, p<0.001). In addition, 
baseline nicotine dependence was significantly associated with time to first e-cigarette (F=5.291, 
p=0.027), with higher levels of baseline nicotine dependence associated with a lower value for 
time to first e-cigarette (β= -0.1, 95% CI: -0.2 to -0.01, p=0.027). No significant effect was 




3.5.3 Urinary cotinine 
Levels of creatinine-corrected urinary cotinine were tested across study conditions to examine 
whether participants compensated for nicotine by smoking tobacco cigarettes and/or using e-
cigarettes – see Figure 3 (see Appendix G for corresponding table).  
Figure 3: Urinary cotinine1 across study conditions (n=48)  
 
Notes:  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
A repeated measures model was conducted to examine urinary cotinine across study conditions, 
with assigned condition order (Group A, Group B), baseline nicotine dependence (FTCD score), 
e-cigarette product type (tank system, other), and e-cigarette nicotine content (nicotine present, 
nicotine absent) as covariates, and an unstructured variance-covariance structure. Measures of 
urinary cotinine were adjusted for creatinine and log-transformed for analyses to ensure 
approximate normality; geometric means in original units are presented above.  
The repeated measures model yielded a significant effect of condition (F=5.788, p=0.002): 
urinary cotinine was significantly higher in the condition of Dual use compared to the conditions 
of Exclusive use of e-cigarettes (mean difference=1.6, 95% CI: 1.1 to 2.4, p=0.027), and of No 
product use (mean difference=2.3, 95% CI: 1.3 to 3.9, p=0.004). In addition, urinary cotinine 
was significantly higher in the condition of Exclusive use of tobacco cigarettes compared to the 
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conditions of Exclusive use of e-cigarettes (mean difference=1.7, 95% CI: 1.2 to 2.5, p=0.003), 
and of No product use (mean difference=2.4, 95% CI: 1.5 to 4.0, p=0.001). Baseline nicotine 
dependence was also significantly associated with urinary cotinine (F=8.366, p=0.006), with 
higher levels of baseline nicotine dependence associated with higher levels of urinary cotinine 
(β=1.3, 95% CI: 1.08 to 1.5, p=0.006). No significant effect was detected for the interaction of 




3.6 Exposure to tobacco smoke constituents 
Several biomarkers of exposure were examined to determine whether participants’ exposure to 
tobacco smoke constituents changed following product switching.  
3.6.1 Exhaled carbon monoxide 
Measures of exhaled carbon monoxide are presented across study conditions in Figure 4 (see 
Appendix G for corresponding table).  
Figure 4: Exhaled carbon monoxide across study conditions (n=48) 
 
Notes:  
Abbreviations: ppm=parts per million.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
A repeated measures model was conducted to examine exhaled carbon monoxide across study 
conditions, with assigned condition order (Group A, Group B), baseline nicotine dependence 
(FTCD score), e-cigarette product type (tank system, other), and e-cigarette nicotine content 
(nicotine present, nicotine absent) as covariates, and an unstructured variance-covariance 
structure. The repeated measures model yielded a significant effect of condition (F=10.115, 
p<0.001): exhaled carbon monoxide was significantly higher in the condition of Exclusive use of 
tobacco cigarettes compared to the conditions of Dual use (mean difference=3.9, 95% CI: 0.4 to 
7.3, p=0.029), of Exclusive use of e-cigarettes (mean difference=10.7, 95% CI: 6.4 to 15.0, 
p<0.001), and of No product use (mean difference=8.4, 95% CI: 4.8 to 12.0, p<0.001). In 
addition, carbon monoxide was significantly higher in the condition of Dual use compared to the 
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conditions of Exclusive use of e-cigarettes (mean difference=6.9, 95% CI: 3.8 to 9.9, p<0.001), 
and of No product use (mean difference=4.6, 95% CI: 1.5 to 7.6, p=0.004).  
A significant interaction between assigned condition order and condition (F=3.704, p=0.019) 
was observed. Stratified analyses indicated that the main effect of condition (described above) 
generally held for participants randomized to both condition orders (Group A: F=9.383, p<0.001; 
Group B: F=3.788, p=0.028) (see Appendix H for detailed results).  
3.6.2 Urinary 1-hydroxypyrene  
Measures of creatinine-corrected urinary 1-hydroxypyrene (1-HOP) are presented across study 
conditions in Figure 5 (see Appendix G for corresponding table).  




Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
A repeated measures model was conducted to examine urinary 1-HOP across study conditions, 
with assigned condition order (Group A, Group B), baseline nicotine dependence (FTCD score), 
e-cigarette product type (tank system, other), and e-cigarette nicotine content (nicotine present, 
nicotine absent) as covariates, and an unstructured variance-covariance structure. Measures of 
urinary 1-HOP were adjusted for creatinine and log-transformed for analyses to ensure 
approximate normality; geometric means in original units are presented above.  
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The repeated measures model yielded a significant effect of condition (F=4.766, p=0.006): 
urinary 1-HOP was significantly higher in the condition of Exclusive use of tobacco cigarettes 
compared to the conditions of Dual use (mean difference=1.3, 95% CI: 1.0 to 1.6, p=0.048), of 
Exclusive use of e-cigarettes (mean difference=1.8, 95% CI: 1.3 to 2.5, p=0.001), and of No 
product use (mean difference=1.4, 95% CI: 1.1 to 1.8, p=0.009). In addition, urinary 1-HOP was 
significantly higher in the condition of Dual use compared to the conditions of Exclusive use of 
e-cigarettes (mean difference=1.4, 95% CI: 1.0 to 1.9, p=0.025). Baseline nicotine dependence 
was also significantly associated with urinary 1-HOP (F=4.377, p=0.043), with higher levels of 
baseline nicotine dependence associated with higher levels of urinary 1-HOP (β=1.1, 95% CI: 
1.0 to 1.3, p=0.043). No significant effect was detected for the interaction of condition and 
assigned condition order (F=1.883, p=0.148). 
3.6.3 Urinary NNAL  
Measures of creatinine-corrected urinary NNAL are presented across study conditions in  
Figure 6 (see Appendix G for corresponding table).  
Figure 6: Urinary NNAL1 across study conditions (n=48) 
 
Notes:  
Abbreviations: NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  




A repeated measures model was conducted to examine urinary NNAL across study conditions, 
with assigned condition order (Group A, Group B), baseline nicotine dependence (FTCD score), 
e-cigarette product type (tank system, other), and e-cigarette nicotine content (nicotine present, 
nicotine absent) as covariates, and an unstructured variance-covariance structure. Measures of 
urinary NNAL were adjusted for creatinine and log-transformed for analyses to ensure 
approximate normality; geometric means in original units are presented above.  
The repeated measures model yielded a significant effect of condition (F=4.593, p=0.007): 
urinary NNAL was significantly higher in the condition of Exclusive use of tobacco cigarettes 
compared to the conditions of Exclusive use of e-cigarettes (mean difference=1.5, 95% CI: 1.2 to 
2.0, p=0.002), and of No product use (mean difference=1.6, 95% CI: 1.2 to 2.0, p=0.001). In 
addition, urinary NNAL was significantly higher in the condition of Dual use compared to the 
conditions of Exclusive use of e-cigarettes (mean difference=1.4, 95% CI: 1.1 to 1.9, p=0.017), 
and of No product use (mean difference=1.5, 95% CI: 1.1 to 2.0, p=0.016). Baseline nicotine 
dependence was also significantly associated with urinary NNAL (F=13.116, p=0.001), with 
higher levels of baseline nicotine dependence associated with higher levels of urinary NNAL 
(β=1.4, 95% CI: 1.1 to 1.6, p=0.001). No significant effect was detected for the interaction of 




3.6.4 Summary  
An overview of exposure to tobacco smoke constituents across study conditions is presented in 
Table 18. Compared to the condition of Dual use, mean levels of all biomarkers of exposure 
among participants declined significantly in the conditions of Exclusive use of e-cigarettes and of 
No product use. In contrast, mean levels of exhaled carbon monoxide and urinary 1-HOP were 
significantly greater in the condition of Exclusive use of tobacco cigarettes compared to Dual 
use; although mean levels of urinary NNAL showed a similar trend, this difference was not 
statistically significant.  









No product use 
Mean (% change from Dual use) 
Exhaled carbon monoxide1  
[ppm] 
17.4 21.1 (+21%)*  10.3 (-41%)* 12.9 (-26%)* 
Urinary 1-HOP2 
[pg/mg creatinine] 
203.3 249.2 (+23%)* 141.1 (-31%)* 175.1 (-14%) 
Urinary NNAL2  
[pg/mg creatinine]  
30.3 32.7 (+8%)  21.2 (-30%)* 19.8 (-35%)* 
Notes:  
Abbreviations: CI=confidence interval; 1-HOP=1-hydroxypyrene; NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Asterisks (*) denote significant differences in biomarker levels compared to the condition of Dual use, p<0.05.  
1 Arithmetic mean. 





3.6.5 Sensitivity analyses  
Sensitivity analyses were conducted in an attempt to examine the effect of non-compliance with 
respect to smoking tobacco cigarettes in the study conditions in which these products were not 
permitted. The analyses were conducted using two approaches: 1) excluding participants with 
exhaled carbon monoxide levels greater than 5 ppm in the condition of No product use (n=37); 
and 2) excluding participants who self-reported smoking tobacco cigarettes in the condition of 
No product use (n=28) (see Appendix I for results). Overall, these analyses yielded a pattern of 
results similar to those outlined above: the exclusion of non-compliant participants resulted in 
greater differences in biomarkers of exposure across study conditions, despite the use of smaller 
samples. However, no significant differences in levels of urinary 1-hydroxypyrene were detected 
across study conditions, likely due to limited statistical power.  
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3.7 Nicotine withdrawal 
To examine changes in nicotine withdrawal experienced by dual users following product 
switching, measures of urges to smoke tobacco cigarettes were examined across study conditions 
using the brief version of the Questionnaire of Smoking Urges (QSU). Participants’ urges to use 
e-cigarettes were examined using an adapted version of the QSU (E-QSU), in which the words 
“smoking cigarettes” were replaced with “use e-cigarettes”. The (E-) QSU yields an overall 
measure of nicotine withdrawal, as well as a Factor 1 score and a Factor 2 score, measuring 
participants’ expectations of positive outcomes from using a particular product, and their 
expectations of relief from the negative effect of using a particular product, respectively.  
Measures of cravings for both tobacco cigarettes and e-cigarettes are presented by study 
condition in Figure 7 (see Appendix G for corresponding table). Although measures of nicotine 
withdrawal for tobacco cigarettes and e-cigarettes were similar in each of the conditions of Dual 
use and of Exclusive use of tobacco cigarettes, participants reported significantly greater 
cravings for tobacco cigarettes as compared to e-cigarettes in study conditions of Exclusive use 
of e-cigarettes (t=4.287, p<0.001) and of No product use (t=4.470, p<0.001).   
Figure 7: Measures of nicotine withdrawal for tobacco cigarettes and e-cigarettes across 




Abbreviations: QSU=Questionnaire of Smoking Urges; E-=adapted for e-cigarettes. 
Asterisks (*) indicate results that are significantly different from one another within a study condition, p<0.05.   
Conditions with different superscript letters were significantly different from one another, p<0.05.  





3.7.1 Urges to smoke tobacco cigarettes  
A repeated measures model was conducted to examine QSU scores across study conditions, with 
assigned condition order (Group A, Group B), and baseline nicotine dependence (FTCD score) 
as covariates, and an unstructured variance-covariance structure. A repeated measures model 
examining overall QSU scores yielded a significant effect of condition (F=6.725, p=0.001): 
participants reported significantly greater urges to smoke tobacco cigarettes in the condition of 
Exclusive use of e-cigarettes as compared to conditions of Dual use (mean difference=0.8, 95% 
CI: 0.3 to 1.2, p=0.002), and of Exclusive use of tobacco cigarettes (mean difference=1.0, 95% 
CI: 0.5 to 1.5, p<0.001). In addition, participants reported significantly greater urges to smoke 
tobacco cigarettes in the condition of No product use as compared to conditions of Dual use 
(mean difference=0.6, 95% CI: 0.2 to 1.1, p=0.009), and of Exclusive use of tobacco cigarettes 
(mean difference=0.9, 95% CI: 0.4 to 1.4, p=0.001) (see Figure 7). No significant effect was 
detected for the interaction of condition and assigned condition order (F=0.750, p=0.529). 
A repeated measures model examining scores for the QSU Factor 1, which reflect expectations 
of positive outcomes from smoking tobacco cigarettes (e.g., a cigarette would taste good right 
now), were also examined across study conditions (see Appendix J). QSU Factor 1 scores 
showed a similar pattern of results across study conditions, with two exceptions: first, 
participants’ expectations of positive outcomes from smoking tobacco cigarettes were not 
significantly greater in the condition of No product use as compared to the condition of Dual use; 
and second, participants reported significantly greater expectations of positive outcomes from 
smoking tobacco cigarettes in the condition of Dual use as compared to the condition of 
Exclusive use of tobacco cigarettes.  
A repeated measures model examining scores for the QSU Factor 2, which reflect expectations 
of relief from the negative effect of smoking tobacco cigarettes (e.g., I would do almost anything 
to be able to smoke a cigarette), were also examined across study conditions. QSU Factor 2 
scores showed a similar pattern of results across study conditions (see Appendix J).  
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3.7.2 Urges to use e-cigarettes  
A repeated measures models were conducted to examine E-QSU scores across study conditions, 
with assigned condition order (Group A, Group B), and baseline nicotine dependence (FTCD 
score) as covariates, and an unstructured variance-covariance structure. As shown in Figure 7, 
there were no statistically significant differences in urges to use e-cigarettes across study 
conditions for the overall E-QSU measure (F=0.879, p=0.460). Repeated measures models 
examining scores for the E-QSU Factor 1 and Factor 2 scores similarly showed no significant 




3.8 Self-efficacy  
To examine changes in self-efficacy experienced by dual users following product switching, 
measures of participants’ confidence in their ability to abstain from tobacco cigarettes were 
examined across study conditions using the Smoking Self-Efficacy Questionnaire (SEQ). 
Participants’ self-efficacy to abstain from e-cigarettes was examined using an adapted version of 
the SEQ (E-SEQ), in which the words “smoking cigarettes” were replaced with “use e-
cigarettes”. The (E-) SEQ yields an overall measure of self-efficacy, as well as a Factor 1 score 
and a Factor 2 score, measuring participants’ confidence in their ability to abstain from using a 
particular product when facing internal stimuli and external stimuli, respectively.  
Measures of self-efficacy for abstaining from tobacco cigarettes and e-cigarettes are presented by 
study condition in Figure 8 (see Appendix G for corresponding table). Measures of self-efficacy 
for e-cigarettes were consistently greater than those for tobacco cigarettes in each study 
condition, although these differences did not reach statistical significance.  
Figure 8: Measures of self-efficacy for abstaining from tobacco cigarettes and e-cigarettes 
across study conditions (n=48) 
 
Notes:  
Abbreviations: SEQ=Self-Efficacy Questionnaire; E-=adapted for e-cigarettes. 
Asterisks (*) indicate results that are significantly different from one another within each study condition, p<0.05.   
Conditions with different superscript letters were significantly different from one another, p<0.05.  





3.8.1 Self-efficacy for abstaining from tobacco cigarettes  
A repeated measures models were conducted to examine SEQ scores across study conditions, 
with assigned condition order (Group A, Group B), and baseline nicotine dependence (FTCD 
score) as covariates, and an unstructured variance-covariance structure. A repeated measures 
model examining SEQ scores yielded a significant effect of condition (F=3.419, p=0.026): 
participants reported significantly greater self-efficacy for abstaining from tobacco cigarettes in 
the condition of No product use as compared to conditions of Exclusive use of tobacco cigarettes 
(mean difference=4.2, 95% CI: 1.3 to 7.1, p=0.006), and of Exclusive use of e-cigarettes (mean 
difference=5.0, 95% CI: 1.5 to 8.5, p=0.006) (see Figure 8).  
A significant interaction between assigned condition order and condition (F=3.222, p=0.032) 
was observed. Stratified analyses indicated that the main effect of condition (described above) 
held for Group A participants (F=6.466, p=0.003): Group A participants reported significantly 
greater self-efficacy for abstaining from tobacco cigarettes in the condition of No product use as 
compared to conditions of Exclusive use of tobacco cigarettes (mean difference=7.4, 95% CI: 3.7 
to 11.0, p<0.001), and of Exclusive use of e-cigarettes (mean difference=5.6, 95% CI: 1.2 to 
10.0, p=0.015) (see Figure 9). In contrast, there were no significant differences in self-efficacy 
for abstaining from tobacco cigarettes among Group B participants across study conditions 








Abbreviations: SEQ=Self-Efficacy Questionnaire. 
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
Repeated measures models examining scores for the SEQ Factor 1 and Factor 2, which reflect 
participants’ confidence in their ability to abstain from smoking when facing internal stimuli 
(e.g., feeling depressed), and external stimuli (e.g., when having a drink with friends), 
respectively, were also examined across study conditions (see Appendix K). SEQ Factor 2 scores 
showed a similar pattern of results across study conditions, while SEQ Factor 1 scores showed 
no significant differences.  
3.8.2 Self-efficacy for abstaining from e-cigarettes  
A repeated measures model was conducted to examine E-SEQ scores across study conditions, 
with assigned condition order (Group A, Group B), and baseline nicotine dependence (FTCD 
score) as covariates, and an unstructured variance-covariance structure. As shown in Figure 8, 
there were no statistically significant differences in participants’ confidence in their ability to 
abstain from vaping across study conditions (F=1.867, p=0.150). Repeated measures models 
examining scores for the E-SEQ Factor 1 and Factor 2 scores similarly showed no significant 




3.9 Perceived health and subjective effects  
3.9.1 Perceived respiratory health  
To examine changes in the perceived health of dual users following product switching, five 
measures of perceived health were examined across study conditions: experiencing shortness of 
breath, frequency of experiencing cough, frequency of experiencing cough with phlegm, sounds 
emanating from the chest, and an overall description of lung function. Each outcome was 
modeled as a binary variable (0=‘worse than usual health’ or ‘no difference in health’; 1=‘better 
than usual health’). Repeated measures models were conducted to examine each domain of 
respiratory health across study conditions, with assigned condition order (Group A, Group B) 




3.9.1.1 Overall lung function 
Participants were asked to indicate whether they perceived a change in their overall lung function 
in each study condition. Figure 10 shows the proportion of dual users reporting better perceived 
lung function following each study condition (see Appendix G for corresponding table). In a 
repeated measures model examining perceived lung function, a significant effect of condition 
was observed (F=6.778, p<0.001): a greater proportion of participants reported better lung 
function in the condition of Exclusive use of e-cigarettes as compared to conditions of Dual use 
(mean difference=0.3, 95% CI: 0.2 to 0.5, p<0.001), and of Exclusive use of tobacco cigarettes 
(mean difference=0.4, 95% CI: 0.2 to 0.5, p<0.001). In addition, a greater proportion of 
participants reported better lung function in the condition of No product use as compared to 
conditions of Dual use (mean difference=0.3, 95% CI: 0.2 to 0.5, p<0.001), and of Exclusive use 
of tobacco cigarettes (mean difference=0.4, 95% CI: 0.2 to 0.5, p<0.001). No significant effect 
was detected for the interaction of condition and assigned condition order (F=0.762, p=0.517). 









3.9.1.2 Other respiratory health domains 
Participants reported similar improvements in experiencing shortness of breath, cough, cough 
with phlegm, or sounds emanating from the chest, across study conditions, as shown in Figure 11 
(see Appendix G for corresponding table).  
Figure 11: Proportion of participants reporting better perceived respiratory health across 
study conditions (n=48) 
 
Notes:  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
 
In a repeated measures model examining change in experiencing shortness of breath, a 
significant effect of condition was observed (F=6.952, p<0.001): a significantly greater 
proportion of participants reported improvement in experiencing shortness of breath in the 
condition of Exclusive use of e-cigarettes as compared to conditions of Dual use (mean 
difference=0.4, 95% CI: 0.2 to 0.5, p<0.001), and of Exclusive use of tobacco cigarettes (mean 
difference=0.4, 95% CI: 0.2 to 0.5, p<0.001). In addition, a significantly greater proportion of 
participants reported improvement in experiencing shortness of breath in the condition of No 
product use as compared to conditions of Dual use (mean difference=0.3, 95% CI: 0.1 to 0.4, 
p<0.001), and of Exclusive use of tobacco cigarettes (mean difference=0.3, 95% CI: 0.1 to 0.4, 
p<0.001). No significant effect was detected for the interaction of condition and assigned 
condition order (F=1.208, p=0.308). 
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In a repeated measures model examining change in frequency of experiencing cough, a 
significant effect of condition was observed (F=6.816, p<0.001): a significantly greater 
proportion of participants reported improvement in experiencing cough in the condition of 
Exclusive use of e-cigarettes as compared to conditions of Dual use (mean difference=0.4, 95% 
CI: 0.2 to 0.5, p<0.001), and of Exclusive use of tobacco cigarettes (mean difference=0.4, 95% 
CI: 0.2 to 0.5, p<0.001). In addition, a significantly greater proportion of participants reported 
improvement in experiencing cough in the condition of No product use as compared to 
conditions of Dual use (mean difference=0.3, 95% CI: 0.1 to 0.4, p<0.001), and of Exclusive use 
of tobacco cigarettes (mean difference=0.3, 95% CI: 0.1 to 0.4, p<0.001). No significant effect 
was detected for the interaction of condition and assigned condition order (F=0.341, p=0.796). 
In a repeated measures model examining change in frequency of experiencing cough with 
phlegm, a significant effect of condition was observed (F=7.561, p<0.001): a significantly 
greater proportion of participants reported improvement in experiencing cough with phlegm in 
the condition of Exclusive use of e-cigarettes as compared to conditions of Dual use (mean 
difference=0.3, 95% CI: 0.2 to 0.5, p<0.001), and of Exclusive use of tobacco cigarettes (mean 
difference=0.4, 95% CI: 0.2 to 0.5, p<0.001). In addition, a significantly greater proportion of 
participants reported improvement in experiencing cough with phlegm in the condition of No 
product use as compared to conditions of Dual use (mean difference=0.3, 95% CI: 0.1 to 0.4, 
p=0.001), and of Exclusive use of tobacco cigarettes (mean difference=0.3, 95% CI: 0.1 to 0.4, 
p<0.001). No significant effect was detected for the interaction of condition and assigned 
condition order (F=0.271, p=0.846). 
In a repeated measures model examining change in experiencing sounds emanating from the 
chest, a significant effect of condition was observed (F=6.799, p<0.001): a significantly greater 
proportion of participants reported improvement in experiencing chest sounds in the condition of 
Exclusive use of e-cigarettes as compared to conditions of Dual use (mean difference=0.3, 95% 
CI: 0.2 to 0.5, p<0.001), and of Exclusive use of tobacco cigarettes (mean difference=0.4, 95% 
CI: 0.2 to 0.5, p<0.001). In addition, a significantly greater proportion of participants reported 
improvement in experiencing chest sounds in the condition of No product use as compared to 
conditions of Dual use (mean difference=0.2, 95% CI: 0.1 to 0.4, p=0.001), and of Exclusive use 
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of tobacco cigarettes (mean difference=0.3, 95% CI: 0.1 to 0.4, p<0.001). No significant effect 
was detected for the interaction of condition and assigned condition order (F=0.221, p=0.881). 
3.9.2 Perceived overall health  
Participants were asked to indicate whether they perceived a change in their overall health in 
each study condition. Table 19 shows participants’ self-reported perceived health by study 
condition.  
Table 19: Changes in perceived health across study conditions (n=48)  
 Condition 
Exclusive use of 
tobacco cigarettes 
Exclusive use of e-
cigarettes 
No product use 
% (n) 
Change in overall health as a result of not using e-cigarettes?  
 Worse than usual  14.6% (7) - - 2.1% (1) 
 No difference 81.3% (39) - - 79.2% (38) 
 Better than usual 4.2% (2) - - 18.8% (9) 
Change in overall health as a result of not using tobacco cigarettes?  
 Worse than usual  - - 4.2% (2) 4.2% (2) 
 No difference - - 54.2% (26) 54.2% (26) 
 Better than usual - - 41.7% (20) 41.7% (20) 
 
A McNemar-Bowker test was used to examine changes in participants’ perceived health in the 
condition of Exclusive use of tobacco cigarettes vs. the condition of Exclusive use of e-
cigarettes. The omnibus test yielded a significant difference: χ2=16.571, p=0.001. McNemar 
post-hoc analyses with Bonferroni adjustment indicated that a significantly greater proportion of 
participants reported better than usual health (vs. no difference) in the condition of Exclusive use 
of e-cigarettes as compared to the condition of Exclusive use of tobacco cigarettes (χ2=13.000, 
p=0.003).  
Changes in participants’ perceived health were also compared in the condition of Exclusive use 
of tobacco cigarettes vs. the condition of No product use. A McNemar-Bowker test indicated no 
significant difference in participants’ perceived health between these study conditions (χ2=7.444, 
p=0.059). Similarly, a McNemar-Bowker test indicated no significant difference in participants’ 
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perceived health in the condition of Exclusive use of e-cigarettes as compared to the condition of 
No product use (χ2=1.400, p=0.706).  
Further, participants were asked to consider any negative or positive effects they experienced as 
a result of abstaining from smoking tobacco cigarettes and/or using e-cigarettes over the course 
of the study. Participants reported the following negative effects as a result of not using e-
cigarettes: body pains (n=1), fatigue (n=1), malaise (n=1), feeling anxious (n=1), feeling 
depressed (n=1), and feeling angry (n=1). Positive effects resulting from not using e-cigarettes 
included: increased appetite/eating better (n=1), and having more energy (n=1).  
On the other hand, participants reported the following negative effects because of not smoking 
tobacco cigarettes: suffering from nicotine withdrawal symptoms (n=1), feeling depressed (n=1), 
and feeling stressed (n=1). Positive effects as a result of not smoking tobacco cigarettes included: 
having more energy (n=12), feeling better/healthier (n=9), increased appetite/eating better (n=6), 
engaging in more physical activity (n=5), socializing with friends who don’t smoke (n=1), 
experiencing better mental health (n=3), experiencing fewer cravings for tobacco cigarettes 
(n=3), increased confidence to quit cigarettes (n=2), improved sense of smell (n=1), and 
improved sleep (n=1).  
3.9.3 Perceived addiction  
Participants were asked whether they considered themselves addicted to either tobacco cigarettes 
or e-cigarettes over the course of the study. Table 20 shows participants’ self-reported perceived 




Table 20: Perceived addiction to tobacco cigarettes and e-cigarettes across study conditions 
(n=48) 
 Condition 
Exclusive use of 
tobacco cigarettes 
Exclusive use of e-
cigarettes 
No product use 
% (n) 
Do you consider yourself addicted to e-cigarettes?  
 Not at all addicted  39.6% (19) - - 41.7% (20) 
 Somewhat addicted 52.1% (25) - - 52.1% (25) 
 Very addicted 8.3% (4) - - 6.3% (3) 
Do you consider yourself addicted to tobacco cigarettes?  
 Not at all addicted  - - 2.1% (1) 2.1% (1) 
 Somewhat addicted - - 35.4% (17) 41.7% (20) 
 Very addicted - - 62.5% (30) 56.3% (27) 
 
A McNemar-Bowker test was used to examine changes in participants’ perceived addiction in 
the condition of Exclusive use of tobacco cigarettes vs. the condition of Exclusive use of e-
cigarettes. The omnibus test yielded a significant difference: χ2=29.842, p<0.001. McNemar 
post-hoc analyses with Bonferroni adjustment indicated that a significantly greater proportion of 
participants perceived themselves as addicted to tobacco cigarettes as compared to e-cigarettes 
(very addicted vs. not at all addicted: χ2=11.000, p=0.003; very addicted vs. somewhat addicted: 
χ2=11.842, p=0.003; and somewhat addicted vs. not addicted: χ2=7.000, p=0.048).  
Participants’ perceived addiction to e-cigarettes was also compared in the condition of Exclusive 
use of tobacco cigarettes vs. the condition of No product use. A McNemar-Bowker test indicated 
no significant difference in participants’ perceived addiction to e-cigarettes between these study 
conditions (χ2=1.077, p=0.584). Similarly, a McNemar-Bowker test indicated no significant 
difference in participants’ perceived addiction to tobacco cigarettes in the condition of Exclusive 
use of e-cigarettes as compared to the condition of No product use (χ2=1.000, p=0.317).  
3.9.4 Perceived difficulty in abstaining from product use 
Participants were asked to reflect on the difficulty they experienced while abstaining from 
smoking tobacco cigarettes or from using e-cigarettes over the course of the study. Table 21 
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shows participants’ perceived difficulty in abstaining from using each of these products, by study 
condition.  
Table 21: Perceived difficulty in abstaining from smoking tobacco cigarettes or from using 
e-cigarettes, across study conditions (n=48) 
 
Condition 
Exclusive use of 
tobacco cigarettes 
Exclusive use of e-
cigarettes 
No product use 
% (n) 
Over the past week, how easy or difficult was it to go without using e-cigarettes?  
 Easy 64.6% (31) - - 54.2% (26) 
 Neither easy nor difficult 10.4% (5) - - 2.1% (1) 
 Difficult  25.0% (12) - - 43.8% (21) 
Over the past week, how easy or difficult was it to go without smoking cigarettes?  
 Easy - - 14.6% (7) 8.3% (4) 
 Neither easy nor difficult - - 8.3% (4) 6.3% (3) 
 Difficult  - - 77.1% (37) 85.4% (41) 
 
A McNemar-Bowker test was used to examine participants’ perceived difficulty in abstaining 
from product use in the condition of Exclusive use of tobacco cigarettes vs. the condition of 
Exclusive use of e-cigarettes. The omnibus test yielded a significant difference: χ2=18.398, 
p<0.001. McNemar post-hoc analyses with Bonferroni adjustment indicated that a significantly 
greater proportion of participants reported difficulty (vs. ease) in abstaining from product use in 
the condition of Exclusive use of e-cigarettes as compared to the condition of Exclusive use of 
tobacco cigarettes (χ2=17.065, p=0.003).  
Participants’ perceived difficulty in abstaining from using e-cigarettes was also compared in the 
condition of Exclusive use of tobacco cigarettes vs. the condition of No product use. A 
McNemar-Bowker test indicated no significant difference in participants’ perceived difficulty in 
abstaining from using e-cigarettes between these study conditions (χ2=7.267, p=0.064). 
Similarly, no significant difference in participants’ perceived difficulty in abstaining from 
smoking tobacco cigarettes was found when comparing the condition of Exclusive use of e-




4.1 Baseline characteristics and patterns of product use among dual users 
4.1.1 Characteristics of dual users  
Dual users in this study exhibited low to moderate nicotine dependence for tobacco cigarettes 
and low nicotine dependence for e-cigarettes. Nicotine dependence for tobacco cigarettes, as 
measured using the FTCD, among this sample of dual users was greater than that of US dual 
users surveyed by Rass and colleagues (2015), likely resulting from the inclusion of non-daily 
smokers reporting lower daily cigarette consumption in the study conducted by Rass and 
colleagues (2015). When measured using the NDSS, dual users’ level of nicotine dependence for 
tobacco cigarettes fell between that characterizing non-dependent smokers or chippers (NDSS -
1.76) and dependent regular smokers, smoking at least 20 cigarettes per day (NDSS 0.12) 
(Shiffman & Sayette, 2005). Nicotine dependence scores for e-cigarettes were difficult to 
interpret, as has been noted by other authors, given that some items in the FTCD and NDSS are 
not well suited for e-cigarettes (e.g., continued product use despite risks) (Etter & Eissenberg, 
2015). Nevertheless, comparison of dependence scores for each product (with respect to both the 
FTCD and NDSS) reflected greater dependence for tobacco cigarettes as compared to e-
cigarettes, mirroring respondents’ perceived addiction to each product. These findings are 
consistent with other studies of dual users (Etter & Eissenberg, 2015; Rass et al., 2015), and are 
supportive of published research suggesting that e-cigarettes have less addictive potential relative 
to tobacco cigarettes (Etter & Eissenberg, 2015; Goniewicz et al., 2013; Vansickel, Weaver & 
Eissenberg, 2012).  
4.1.2 Patterns of product use among dual users 
In the current study, the vast majority of dual users reported using tank system e-cigarette 
products and e-liquids containing nicotine, with low to moderate nicotine concentrations being 
the most commonly used. These findings are consistent with other published surveys of dual 
users (Berg, 2016; Farsalinos, Romagna & Voudris, 2015; Rüther et al., 2016). The consistency 
of these findings provides further evidence that the restriction on nicotine-containing products in 
Canada has not prevented individuals from obtaining and using such products (Hammond et al., 
2015; Standing Committee on Health, 2015). The reported use of flavoured e-cigarettes/e-liquids 
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supports previously published findings regarding the popularity of such flavours, and particularly 
fruit flavours, among e-cigarette users (Shiplo, Hammond & Czoli, 2015).  
4.1.3 Dual use behaviour 
The findings highlight the dominant role that tobacco cigarettes play among dual users. First, all 
dual users in the study sample began smoking tobacco cigarettes before taking up e-cigarettes, 
consistent with a survey of adult US dual users (Rass et al., 2015). Second, although daily 
consumption of tobacco cigarettes and e-cigarettes were similar, a greater proportion of dual 
users reported smoking tobacco cigarettes within the first hour of waking, as compared to e-
cigarettes. Third, these patterns of use complemented differential scores of nicotine dependence - 
the results of several measures of nicotine dependence converged to reflect greater dependence 
for tobacco cigarettes as compared to e-cigarettes. Fourth, dual users perceived e-cigarettes as 
less satisfying and pleasurable than tobacco cigarettes. Fifth, with respect to their behavioural 
identity, more respondents self-identified as tobacco cigarette smokers rather than either dual 
users or e-cigarette vapers. 
At the same time, several findings from the current study illustrate the potential of e-cigarettes to 
compete with, and potentially substitute for, tobacco cigarettes. For instance, the finding that 
dual users commonly used e-cigarettes and tobacco cigarettes in similar places suggests that e-
cigarette use is not confined to settings in which smoking is prohibited. Dual users also reported 
greater motivation to cease their use of tobacco cigarettes, reflecting a longer-term preference for 
e-cigarettes, as evidenced by a greater number of past quit attempts and future quit intentions. 
Furthermore, dual users’ most common reasons for initiating and for currently using e-cigarettes 
included to reduce or quit smoking and as a result of the belief that these products are less 
harmful than tobacco cigarettes, consistent with other research (Berg, 2016; Etter, 2015; 
Farsalinos, Romagna & Voudris, 2015; Patel et al., 2016; Rass et al., 2015; Rutten et al., 2015). 
These findings were further supported by dual users’ perceptions of e-cigarettes as less harmful 
than tobacco cigarettes, which has also been shown in the literature (Farsalinos, Romagna & 
Voudris, 2015; Rass et al., 2015). Finally, a majority of dual users believed that e-cigarettes 
would make it easier to quit smoking tobacco cigarettes, and reported smoking fewer tobacco 
cigarettes from the time they began using e-cigarettes daily, similar to other published studies 
(Farsalinos, Romagna & Voudris, 2015; Rass et al., 2015; Rutten et al., 2015).    
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4.1.4 Compensatory behaviour and exposure to nicotine  
Dual use vs. exclusive smoking  
Compensatory behaviour for nicotine was assessed by examining participants’ patterns of 
product use and levels of urinary cotinine across study conditions in the product switching 
experiment. In the current study, dual users were able to effectively take in nicotine when they 
switched from dual use to smoking, as evidenced by their relatively stable cotinine levels. The 
stability of cotinine levels across dual use and exclusive smoking supports Hypothesis 1c and is 
consistent with published studies examining switching from exclusive smoking to dual use 
(Pacifici et al., 2015; Meier et al., 2017). This switch does not limit participants’ nicotine intake, 
given that both these behaviours involve use of tobacco cigarettes, which deliver nicotine 
efficiently (USDHHS, 2010). However, participants’ daily tobacco cigarette consumption was 
not significantly greater when exclusively smoking as compared to when engaging in dual use, in 
contrast to Hypothesis 1a. In fact, study participants reported smoking a greater number of 
tobacco cigarettes per day when engaging in dual use as opposed to exclusive smoking. 
However, the magnitude of this difference was modest, and may have been subject to several 
measurement issues. First, measures of cigarette consumption were based on self-report, which 
are subject to biases that do not apply to objective measures, such as biomarkers of exposure 
(discussed below). Second, patterns of dual use were measured retrospectively, prior to 
participants’ entry into the study; as a result, aspects of study participation, such as monitoring 
and remuneration, may have had an effect on participants’ accounts of their behaviour. On the 
other hand, despite smoking fewer tobacco cigarettes per day when exclusively smoking, 
participants may have compensated for nicotine by smoking each tobacco cigarette more 
intensely (Hammond, Fong, Cummings & Hyland, 2005). Due to the fact that daily cigarette 
consumption is only a crude measure of nicotine intake, it is not clear which of these potential 
reasons accounts for the study findings.  
Dual use vs. exclusive vaping  
When comparing the behaviours of dual use and exclusive vaping in the current study, 
participants’ urinary cotinine levels were significantly lower when they exclusively vaped, 
despite significant increases in self-reported e-cigarette consumption in this study condition. 
Specifically, participants exhibited compensatory behaviour with respect to e-cigarettes, 
reporting using e-cigarettes a greater number of times per day as well as using e-cigarettes earlier 
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in the day, providing support for Hypothesis 1b. However, this behavioural change appeared 
insufficient to maintain stable cotinine levels. This finding contrasts with Hypothesis 1c and is 
inconsistent with several published studies in which smokers were able to achieve similar 
cotinine levels while using advanced e-cigarette products (Berg et al., 2014; Pacifici et al., 2015). 
Although the vast majority of dual users in the current study reported using tank systems and e-
liquids with nicotine, the nicotine delivery potential of these devices was not tested, and may 
account for these results. Indeed, similar levels of cotinine among study participants across 
conditions of exclusive vaping and no product use supports the notion that participants’ e-
cigarette devices may have been limited in their ability to deliver nicotine. Given that nicotine is 
the substance that drives tobacco addiction, the inability of dual users to obtain sufficient 
nicotine exclusively from their e-cigarettes may limit the smoking cessation potential of these 
devices.  
4.1.5 Exposure to tobacco smoke constituents  
Dual use vs. exclusive vaping and no product use  
Levels of several tobacco smoke exposure biomarkers, including exhaled carbon monoxide, 1-
hydroxypyrene, and NNAL, were consistently lower when participants exclusively vaped as 
compared to when they engaged in dual use, providing support for Hypotheses 2a, 2b, and 2c. 
Reduction in exposure to carbon monoxide is consistent with published studies examining 
smokers’ switch to use of e-cigarettes (Adriaens et al., 2014; Caponnetto et al., 2013; Cravo et 
al., 2016; Goniewicz et al., 2016; Litt et al., 2016; McRobbie et al., 2015; O’Connell et al., 2016; 
Pacifici et al., 2015; van Staden et al., 2013). In addition, reduction in exposure to pyrene 
supports the findings of Hecht and colleagues (2015) comparing exposure to PAHs among 
vapers and smokers, as well as the findings of O’Connell and colleagues (2016) examining 
smokers’ exposure to these compounds following their switch to exclusive vaping. Similarly, 
significant reduction in exposure to the carcinogen NNK supports published comparative 
analyses (Hecht et al., 2015; Wagener et al., 2016) as well as switching studies (Cravo et al., 
2016; O’Connell et al., 2016; Goniewicz et al., 2016).  
Biomarkers of exposure were also reduced when participants abstained from both tobacco 
cigarettes and e-cigarettes, as compared to dual use. Significant reductions were observed for 
carbon monoxide and NNK biomarkers when participants used neither product; although levels 
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of 1-HOP also decreased, this difference did not reach statistical significance. In addition, while 
exposure to all examined tobacco smoke constituents decreased when participants were not 
permitted to smoke nor vape, exposure did not reduce to nil. Although this is likely the result of 
some respondents continuing to smoke tobacco cigarettes, as well as slow clearance of some 
biomarkers, particularly NNAL (Hecht et al., 1999), it may also reflect the presence of 
contaminants in e-cigarette products, or other sources of environmental exposure, particularly for 
PAHs (WHO, 2007).  
Dual use vs. exclusive smoking  
Exposure to carbon monoxide and polycyclic aromatic hydrocarbons was significantly greater 
when individuals exclusively smoked as compared to when they engaged in dual use (21% and 
23%, respectively). With respect to this comparison, a non-significant increase in exposure to 
NNK was also observed (8%). These findings are generally consistent with two published 
switching studies. First, in a switching study with 4-week follow-up, McRobbie and colleagues 
(2015) reported significant reduction in exposure to carbon monoxide among smokers taking up 
e-cigarettes, with greater reduction observed among exclusive vapers as compared to dual users 
(80% vs. 52%) (McRobbie et al., 2015). Further, in an industry-sponsored 1-week switching 
study, O’Connell and colleagues (2016) reported similar findings, with all examined biomarkers 
showing a decreasing trend with decreasing tobacco cigarette consumption among parallel 
groups of smokers. Specifically, compared to their baseline smoking behaviour, reduction in 
exposure to carbon monoxide, PAHs, and NNK, respectively, were observed among smokers 
who switched to dual use (26-32%, and 25-35%, [NNK exposure value not published]), among 
smokers who switched to exclusive vaping (89%, 62-69%, and 62-64%), and among smokers 
who quit tobacco/nicotine products entirely ([carbon monoxide exposure value not published], 
70%, and 66%). Notably, greater reduction in exposure was observed in these switching studies 
when compared with findings from the current study. Factors that may account for these 
differing results include the motivation of smokers in the study by McRobbie and colleagues 
(2015) to quit smoking, and the clinical confinement of smokers in the study by O’Connell and 
colleagues (2016), which may have contributed to greater potential substitution of tobacco 
cigarettes with e-cigarettes and greater compliance with forced product switching.  
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To date, only one study has examined tobacco-related biomarkers of exposure in real-world 
settings. Shahab and colleagues (2017) examined a suite of biomarkers of exposure to TSNAs 
and volatile organic compounds in several groups of long-term nicotine product users. Cross-
sectional comparative analyses indicated that exclusive vaping, but not dual use of tobacco 
cigarettes and e-cigarettes, was associated with lower levels of exposure to several tobacco 
constituents, as compared to exclusive smoking (Shahab et al., 2017). Although the authors 
noted that their statistical power to detect small differences (such as that between dual users and 
exclusive smokers) was limited, the magnitude of observed differences in exposure were similar 
to those observed in the current study, at least with respect to NNK exposure. This may reflect 
the fact that both studies assessed experienced nicotine product users in real-world settings.  
Overall, study findings regarding exposure to tobacco smoke constituents are consistent with the 
product design and properties of e-cigarettes, which do not contain tobacco and do not undergo 
combustion when used (Bertholon et al., 2013; Besaratinia & Tommasi, 2014), and support 
research evidence suggesting that use of e-cigarettes is likely to be less harmful than smoking 
(Hajek, Etter, Benowitz, Eissenberg, & McRobbie, 2014). Although the current study is unable 
to discern whether dual users reduce their tobacco cigarette consumption by substitution with e-
cigarettes or simply use e-cigarettes alongside their usual smoking to bridge periods of non-
smoking, it appears dual users use their products to achieve a desired level of nicotine, consistent 
with other research (Benowitz, 2001; Shahab et al., 2017). Despite slight reductions in exposure 
associated with dual use, the findings demonstrate that abstaining from tobacco cigarettes is the 
most important factor in reducing exposure to toxic smoke constituents. Research evidence 
indicates that smokers who quit tobacco cigarettes completely reduce their risk of premature 
death to levels comparable to non-smokers (Doll, Peto, Boreham & Sutherland, 2004; USDHHS, 
2010). However, the potential benefits of smoking reduction, as may be the case of dual use, are 
less clear. Despite the fact that many tobacco smoke constituents, including carbon monoxide, 
TSNAs, and PAHs, have been implicated in the development of cardiovascular disease and 
various cancers (IARC, 2004; USDHHS, 2010), evidence regarding how changes in smoking-
related biomarkers predict future risk of disease is lacking (USDHHS, 2010). For instance, with 
respect to cardiovascular disease, epidemiologic evidence demonstrates a strong dose-response 
relationship between the number of cigarettes smoked per day and cardiovascular risk. However, 
the relationship is not linear, meaning that even low levels of exposure to tobacco are sufficient 
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to substantially increase cardiovascular risk (USDHHS, 2010). To date, significant health 
benefits from reducing the amount of tobacco cigarettes smoked have not been demonstrated 
with respect to various disease outcomes (USDHHS, 2010). While it is plausible that dual use 
could reduce individual risk if it results in substantial reductions in smoking, the threshold for 
meaningful reductions is unclear, particularly given that smokers may compensate for reductions 
in the number of cigarettes they smoke by smoking each cigarette more intensely (Hammond, 
Fong, Cummings & Hyland, 2005; USDHHS, 2010). This is generally supported by the current 
findings, in which the differences between dual use and exclusive smoking were modest. 
Therefore, dual use is likely to have public health benefit only to the extent that it leads to 
complete smoking cessation.  
4.1.6 Nicotine withdrawal and self-efficacy  
In the current study, participants experienced significantly greater cravings for tobacco cigarettes 
when they were not permitted to use these products. This finding supports Hypothesis 3a, and 
indicates that dual users perceived smoking tobacco cigarettes as a desirable and rewarding 
behaviour, and also anticipated relief from nicotine withdrawal (Cox, Tiffany & Christen, 2001). 
This finding contrasts with other studies examining smokers’ switch to use of e-cigarettes, in 
which smokers’ cravings either declined (Goniewicz et al., 2016), or did not change (Meier et al., 
2017; Wagener et al., 2014). When compared to the current study, these switching studies 
involved different design parameters, such as the study length and the type of e-cigarette 
products used: the studies by Meier et al. (2017) and by Goniewicz et al. (2016) examined first-
generation products for one- and two-weeks, respectively, while Wagener and colleagues (2014) 
evaluated use of a second-generation product for a one-week period. Participants in these studies 
also differed with respect to their intentions to quit smoking tobacco cigarettes: while Goniewicz 
et al. (2016) studied smokers who may have intended to quit, the study by Wagener and 
colleagues (2014) examined smokers not intending to quit smoking. However, it is not entirely 
clear whether these factors account for these inconsistent results.  
Changes in participants’ self-efficacy for abstaining from smoking tobacco cigarettes depended 
on the order in which they experienced study conditions, providing partial support for Hypothesis 
4a. Participants who were assigned to a ‘step-wise’ sequence of product switching – from dual 
use at baseline to exclusive smoking, to exclusive vaping, and finally to use of neither product – 
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experienced no significant changes in their self-efficacy with respect to tobacco cigarettes. In 
contrast, the self-efficacy of participants who were assigned to a more challenging sequence of 
product switching – from dual use at baseline to exclusive vaping, to exclusive smoking, and 
finally to use of neither product – reflected this challenge, decreasing non-significantly following 
their first and second product switches, and then increasingly significantly in the final week of 
the study. Overall, at the end of the product-switching experiment, the self-efficacy of 
participants assigned to both sequences did not differ significantly from their baseline values, 
which is consistent with the findings of other switching studies involving smokers not intending 
to quit (Meier et al., 2017; Wagener et al., 2014).  
Participants reported no changes in cravings for e-cigarettes and self-efficacy to abstain from 
using e-cigarettes across study conditions. In contrast to Hypothesis 3b, these findings indicate 
that dual users did not experience marked changes in either their desire to vape or nicotine 
withdrawal symptoms with respect to these products. Further, in contrast to Hypothesis 4b, 
participants were confident in their ability to abstain from vaping, even when they were not 
permitted to use e-cigarettes. These findings were supported by participants’ subjective 
experiences throughout the study, in which they perceived themselves as more addicted to 
tobacco cigarettes versus e-cigarettes, and perceived greater difficulty in abstaining from 
smoking as compared to vaping. Overall, the study findings show that dual users are comfortable 
both using and abstaining from e-cigarettes, and may reflect the lower addictive potential of 
these products (Etter & Eissenberg, 2015; Goniewicz et al., 2013; Vansickel, Weaver & 
Eissenberg, 2012).  
4.1.7 Perceived health  
Dual users reported that their respiratory health significantly improved when they abstained from 
smoking tobacco cigarettes. Participants consistently reported improvement in experiencing 
shortness of breath, cough, cough with phlegm, sounds emanating from the chest, and in 
perceived lung function in conditions in which they were not permitted to smoke, providing 
support for Hypothesis 5. Additional health improvements associated with not smoking included 
having more energy, feeling better/healthier, increased appetite/eating better, engaging in more 
physical activity, experiencing better mental health, experiencing fewer cravings for tobacco 
cigarettes, increased confidence to quit cigarettes, improved sense of smell, and improved sleep. 
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These findings are consistent with other published studies, in which smokers switching to use of 
e-cigarettes similarly reported experiencing health improvements, particularly respiratory health, 
with few reports of adverse effects associated with vaping (Adriaens et al., 2014; Berg et al., 
2014; Caponnetto et al., 2013; Cibella et al., 2016; Goniewicz et al., 2016; Polosa et al., 2014; 
van Staden et al., 2013). Overall, the study findings demonstrate that abstaining from smoking 
tobacco cigarettes is associated with significant improvements in perceived health, with many of 
these benefits experienced very quickly after a change in behaviour, even within a week-long 
period.  
4.2 Limitations and strengths  
The current study faced several limitations, the first of which is the study’s use of a non-
probability-based sample. However, a comparison of characteristics of the current study’s 
sample with a nationally representative data indicate that daily dual users in the current study 
resembled those in the Canadian population (CTADS [data not published], 2015). The current 
study sample reported similar daily tobacco cigarette consumption as Canadian daily dual users 
at large (13.7 vs. 13.0 cigarettes per day), although daily dual users in the current study exhibited 
greater dependence (mean Heaviness of Smoking Index 2.8 vs. 1.8), given that they reported 
smoking their first tobacco cigarette earlier in the day (83.4% vs. 75.8% reported smoking their 
first tobacco cigarette within 30 minutes) (CTADS [data not published], 2015). Although a 
greater proportion of Canadian daily dual users report intentions to quit smoking in the next six 
months as compared to the current study sample (81.3% vs. 46.8%), it is important to note that 
an exclusion criterion of the current study was that potential participants not have serious 
intentions to quit smoking in the next six months. With respect to sociodemographic 
characteristics, the current study sample was younger (mean age 35.9 years vs. 48.7 years), and 
consisted of a greater proportion of males (70.8% vs. 61.9%) (CTADS [data not published], 
2015). These differences in sociodemographic characteristics also differentiate the current 
sample of daily dual users from samples of dual users surveyed in the US (Rass et al., 2015; 
Rutten et al., 2015). Overall, daily dual users in the current study appear to resemble those in the 
Canadian population at large, indicating that potential biases stemming from participant 
recruitment may not overly influence the study findings.  
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Next, dual users’ patterns of use of both tobacco cigarettes and e-cigarettes were based on self-
reported data, which are subject to various biases. Although self-reported measures of tobacco 
cigarette consumption used in population surveys have been shown to be valid and reliable 
(Hatziandreu et al., 1989; Ramo, Hall, & Prochaska, 2011), the data may nevertheless be subject 
to social desirability bias, given that participants were asked to consciously monitor their 
behaviour in a context in which smoking is increasingly perceived as socially undesirable. With 
respect to use of e-cigarettes, although measures of patterns of use were selected based upon a 
review of the literature, and are reflected in a recently published list of core items recommended 
for assessing e-cigarette use (Pearson et al., 2017b), they nevertheless face potential limitations. 
For instance, self-reported measures of the number of daily bouts of e-cigarette use and number 
of puffs per bout may be subject to recall bias. One challenge associated with measuring e-
cigarette use is posed by the physical properties of e-cigarettes themselves: unlike tobacco 
cigarettes, which have a distinct beginning and end point, e-cigarettes can last several days 
before they need to be re-filled or replaced (Pearson et al., 2017a). In addition, qualitative 
research has indicated that much vaping behaviour is not consciously tracked, at least among 
novice users (Kim, Davis, Dohack, & Clark, 2017). Indeed, a study comparing self-reported 
puffing frequency collected via ecological momentary assessment (EMA) to objective data 
collected by a Bluetooth-enabled e-cigarette device indicated that vaping participants 
significantly under-reported their e-cigarette puffs (Pearson et al., 2017a). Given that EMA 
reduces recall bias by collecting behavioural information in the time and place where the 
behaviour occurs (Pearson et al., 2017a), these findings may imply that self-reported measures 
collected using surveys may be subject to even greater under-reporting. Overall, measures of 
consumption of tobacco cigarettes and e-cigarettes in the current study may be subject to various 
biases, potentially resulting in under-reported values. However, these limitations are tempered 
with the study’s use of biomarkers of exposure, which provide more robust measures with which 
to examine product switching behaviour.  
Measures used to assess e-cigarette use were limited in several other ways. For instance, the 
current study did not collect data regarding the quantity of e-liquid dual users consumed. 
Although the potential value of this measure is not yet well understood (Pearson et al., 2017b), 
such information may have contributed to our understanding of the relationship between 
smoking and vaping behaviours among dual users, and may have informed interpretations of 
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compensatory behaviour in the product-switching experiment. In addition, several measures used 
to assess nicotine dependence, nicotine withdrawal, and self-efficacy were adapted from the 
smoking literature and applied to e-cigarettes, but have yet to be validated for this purpose. 
Therefore, these results should be interpreted with caution.  
The study’s product-switching experiment also faced several limitations, one of which relates to 
its naturalistic design. Unlike other switching studies, the current study did not confine 
participants to a laboratory setting. As a result, participants’ adherence to the study protocol was 
not absolute. Biomarker data reflected this lack of compliance, particularly in the conditions in 
which participants were not permitted to smoke tobacco cigarettes. This is particularly relevant 
for the final study condition of no product use, which was expected to be the most challenging 
for study participants. The use of non-permitted tobacco cigarettes was monitored throughout the 
study, and sensitivity analyses showed that accounting for ‘cheating’ adjusted the levels of 
biomarkers of exposure in the expected direction. Although ‘cheating’ undermines the internal 
validity of the study to some extent, it also enables the study to reflect what product-switching 
behaviour might look like in real-world conditions, which was the primary objective of the 
current study.  
In addition, dietary and environmental sources of exposure to polycyclic aromatic hydrocarbons 
and carbon monoxide were not assessed in the study, limiting the extent to which exposure to 
these constituents can be attributed to intake of tobacco smoke; however, assessment of NNAL 
exposure provides a source of tobacco-specific exposure against which the findings may be 
interpreted. The study was also limited in its examination of biomarkers of exposure: although 
three biomarkers of exposure to tobacco smoke constituents were examined, there are many 
others that could have been assessed. In addition, the study did not assess constituents specific to 
e-cigarette aerosol, meaning the results reflect only a limited examination of human-level 
exposure to tobacco cigarettes and e-cigarettes. Finally, although analyses relating to the 
product-switching experiment may have been impacted by the modest sample size, the detection 
of significant differences in several outcomes across study conditions reflects sufficient 
statistical power.  
Despite these limitations, the current study has several notable strengths. The current study is the 
first to examine detailed patterns and perceptions of use of dual users of tobacco cigarettes and e-
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cigarettes in the Canadian context. An additional strength of the study is its use of 
complementary measures for assessment of behavioural use of both tobacco cigarettes and e-
cigarettes. Such a distinction may aid in understanding the ways in which e-cigarettes may affect 
smoking behaviour, and reflects the tobacco/nicotine market’s recent evolution (Benowitz & 
Goniewicz, 2013; Zeller, 2012). Furthermore, the study is strengthened by its use of objective 
measures of exposure. All biomarkers assessed in the current study have been recommended for 
use in studies of tobacco use and harm (WHO, 2007), and in contrast to laboratory animal 
models and smoking machines, provide valid measures of body-level exposure that take into 
account user characteristics. A final strength of the study is its enhanced external validity, 
reflected in its naturalistic design and inclusion of experienced dual users using their own 
products. These features enable the study to capture realistic interactions between e-cigarette 
users and their devices, meaning the study findings are likely to be more reflective of user 
populations and products in today’s market.  
4.3 Future research 
Future research may consider several key areas. As noted above, there are few standardized 
behavioural assessments for the emerging behaviour of e-cigarette use. Although researchers 
have begun to consolidate measures (Pearson et al., 2017b), more work is needed to develop 
valid and reliable measures that assess this behaviour accurately and in a way that can inform the 
development of policy. For instance, it is not yet known what frequency or level of e-cigarette 
use is relevant to behavioural and health outcomes (Pearson et al., 2017b). In addition, the 
diversity of tobacco/nicotine products presents challenges for measuring nicotine dependence. 
Although some researchers (e.g., Fagerström, 2012) have recommended the development and 
use of measures to assess dependence to specific products – thereby acknowledging the role 
played by psychosocial and physical properties other than nicotine in determining dependence – 
others have pointed out that dependence to other drugs, such as opioids, is not typically 
measured in product-specific terms, such as for heroin and prescription opioids (e.g., Rass et al., 
2015). Thus, it will be important for researchers to select measures carefully, and share their 
learnings to advance the field.  
Future research should assess a wider range of biomarkers of exposure among a larger sample of 
established dual users to examine potential health effects. Although some e-cigarette product 
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characteristics were examined in the current study, the sample size and low variability limited 
the extent to which the association of such characteristics with nicotine intake and exposure to 
key constituents could be examined. In addition, the long-term health effects of e-cigarette use 
need to be evaluated in longitudinal observation studies. Although evidence to date suggests that 
the health risks of e-cigarettes are comparable to those of nicotine replacement therapy (Grana, 
Benowitz & Glantz, 2014; Hajek, Etter, Benowitz, Eissenberg, & McRobbie, 2014; Shahab et 
al., 2017), such research would help firmly establish the risk profile of e-cigarettes, and may 
potentially inform a harm reduction strategy for nicotine.  
The current study did not evaluate the effectiveness of e-cigarettes in supporting smoking 
cessation and/or reduction, which remains a central question in understanding the potential 
public health impact of these products. Although several longitudinal cohort studies and 
randomized controlled trials have been conducted to date (McRobbie, Bullen, Hartmann-Boyce 
& Hajek, 2014; Hartmann-Boyce et al., 2016), further research involving advanced products is 
needed to evaluate the cessation potential of these devices (Lopez & Eissenberg, 2015).  
Data regarding dependence and patterns of use among smokers and vapers in the Canadian 
context is scarce. Although the current study sheds some light on dual use behaviour in this 
context, research using nationally representative samples would greatly contribute to our 
understanding of smoking, vaping, and dual use behaviours. Robust longitudinal data assessing 
these user populations and their characteristics over time will also help ascertain whether dual 
use sustains smoking or promotes cessation. As the nicotine market continues to evolve—and an 
increasing number of Canadians report dual use of combustible and non-combustible nicotine 
products—future research should examine the behaviours and perceptions of tobacco/nicotine 
product users to understand the public health implications of the shifting product market.  
4.4 Policy implications 
Findings from the current study can inform policy pertaining to e-cigarettes in Canada in several 
ways. For instance, the findings suggest that dual use behaviour is similar to that in other 
jurisdictions, despite Canada’s restrictive regulatory framework for these products. Consistent 
with a body of research evidence (Hamilton et al., 2015; Hammond et al., 2015; Reid et al., 
2017), these findings demonstrate that the current restriction on nicotine-containing e-cigarettes 
is a restriction in name only, which has not prevented individuals from obtaining and using such 
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products (Hammond et al., 2015). This underscores the need for a new regulatory framework for 
e-cigarettes, supporting recommendations made by Canadian legislators (Standing Committee on 
Health, 2015; Standing Senate Committee on Social Affairs, Science and Technology, 2017). 
Although several provinces have developed policies to address this issue (Province of British 
Columbia, 2015; Province of Manitoba, 2015; Province of Newfoundland and Labrador, 2016; 
Province of New Brunswick, 2015; Province of Nova Scotia, 2014; Province of Ontario, 2015; 
Province of Prince Edward Island, 2015; Province of Quebec, 2015), stakeholders anticipate that 
forthcoming legislation introduced in the Senate in November 2016 may better address and 
regulate both nicotine- and non-nicotine-containing vaping products (Parliament of Canada, 
2016).  
The study findings support other research demonstrating that complete smoking cessation is the 
best option to reduce health risks associated with smoking over the long term. Although 
exclusive vaping is associated with significant reduction in exposure to tobacco smoke 
constituents, dual use is not likely to result in reduced potential health risks, due to the magnitude 
of harm associated with even low levels of tobacco cigarette consumption. Therefore, smokers – 
including those concurrently using e-cigarettes – should be encouraged to completely quit 
tobacco cigarettes in order to avoid harm. These findings have direct implications for public 
health policy and practice. First, public health authorities should acknowledge differences in risk 
between smoking and exclusive e-cigarette use and communicate this clearly to the general 
public. Communicating the relative risk of e-cigarettes and tobacco cigarettes should focus on 
two salient points: 1) e-cigarettes are not harmless, but they are less harmful than smoking 
tobacco cigarettes; and 2) using e-cigarettes while smoking may not necessarily reduce health 
risks, and consumers should stop smoking to maximize any health benefit. Although the 
communication of relative risk information is fraught with difficulties, public health authorities 
must rise to this challenge for several reasons: because consumers have a right to be accurately 
informed of product risks (Kozlowski & Edwards, 2005; Kozlowski & Sweanor, 2016); because 
the rapid growth of the e-cigarette market in recent years means e-cigarettes are likely here to 
stay (Benowitz & Goniewicz, 2013); and because in the absence of evidence-based 
communication from such authorities, consumers’ reliance on industry-sponsored marketing, 
media, and anecdotal evidence is likely to increase (Zeller & Hatsukami, 2009). 
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Relative health risk communication regarding e-cigarettes and tobacco cigarettes can also inform 
clinical practice. E-cigarettes represent a challenge for the medical community, as health care 
professionals are increasingly encountering patients with questions about vaping, but have 
limited scientific evidence to inform their practice (Palazzolo, 2013; Orellana-Barrios, Payne, 
Mulkey & Nugent, 2015). Currently, health professionals may be limited in the clinical 
recommendations they provide regarding the cessation potential of e-cigarettes to smokers 
(McRobbie, Bullen, Hartmann-Boyce & Hajek, 2014; Hartmann-Boyce et al., 2016). However, 
findings from the current study, together with evidence regarding the long-term health effects of 
e-cigarettes (Shahab et al., 2017), may help them have more productive conversations with those 
patients who already use e-cigarettes. Relative risk communication, such as that noted above, 
delivered by health professionals, can help ensure that patients are adequately informed of 
products’ relative risks, and may encourage smokers using e-cigarettes to quit smoking.  
Finally, the relative risks of e-cigarettes and tobacco cigarettes can inform broad regulatory 
measures, such as product availability and access, labelling, marketing, and pricing. Public 
health authorities can implement regulations that are proportional to product risk, thereby 
creating market differentials that can help shift smokers away from use of tobacco cigarettes 
(Zeller & Hatsukami, 2009). The development of such evidence-based policies would better 
address the substantial risks of tobacco cigarettes and have greater potential to benefit public 





The findings suggest that dual use behaviour is similar to that in other jurisdictions, despite 
Canada’s restrictive regulatory framework for these products. Although dual users seem 
primarily motivated to use e-cigarettes for health reasons, tobacco cigarettes remain an important 
component of nicotine use. In addition, tobacco cigarettes appear superior to e-cigarettes in their 
ability to deliver nicotine. Although abstaining from smoking tobacco cigarettes elicits cravings, 
it is also associated with significant improvements in perceived respiratory health. Consistent 
with other research, results from the current study demonstrate that abstaining from tobacco 
cigarettes is the most important factor in reducing exposure to toxic smoke constituents. 
Therefore, dual use is likely to have public health benefit only to the extent that it leads to 
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Appendix A: Recruitment materials  










Appendix B: Informed consent 





Title of Project: Smoking Study 
Principal Investigator:   
Dr. David Hammond (PhD), School of Public Health & Health Systems  
University of Waterloo       
519-888-4567 ext. 36462   dhammond@uwaterloo.ca    
Please read this Information Letter and Consent Form carefully and ask as many questions as 
you like before deciding whether to participate in this research study. 
INTRODUCTION 
You have been asked to participate in a research project entitled: Smoking Study. You are being 
approached to participate in this study because you are a current cigarette smoker and a current 
user of electronic cigarettes (e-cigarettes) or another form of vapourized nicotine.  
The purpose of this study is to examine behaviours related to the use of cigarettes and e-
cigarettes among adults in Ontario. Your participation will help the investigators to examine if 
and how smokers use e-cigarettes, including how e-cigarette use may affect nicotine uptake.  
This study is being conducted by researchers at the University of Waterloo, and is funded by a 
grant from the Ontario Ministry of Health and Long Term Care (MOHLTC). About 100 
participants will be included in the study. Each participant will be involved with the study for 3 
weeks.  
PROCEDURE 
If you agree to participate in this study, you will be asked to visit the lab at the University of 
Waterloo for a total of 4 visits over a 3 week period. Each visit to the lab will last approximately 
45 minutes and will take place in a small group setting. Over the 3 week period, participants will 
be asked to refrain from using cigarettes or e-cigarettes or both products, in a random order.  
Visit 1 
During Visit 1, you will be asked to complete online questionnaires about your smoking and 
vaping history, any previous quit attempts, level of nicotine dependence, cravings and symptoms 
of nicotine withdrawal, and a few questions about your lung health. These questionnaires will 




We will ask all participants to provide a urine sample, following the same procedure used in a 
doctor’s office. This urine sample will be analyzed in a laboratory at the Roswell Park Cancer 
Institute for levels of nicotine and chemicals from tobacco products. No other tests will be 
conducted and the sample will be destroyed after it is analyzed.  
We will also ask you to provide a breath sample to measure the amount of carbon monoxide in 
your lungs. This procedure consists of you blowing into a new, sterile mouthpiece that is 
connected to a hand-held unit. You will then be provided with instructions for Week 1 and told 
which product(s) to refrain from using for that week. 
Visit 2 
During Visit 2, you will be asked to complete an online questionnaire about your smoking and 
vaping behaviours over the past week. The questionnaire will take approximately 20 minutes to 
complete. In addition, you will be asked to provide a urine sample and a breath sample, 
following the same procedures as in your previous visit. You will then be provided with 
instructions for Week 2 and told which product(s) to refrain from using for that week. 
Visit 3 
During Visit 3, you will be asked to complete an online questionnaire about your smoking and 
vaping behaviours over the past week. The questionnaire will take approximately 20 minutes to 
complete. In addition, you will be asked to provide a urine sample and a breath sample, 
following the same procedures as in your previous visit. You will then be provided with 
instructions for Week 3 and told which product(s) to refrain from using for that week. For Week 
3, we will provide you with resources to help you refrain from using cigarettes and e-cigarettes, 
if you are interested. 
Visit 4 
During Visit 4, you will be asked to complete an online questionnaire about your smoking and 
vaping behaviours over the past week. The questionnaire will take approximately 20 minutes to 
complete. In addition, you will be asked to provide a final urine sample and a breath sample, 
following the same procedures as in your previous visit. At the end of the study, you will receive 
a feedback letter about the study, and, if you are interested, resources to help you quit smoking. 
Daily Diaries 
During all 3 weeks of the study period, participants will be asked to complete brief online daily 
diaries about their smoking and vaping behaviours at the end of each day (after 9pm). The daily 
diaries will take approximately 5 minutes to complete. 
POSSIBLE RISKS AND DISCOMFORTS 
The risks from taking part in this study are no greater than the risks associated with regular 
smoking or regular use of e-cigarettes. There is very minimal risk in giving urine and exhaled 
breath samples. Breathing into the device to measure carbon monoxide should pose no concern 
as the mouthpiece will be new and sterile. Collection of urine is a non-invasive procedure that 
does not require direct assistance. We will be using universal precautions while handling the 




Completing the online daily diaries, and providing your biological samples on time will be very 
important. We will keep the daily diaries as brief as possible to minimize any inconvenience. If 
you do not complete the tasks in a timely fashion, you will not be allowed to participate in the 
remainder of the study.  
Coming to the laboratory at the time you are scheduled for your visits is also important. We will 
do everything we can to accommodate your schedule. Visits will be made in the evening, or for 
those who work during the evening, we will try to schedule you during convenient daytime 
hours. 
You may experience withdrawal symptoms when asked to refrain from using certain products, 
particularly in Week 3 of the study period, when you will be asked to refrain from both cigarettes 
and e-cigarettes. In order to assist you in Week 3, we will provide you with resources to help you 
refrain from using cigarettes and e-cigarettes, if you are interested. 
POSSIBLE BENEFITS 
By participating, you will help researchers better understand how smokers use different nicotine 
and tobacco products. The findings will also be used to help inform regulations on tobacco 
products and e-cigarettes. We also have information on smoking cessation resources, should 
these be of interest to you.  
FINANCIAL CONSIDERATIONS 
In appreciation of your time and to cover the cost of parking or transit, you will receive the 
following amounts for your participation: 
Visit Remuneration Amount 
Visit 1  $50  (cash) 
Visit 2  $70  (cash or Interac e-transfer) 
Visit 3  $75  (cash or Interac e-transfer) 
Visit 4 $100 (cash or Interac e-transfer) 
Total $295   
 
In total, you will receive $295 for your participation in the study. You will receive $50 after Visit 
1, $70 at the end of Visit 2, $75 at the end of Visit 3, and $100 after the final Visit. Although the 
Visit 1 amount will be provided as cash, the remaining amounts can be provided as cash or as an 
Interac e-transfer, whichever you prefer. The amount received is taxable. It is your responsibility 
to report this amount for income tax purposes. 
OWNERSHIP AND DOCUMENTATION OF YOUR URINE SAMPLES 
Your urine samples that are collected over the course of the study will be sent to the lab for 
testing. Testing will only be conducted for components of tobacco and nicotine products. The 
samples will be the property of the scientists doing the study. The samples will be labelled only 
114 
 
with your study ID number in order to protect your privacy. The samples will be destroyed after 
the study is completed. 
CONFIDENTIALITY 
All of the information you provide in this study will be kept strictly confidential. For your 
protection, we will assign you a number that will be used to label all information, including any 
urine samples. Personal information, such as your name and contact information, will be kept in 
a separate file that is locked away. No personal information such as your name or contact details 
will be kept on the urine samples, and your samples will be destroyed after we conduct the 
analyses: they will not be used for any other purposes than examining levels of nicotine and 
chemicals from tobacco smoke. All paper records will be stored in a secure facility at the 
University of Waterloo, and destroyed after 7 years. Electronic copies of your survey data will 
not contain any personal identifiers and will be encrypted and stored in password-protected files 
on a secure server and retained for a period of 7 years. Only the research team will have access to 
the data. You will not be identifiable in any publications or presentations resulting from this 
study.  
WITHDRAWAL FROM STUDY 
You are free to choose to whether or not to participate in this study, and may refuse to answer 
any specific questions. You can also choose to stop being a part of the study at any time. If you 
do choose to stop participating before the end of the study, you will still be remunerated a certain 
amount of money depending on when you withdraw (see remuneration chart in Section 5 of this 
document). Any data already collected may be used in the study, unless you contact the 
researcher to have it deleted.  
ETHICS REVIEW 
This project has been reviewed by and received ethics clearance through a University of 
Waterloo Research Ethics Committee.  Should you have any comments or concerns resulting 
from your participation in this study, please contact the Chief Ethics Officer, Office of Research 
Ethics at 519-888-4567 ext. 36005 or by email at maureen.nummelin@uwaterloo.ca. 
AVAILABLE SOURCES OF INFORMATION 
If you have any questions later or if you require additional information about the study, please 







Title of Project: Smoking Study 
Principal Investigator:   
Dr. David Hammond (PhD), School of Public Health & Health Systems  
University of Waterloo       
519-888-4567 ext. 36462   dhammond@uwaterloo.ca    
I have read the information presented in the information letter. I have had the opportunity to ask any questions 
related to this study, to receive satisfactory answers to my questions, and to request any additional details I wanted. I 
understand the purposes, procedures and risks of the research described in the project. I understand that I will be 
asked to refrain from using cigarette or e-cigarettes or both products at certain points throughout the study. I 
understand that I will be asked to complete online daily diaries at the end of each day of the study period. I 
understand that I will be asked to attend 4 scheduled visits to the lab at the University of Waterloo, at which I will be 
asked to complete online questionnaires and provide urine and exhaled breath samples.  
I am aware that I may withdraw from the study without penalty at any time by advising the researchers of this 
decision. In appreciation of my time and to cover the cost of parking or transit, I am aware that I will be provided 
with $50 today. I am aware that I will be provided with $70 following Visit 2, $75 following Visit 3, and $100 
following Visit 4, which will be sent to me as an Interac e-transfer, unless I request to pick it up as cash from the lab. 
If I do not attend the scheduled lab visits, or complete the online daily diaries, I am aware that I will be discontinued 
from the study. 
This project has been reviewed by, and received ethics clearance through a University of Waterloo Research Ethics 
Committee. I understand that if I have any comments or concerns resulting from my participation in this study, I 
may contact the Chief Ethics Officer, Office of Research Ethics at 519-888-4567 ext. 36005. 
With full knowledge of all foregoing, I agree, of my own free will to participate in this study, and provide urine and 
exhaled breath samples.  
YES     NO     
I give permission that my urine and exhaled breath samples can be analyzed for levels of nicotine and chemicals 
from tobacco products. 
YES    NO     
By signing this consent form, you are not waiving your legal rights or releasing the investigator(s) or involved 
institution(s) from their legal and professional responsibilities.   
___________________________________________ 
Participant Name (Please Print) 
___________________________________________     




Witness Name (Please Print) 
___________________________________________      







Appendix C: Study questionnaires 
Visit questionnaires 
Questionnaires were completed by participants at each of four scheduled visits to the laboratory.  
The Visit 1 questionnaire was completed by all participants at baseline.  




Please enter your participant ID: ______________ [insert] 





To start, we would like to ask you a few questions about yourself to make sure we have interviewed a true cross-section of 
people. Please be assured that all your responses will be kept entirely confidential. 




77. Don’t know 
88. Refused 
 
Age How old are you? 
___ years 
77. Don’t know 
88. Refused 
 
Height What is your height? 
___ ft ___ inches OR ___ cm 
77. Don’t know 
88. Refused 
 
Weight What is your weight? 
___ lbs OR ___ kg 
77. Don’t know 
88. Refused 
 
Education What is the highest level of formal education that you have completed? 
1. Grade school or some high school 
2. Completed high school 
3. Technical or trade school or community college (some or completed) 
4. Some university (no degree) 
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5. Completed university degree 
6. Post-graduate degree 
77. Don’t know 
88. Refused 
 
Ethnicity People in Canada come from many racial and cultural groups. Do you consider yourself to be: 
[Please check all that apply] 
1. White 




6. Latin American 
7. Arab 
8. Southeast Asian (e.g., Vietnamese, Cambodian, Malaysian, Laotian) 
9. West Asian (e.g., Iranian, Afghan) 
10. Korean 
11. Japanese 
12. Aboriginal (e.g., First Nations, Métis, Inuk/Inuit) 
13. Other: ___ [open-ended text] 





Next, we would like to ask you some questions about your behaviours and experiences related to smoking cigarettes – you 




Do you smoke cigarettes every day, occasionally, or not at all?  
1. Every day 
2. Occasionally 
3. Not at all  
77. Don’t know 




Progammer note: Ask only if V1.smokingstatus1=2 or 3. 
Just to confirm, do you smoke cigarettes everday or less than everyday? 
1. Every day 
2. Less than every day 
77. Don’t know 
88. Refused  
 
V1.smokingstatus.terminate Progammer note: If V1.smokingstatus2=2: 
Unfortunately, because you do not smoke cigarettes every day, you are not eligible to 
participate in the study.  
Please return the iPad to the Research Assistant. Thank you. 
 
V1.smoketime How long have you been smoking cigarettes daily?  
___ months OR ___ years 





V1.DD.cig.CPD How many cigarettes did you smoke today?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.DD.cig.wake Progammer note: If V1.DD.cig.CPD>0, ask: 
How soon after waking today did you smoke your first cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V1.cig.CPD  In the past 7 days, on average, how many cigarettes did you smoke per day?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.cig.wake In the past 7 days, on average, how soon after waking did you smoke your first cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V1.cig.lastcig How long has it been since you last smoked a cigarette? 
___ minutes OR ___ hours OR ___ days 
77. Don’t know 
88. Refused 
 
V1.cig.brand Please specify the usual brand of cigarettes you smoke (include any specific flavours or 
varieties): 
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.cig.where Please specify where you smoked cigarettes in the past 7 days. 
[Please check all that apply] 
1. At home       
2. At school or work      
3. At a restaurant or bar      
4. In a vehicle       
5. While walking on the street     
6. In a park or other outdoor venue   
7. Other: ___  [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.cig.home Programmer Note: Ask only if V1.cig.where=1. 
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3. Both indoors and outdoors 
77. Don’t know 
88. Refused   
 
V1.cig.work Programmer Note: Ask only if V1.cig.where=2. 




3. Both indoors and outdoors 
77. Don’t know 
88. Refused  
 
V1.cig.restbar Programmer Note: Ask only if V1.cig.where=3. 
In the past 7 days, when you smoked cigarettes at a restaurant or bar, did you smoke them 
indoors or outdoors? 
1. Indoors 
2. Outdoors 
3. Both indoors and outdoors 
77. Don’t know 
88. Refused 
 
V1.cig.everquit How many times, if ever, have you ever tried to quit smoking? 
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.cig.lastquit Progammer note: If V1.cig.everquit>0, ask: 
How long ago did your most recent serious quit attempt (for regular tobacco cigarettes) end? 
___ days ago OR ___ months ago OR ___ years ago 
77. Don’t know 
88. Refused 
 
V1.cig.planquit Are you seriously planning to quit smoking: 
1. Within the next month? 
2. Within the next 6 months? 
3. Sometime in the future, beyond 6 months? 
4. I am not planning to quit 
77. Don’t know 
88. Refused 
 
V1.cig.quitmethod Programmer Note: Ask only if V1.cig.planquit=1-3. 
If you were to quit smoking, would you consider using any of the following products to help you 
quit? 
1. Nicotine patch, gum, or lozenge? Yes / No / Don’t know 
2. E-cigarette? Yes / No / Don’t know 






Please answer the following questions based on your behaviours in general. 
 
V1.FTCD1 How soon after you wake up do you smoke your first cigarette?  
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V1.FTCD2 Do you find it difficult to refrain from smoking cigarettes in places where it is forbidden? 
1. Yes 
2. No 
77. Don’t know 
88. Refused 
 
V1.FTCD3 Which cigarette would you most hate to give up? 
1. The first one in the morning 
2. All others 
77. Don’t know 
88. Refused 
 
V1.FTCD4 How many cigarettes do you smoke per day? 
1. 10 or less 
2. 11-20 
3. 21-30 
4. 31 or more 
77. Don’t know 
88. Refused 
 




77. Don’t know 
88. Refused 
 
V1.FTCD6 Do you smoke cigarettes when you are so ill that you are in bed most of the day? 
1. Yes 
2. No 









Please answer the following questions based on your behaviours in general. 
Select the number that indicates how well the following statements describe you:                                        
1. After not smoking cigarettes for a while, I need to smoke a cigarette to relieve feelings of restlessness and irritability. 
1 










2. Whenever I go without smoking cigarettes for a few hours, I experience craving.  
1 










3. After not smoking cigarettes for a while, I need to smoke a cigarette in order to keep myself from experiencing any discomfort.  
1 










4. When I’m really craving a cigarette, it feels like I’m in the grip of some unknown force that I cannot control. 
1 










5. I feel a sense of control over my cigarette smoking. I can “take it” or “leave it” at any time.  
1 










6. I tend to avoid restaurants that don’t allow cigarette smoking, even if I would otherwise enjoy the food.  
1 










7. Sometimes I decline offers to visit with my non-smoking friends because I know I’ll feel uncomfortable if I smoke cigarettes.  
1 










8. Even if traveling a long distance, I’d rather not travel by airplane because I wouldn’t be allowed to smoke cigarettes. 
1 










9. Since the time when I became a regular cigarette smoker, the amount I smoke has either stayed the same or has decreased somewhat.  
1 
























11. Compared to when I first started smoking cigarettes, I can smoke much, much more now before I start to feel nauseated or ill.  
1 










12. It’s hard to estimate how many cigarettes I smoke per day because the number often changes.  
1 










13. My smoking pattern is very irregular throughout the day. It is not unusual for me to smoke many cigarettes in an hour, then not have 
another one until hours later.  
1 










14. The number of cigarettes I smoke per day is often influenced by other factors – how I’m feeling, what I’m doing, etc. 
1 










15. I smoke cigarettes at different rates in different situations.  
1 










16. My smoking is not much affected by other things. I smoke cigarettes about the same amount whether I’m relaxed or working, happy or 
sad, alone or with others, etc.  
1 










17. My cigarette smoking is fairly regular throughout the day. 
1 










18. I smoke cigarettes consistently and regularly throughout the day. 
1 










19. I smoke cigarettes about the same amount on weekends as on weekdays.  
1 













Please answer the following questions based on your thoughts and behaviours today. 
Select the number that indicates how well the following statements describe you:                                           
































































































































9. I would do almost anything to be able to smoke a cigarette right now.   
1 2 3 4 5 6 7 
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Strongly Disagree Disagree Disagree 
Somewhat 
Undecided Agree Somewhat Agree Strongly Agree 


















The following are some situations in which certain people might be tempted to smoke cigarettes.                              
Please indicate whether you are sure that you could go without smoking cigarettes in each situation. 
1. When I feel nervous   
1 














2. When I feel depressed   
1 














3. When I am angry 
1 














4. When I feel very anxious 
1 














5. When I want to think about a difficult problem   
1 














6. When I feel the urge to smoke cigarettes 
1 














7. When having a drink with friends   
1 
















8. When celebrating something   
1 














9. When drinking beer, wine, or other spirits   
1 














10. When I am with cigarette smokers   
1 














11. After a meal 
1 














12. When having coffee or tea 
1 
















Next, we would like to ask you some questions about your behaviours and experiences related to using e-cigarettes – you 




Do you use e-cigarettes every day, occasionally, or not at all?  
1. Every day 
2. Occasionally 
3. Not at all  
77. Don’t know 




Progammer note: Ask only if V1.vapingstatus1=2 or 3. 
Just to confirm, do you use e-cigarettes everyday or less than everyday? 
1. Every day 
2. Less than every day 
77. Don’t know 
88. Refused  
 
V1.vapingstatus.terminate Progammer note: If V1.vapingstatus2=2: 
Unfortunately, because you do not use e-cigarettes every day, you are not eligible to 
participate in the study.  
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Please return the iPad to the Research Assistant. Thank you. 
 
V1.vapetime How long have you been using e-cigarettes daily?  
___ months OR ___ years 
77. Don’t know 
88. Refused 
 
V1.ecig.reasons.initiation.all What are the reason(s) you began to use e-cigarettes daily? Please check all the reasons that 
apply. 
[Please check all that apply] 
1. I like their taste / flavour 
2. They are less harmful to me than smoking 
3. They are less harmful to others around me than smoking 
4. To help me with cravings for cigarettes 
5. To help me quit smoking 
6. To help me to smoke fewer cigarettes 
7. They cost less 
8. They were recommended by a health professional 
9. They were recommended by a family/friend 
10. I can use them in places where smoking is not allowed 
11. Due to boredom 
12. To reduce stress 
13. To control body weight 
14. Other reason – please specify: ___________ [open-ended] 
77. Don’t know 
88. Refused 
 
V1.ecig.reasons.initiation.most What is the most important reason you began to use e-cigarettes daily? Please select one 
reason. 
1. I like their taste / flavour 
2. They are less harmful to me than smoking 
3. They are less harmful to others around me than smoking 
4. To help me with cravings for cigarettes 
5. To help me quit smoking 
6. To help me to smoke fewer cigarettes 
7. They cost less 
8. They were recommended by a health professional 
9. They were recommended by a family/friend 
10. I can use them in places where smoking is not allowed 
11. Due to boredom 
12. To reduce stress 
13. To control body weight 
14. Other reason – please specify: ___________ [open-ended] 
77. Don’t know 
88. Refused 
 
V1.DD.ecig.times How many times did you use an e-cigarette today?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.DD.ecig.puffs Progammer note: If V1.DD.ecig.times>0, ask: 
127 
 
On average, for each time you used an e-cigarette today, how many puffs did you take? 
___ Puffs 
77. Don’t know 
88. Refused 
 
V1.DD.ecig.length Progammer note: If V1.DD.ecig.times>0, ask: 
On average, for each time you used an e-cigarette today, how long did you use it for? 
___ Minutes 
77. Don’t know 
88. Refused 
 
V1.DD.ecig.wake Progammer note: If V1.DD.ecig.times>0, ask: 
How soon after waking today did you use your first e-cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V1.ecig.times In the past 7 days, on average, how many times did you use an e-cigarette per day?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.ecig.puffs In the past 7 days, on average, for each time you used an e-cigarette, how many puffs did 
you take? 
___ Puffs 





In the past 7 days, on average, for each time you used an e-cigarette, how long did you use it 
for? 
___ Minutes 
77. Don’t know 
88. Refused 
 
V1.ecig.wake In the past 7 days, on average, how soon after waking did you use your first e-cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V1.ecig.lastecig How long has it been since you last used an e-cigarette? 
___ minutes OR ___ hours OR ___ days 





Please indicate the flavour(s) of the e-cigarette(s)/e-liquid you used in the past 7 days. 









7. Other: ___ [open-ended text] 





What type of e-cigarette(s) have you used in the past 7 days?  
[Please check all that apply] 
1. A disposable e-cigarette 
2. An e-cigarette that uses re-placeable pre-filled cartridges 
3. An e-cigarette that is re-chargeable and has a tank or reservoir that you fill with liquid  





Programmer Note: Ask only if V1.ecig.type=1 or 2. 
What brand(s) of e-cigarette have you used in the past 7 days? 
1. ___ [open-ended text] 





Programmer Note: Ask only if V1.ecig.type=3. 
What brand(s) of e-liquid have you used in the past 7 days? 
1. ___ [open-ended text] 





What type of e-cigarettes did you use in the past 7 days? 
1. Only e-cigarettes with nicotine 
2. Only nicotine-free / non-nicotine e-cigarettes 
3. Some e-cigarettes with nicotine and some nicotine-free / non-nicotine e-cigarettes 
4. Don’t know 
88. Refused 
 
V1.ecig.nic.conc Progammer note: Ask only if V1.ecig.nic=1 or 3. 
What was the concentration/strength of nicotine in your e-cigarette? 
1. 1-8 mg/mL (0.1-0.8%) 
2. 9-14 mg/mL (0.9-1.4%) 
3. 15-20 mg/mL (1.5-2.0%) 
4. 21-24 mg/mL (2.1-2.4%) 
5. 25 mg/mL (2.5%) or more 
77. Don’t know 
88. Refused 
 
V1.ecig.where Please specify where you used e-cigarettes in the past 7 days. 
[Please check all that apply] 
1. At home       
2. At school or work      
3. At a restaurant or bar      
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4. In a vehicle       
5. While walking on the street     
6. In a park or other outdoor venue   
7. Other: ___  [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.ecig.home Programmer Note: Ask only if V1.ecig.where=1. 




3. Both indoors and outdoors 
77. Don’t know 
88. Refused   
 
V1.ecig.work Programmer Note: Ask only if V1.ecig.where=2. 




3. Both indoors and outdoors 
77. Don’t know 
88. Refused  
 
V1.ecig.restbar Programmer Note: Ask only if V1.ecig.where=3. 
In the past 7 days, when you used e-cigarettes at a restaurant or bar, did you use them 
indoors or outdoors? 
1. Indoors 
2. Outdoors 
3. Both indoors and outdoors 
77. Don’t know 
88. Refused 
 
V1.ecig.reasons.cu.all What are the reason(s) you currently use e-cigarettes? Please check all the reasons that 
apply. 
[Please check all that apply] 
1. I like their taste / flavour 
2. They are less harmful to me than smoking 
3. They are less harmful to others around me than smoking 
4. To help me with cravings for cigarettes 
5. To help me quit smoking 
6. To help me to smoke fewer cigarettes 
7. They cost less 
8. They were recommended by a health professional 
9. They were recommended by a family/friend 
10. I can use them in places where smoking is not allowed 
11. Due to boredom 
12. To reduce stress 
13. To control body weight 
14. Other reason – please specify: ___________ [open-ended] 





V1.ecig.reasons.cu.most What is the most important reason you currently use e-cigarettes? Please select one reason. 
1. I like their taste / flavour 
2. They are less harmful to me than smoking 
3. They are less harmful to others around me than smoking 
4. To help me with cravings for cigarettes 
5. To help me quit smoking 
6. To help me to smoke fewer cigarettes 
7. They cost less 
8. They were recommended by a health professional 
9. They were recommended by a family/friend 
10. I can use them in places where smoking is not allowed 
11. Due to boredom 
12. To reduce stress 
13. To control body weight 
14. Other reason – please specify: ___________ [open-ended] 
77. Don’t know 
88. Refused 
 
V1.ecig.everquit How many times, if ever, have you ever tried to quit using e-cigarettes? 
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V1.ecig.lastquit Progammer note: If V1.ecig.everquit>0, ask: 
How long ago did your most recent serious quit attempt (for e-cigarettes) end? 
___ days ago OR ___ months ago OR ___ years ago 
77. Don’t know 
88. Refused 
 
V1.ecig.planquit Are you seriously planning to quit using e-cigarettes: 
1. Within the next month? 
2. Within the next 6 months? 
3. Sometime in the future, beyond 6 months? 
4. I am not planning to quit 







Please answer the following questions based on your behaviours in general. 
 
V1.EFTCD1 How soon after you wake up do you use your first e-cigarette?  
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 





V1.EFTCD2 Do you find it difficult to refrain from using e-cigarettes in places where it is forbidden? 
1. Yes 
2. No 
77. Don’t know 
88. Refused 
 
V1.EFTCD3 Which e-cigarette would you most hate to give up? 
1. The first one in the morning 
2. All others 
77. Don’t know 
88. Refused 
 
V1.EFTCD4 How many times do you use an e-cigarette per day? 
1. 10 or less 
2. 11-20 
3. 21-30 
4. 31 or more 
77. Don’t know 
88. Refused 
 




77. Don’t know 
88. Refused 
 
V1.EFTCD6 Do you use e-cigarettes when you are so ill that you are in bed most of the day? 
1. Yes 
2. No 













Please answer the following questions based on your behaviours in general. 
Select the number that indicates how well the following statements describe you:                                           
20. After not using e-cigarettes for a while, I need to use an e-cigarette to relieve feelings of restlessness and irritability. 
1 










21. Whenever I go without using e-cigarettes for a few hours, I experience craving.  
1 










22. After not using e-cigarettes for a while, I need to use an e-cigarette in order to keep myself from experiencing any discomfort.  
1 










23. When I’m really craving an e-cigarette, it feels like I’m in the grip of some unknown force that I cannot control. 
1 










24. I feel a sense of control over my vaping. I can “take it” or “leave it” at any time.  
1 










25. I tend to avoid restaurants that don’t allow vaping, even if I would otherwise enjoy the food.  
1 










26. Sometimes I decline offers to visit with my non-vaping friends because I know I’ll feel uncomfortable if I use e-cigarettes.  
1 










27. Even if traveling a long distance, I’d rather not travel by airplane because I wouldn’t be allowed to use e-cigarettes. 
1 










28. Since the time when I became a regular e-cigarette user, the amount I vape has either stayed the same or has decreased somewhat.  
1 
























30. Compared to when I first started using e-cigarettes, I can vape much, much more now before I start to feel nauseated or ill.  
1 










31. It’s hard to estimate how many e-cigarettes I use per day because the number often changes.  
1 










32. My vaping pattern is very irregular throughout the day. It is not unusual for me to use many e-cigarettes in an hour, then not have 
another one until hours later.  
1 










33. The number of e-cigarettes I use per day is often influenced by other factors – how I’m feeling, what I’m doing, etc. 
1 










34. I use e-cigarettes at different rates in different situations.  
1 










35. My vaping is not much affected by other things. I use e-cigarettes about the same amount whether I’m relaxed or working, happy or 
sad, alone or with others, etc.  
1 










36. My e-cigarette vaping is fairly regular throughout the day. 
1 










37. I use e-cigarettes consistently and regularly throughout the day. 
1 










38. I use e-cigarettes about the same amount on weekends as on weekdays.  
1 













Please answer the following questions based on your thoughts and behaviours today. 
Select the number that indicates how well the following statements describe you:                                           
































































































































19. I would do almost anything to be able to use an e-cigarette right now.   
1 2 3 4 5 6 7 
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Strongly Disagree Disagree Disagree 
Somewhat 
Undecided Agree Somewhat Agree Strongly Agree 


















The following are some situations in which certain people might be tempted to use e-cigarettes.                              
Please indicate whether you are sure that you could go without using e-cigarettes in each situation. 
13. When I feel nervous   
1 














14. When I feel depressed   
1 














15. When I am angry 
1 














16. When I feel very anxious 
1 














17. When I want to think about a difficult problem   
1 














18. When I feel the urge to use e-cigarettes 
1 














19. When having a drink with friends   
1 
















20. When celebrating something   
1 














21. When drinking beer, wine, or other spirits   
1 














22. When I am with e-cigarette users   
1 














23. After a meal 
1 














24. When having coffee or tea 
1 















DUAL USE BEHAVIOURS 
Next, we would like to ask you some questions about both your cigarette smoking and use of e-cigarettes. Please pay careful 
attention to the behaviours asked about in each question.  
V1.productorder Which behaviour did you begin first, smoking cigarettes or using e-cigarettes? 
1. I began smoking cigarettes first 
2. I began using e-cigarettes first 
77. Don’t know 
88. Refused 
 
V1.identity Which behaviour do you identify yourself with more, smoking cigarettes or using e-cigarettes? 
1. I identify myself more as a cigarette smoker 
2. I identify myself more as an e-cigarette user 
3. Both a cigaretet smokers and an e-cigarette user 
4. Neither 
77. Don’t know 
88. Refused 
 
V1.vapechange Since you started using e-cigarettes daily, have you changed the amount you use per day? 
1. I use much more 
2. I use a little more 
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3. I use about the same amount 
4. I use a little less 
5. I use much less 
77. Don’t know 
88. Refused 
 
V1.vapenic Since you started using e-cigarettes daily, have you changed the strength of nicotine that you use 
most? 
1. I increased the strength 
2. No change in strength 
3. I decreased the strength 
77. Don’t know 
88. Refused 
 
V1.vapeCPD Programmer Note: Ask only if V1.productorder=1. 
Since you started using e-cigarettes daily, has the number of cigarettes you smoke changed?  
1. I smoke fewer cigarettes 
2. I smoke the same amount of cigarettes 
3. I smoke more cigarettes 
77. Don’t know 
88. Refused 
 
V1.cig.selfcaddict Do you consider yourself addicted to regular tobacco cigarettes? 
1. Not at all 
2. Somewhat addicted 
3. Very addicted 
77. Don’t know 
88. Refused 
 
V1.ecig.selfaddict Do you consider yourself addicted to e-cigarettes? 
1. Not at all 
2. Somewhat addicted 
3. Very addicted 
77. Don’t know 
88. Refused 
 
V1.cig.easy.quit Do you think using e-cigarettes would make it easier to quit smoking cigarettes? 
1. Not at all 
2. A little 
3. A lot 





Next, we would like to ask you some questions about other behaviours – you might recognize some of these questions from 
our previous telephone conversation.  
V1.ATP In the past 7 days, have you used any other tobacco products, such as kreteks, bidis, cigars, pipe 
tobacco, smokeless tobacco or hookah/waterpipe? 
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4. Pipe tobacco 
5. Smokeless tobacco 
6. Hookah/waterpipe 
7. Other: ___  [open-ended text] 
8. I have not used any other tobacco product in the past 7 days 
77. Don’t know 
88. Refused 
 
V1.ATP.terminate Programmer Note: If V1.ATP= not equal to 8: 
Unfortunately, because you have used other tobacco products in the past 7 days, you are not 
eligible to participate in the study. 
Please return the iPad to the Research Assistant. Thank you. 
 
V1.NRT In the past 7 days, have you used any nicotine replacement therapy products, such as the patch, 
gum, inhaler, or lozenges? 
1. Yes 
2. No 
3. Don’t know 
88. Refused 
 
V1.NRT.terminate Programmer Note: If V1.NRT=1: 
Unfortunately, because you have used nicotine replacement therapy products in the past 7 days, 
you are not eligible to participate in the study. 
Please return the iPad to the Research Assistant. Thank you. 
 
V1.SSM In the past 7 days, have you used any medications, such as “Zyban”, “Wellbutrin”, or “Champix”, 
to help you quit smoking? 
1. Yes 
2. No 
3. Don’t know 
88. Refused 
 
V1.SSM.terminate Programmer Note: If V1.SSM=1: 
Unfortunately, because you have used stop-smoking medications in the past 7 days, you are not 
eligible to participate in the study. 
Please return the iPad to the Research Assistant. Thank you. 
 
V1.counselling In the past 7 days, have you participated in any group or individual counselling programs to help 
you quit smoking? 
1. Yes 
2. No 
3. Don’t know 
88. Refused 
 
V1.counselling.terminate Programmer Note: If V1.counselling=1: 
Unfortunately, because you have participated in smoking cessation counselling programs in the 
past 7 days, you are not eligible to participate in the study. 




PERCEPTIONS OF E-CIGARETTES 
 
We would like to ask you some questions about your opinion regarding e-cigarettes. There is no right or wrong answer – we 
are simply interested in your thoughts. 
V1.ecig.accept Compared to smoking regular tobacco cigarettes, using e-cigarettes is…  
1. Using e-cigarettes is … a lot less socially acceptable  
2. … a little less socially acceptable 
3. … equally as socially acceptable 
4. … a little more socially acceptable  
5. Using e-cigarettes is … a lot more socially acceptable 
77. Don’t know 
88. Refused 
V1.ecig.satisf Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less satisfying 
2. … a little less satisfying  
3. … equally as satisfying  
4. … a little more satisfying  
5. Using e-cigarettes is … a lot more satisfying  
77. Don’t know 
88. Refused 
V1.ecig.pleasure Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less pleasurable  
2. … a little less pleasurable 
3. … equally as pleasurable 
4. … a little more pleasurable  
5. Using e-cigarettes is … a lot more pleasurable  
77. Don’t know 
88. Refused 
V1.ecig.harm Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less harmful  
2. … a little less harmful  
3. … equally as harmful  
4. … a little more harmful  
5. Using e-cigarettes is … a lot more harmful 
77. Don’t know 
88. Refused 
V1.ecig.cost Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less expensive 
2. … a little less expensive 
3. … equally as expensive 
4. … a little more expensive  
5. Using e-cigarettes is … a lot more expensive 










We would like to ask you about your lung function and breathing. Please note, the following questions specifically ask about 
changes in the past 7 days. For example, many smokers experience shortness of breath; if this has not changed for you in the 
past 7 days, please respond “no difference”. 
 
V1.HC.short.breath In the past 7 days, have you noticed any change in experiencing shortness of breath? 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V1.HC.cough.freq In the past 7 days, have you noticed any change in how often you cough? 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V1.HC.phlegm In the past 7 days, have you noticed any change in how often you cough up phlegm? 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V1.HC.chest.sound In the past 7 days, have you noticed any change in how your chest sounds, such as wheezing or 
whistling?  
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V1.HC.overall.lung Overall, in the past 7 days, would you describe your lung function as: 
1. Worse than usual 
2. No difference 
3. Better than usual 










Visit 2-4 questionnaires 
Participants completed the Visit 2 questionnaire following Week 1, and the Visit 3 questionnaire 
following Week 2, as per their condition order (Group A or Group B). 
A sample Visit 2 questionnaire is included below for participants assigned to Group A 
(equivalent to the Visit 3 questionnaire for participants assigned to Group B).  
 
The Visit 2 questionnaire for participants assigned to Group B as well as the Visit 3 
questionnaire for participants assigned to Group A were similarly structured to the sample below, 
with the only difference being that questions regarding smoking behaviours (permitted) and the 
QSU are presented before questions regarding vaping behaviours (not permitted) and the E-QSU.  
 
The Visit 4 questionnaire was completed by all participants at the end of the study period. The 
Visit 4 questionnaire was similarly structured to the sample below, with the only difference 
being that use of both tobacco cigarettes and e-cigarettes was not permitted. Questions that were 





Please enter your participant ID: ______________ [insert] 
Please enter your email address: ______________ [insert] 
 
 
DAILY DIARY (DAY 8) 
We would like to ask you some questions about your behavior and experiences today, up until your current visit to the lab. 
 
V2.D8.ecig.times How many times did you use an e-cigarette today?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V2.D8.ecig.puffs Progammer note: If V2.D8.ecig.times>0, ask: 
On average, for each time you used an e-cigarette today, how many puffs did you take? 
___ Puffs 





V2.D8.ecig.length Progammer note: If V2.D8.ecig.times>0, ask: 
On average, for each time you used an e-cigarette today, how long did you use it for? 
___ Minutes 
77. Don’t know 
88. Refused 
 
V2.D8.ecig.wake Progammer note: If V2.D8.ecig.times>0, ask: 
How soon after waking today did you use your first e-cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V2.D8.cig.CPD How many cigarettes did you smoke today?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V2.D8.cig.wake Progammer note: If V2.D8.cig.CPD>0, ask: 
How soon after waking today did you smoke your first cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V2.D8.cig.lastcig How long has it been since you last smoked a cigarette? 
___ minutes OR ___ hours OR ___ days 




VAPING BEHAVIOURS (PERMITTED) 
Next, we would like to ask you some questions about your behavior and experiences in the past 7 days. 
 
V2.ecig.times In the past 7 days, on average, how many times did you use an e-cigarette per day?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V2.ecig.puffs In the past 7 days, on average, for each time you used an e-cigarette, how many puffs did you 
take? 
___ Puffs 







In the past 7 days, on average, for each time you used an e-cigarette, how long did you use it 
for? 
___ Minutes 
77. Don’t know 
88. Refused 
 
V2.ecig.wake In the past 7 days, on average, how soon after waking did you use your first e-cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
V2.ecig.lastecig How long has it been since you last used an e-cigarette? 
___ minutes OR ___ hours OR ___ days 






Please indicate the flavour(s) of the e-cigarette(s)/e-liquid you used in the past 7 days. 







7. Other: ___ [open-ended text] 





What type of e-cigarette(s) have you used in the past 7 days?  
[Please check all that apply] 
1. A disposable e-cigarette 
2. An e-cigarette that uses re-placeable pre-filled cartridges 
3. An e-cigarette that is re-chargeable and has a tank or reservoir that you fill with liquid  





Programmer Note: Ask only if V2.ecig.type=1 or 2. 
What brand(s) of e-cigarette have you used in the past 7 days? 
1. ___ [open-ended text] 





Programmer Note: Ask only if V2.ecig.type=3. 
What brand(s) of e-liquid have you used in the past 7 days? 
1. ___ [open-ended text] 







What type of e-cigarettes did you use in the past 7 days? 
1. Only e-cigarettes with nicotine 
2. Only nicotine-free / non-nicotine e-cigarettes 
3. Some e-cigarettes with nicotine and some nicotine-free / non-nicotine e-cigarettes 
4. Don’t know 
88. Refused 
 
V2.ecig.nic.conc Progammer note: Ask only if V2.ecig.nic=1 or 3. 
What was the concentration/strength of nicotine in your e-cigarette? 
1. 1-8 mg/mL (0.1-0.8%) 
2. 9-14 mg/mL (0.9-1.4%) 
3. 15-20 mg/mL (1.5-2.0%) 
4. 21-24 mg/mL (2.1-2.4%) 
5. 25 mg/mL (2.5%) or more 
77. Don’t know 
88. Refused 
 
V2.ecig.where Please specify where you used e-cigarettes in the past 7 days. 
[Please check all that apply] 
1. At home       
2. At school or work      
3. At a restaurant or bar      
4. In a vehicle       
5. While walking on the street     
6. In a park or other outdoor venue   
7. Other: ___  [open-ended text] 
77. Don’t know 
88. Refused 
 
V2.ecig.home Programmer Note: Ask only if V2.ecig.where=1. 
In the past 7 days, when you used e-cigarettes at home, did you use them indoors or outdoors? 
1. Indoors 
2. Outdoors 
3. Both indoors and outdoors 
77. Don’t know 
88. Refused   
 
V2.ecig.work Programmer Note: Ask only if V2.ecig.where=2. 




3. Both indoors and outdoors 
77. Don’t know 
88. Refused  
 
V2.ecig.restbar Programmer Note: Ask only if V2.ecig.where=3. 






3. Both indoors and outdoors 
77. Don’t know 
88. Refused 
 
V2.ecig.reasons.cu.all In the past 7 days, what were the reason(s) you used e-cigarettes?  
[Please check all that apply] 
1. I like their taste / flavour 
2. They are less harmful to me than smoking 
3. They are less harmful to others around me than smoking 
4. To help me with cravings for cigarettes 
5. To help me quit smoking 
6. To help me to smoke fewer cigarettes 
7. They cost less 
8. They were recommended by a health professional 
9. They were recommended by a family/friend 
10. I can use them in places where smoking is not allowed 
11. Due to boredom 
12. To reduce stress 
13. To control body weight 
14. Other reason – please specify: ___________ [open-ended] 
77. Don’t know 
88. Refused 
 
V2.ecig.reasons.cu.most In the past 7 days, what was the most important reason you used e-cigarettes? Please select 
one reason. 
1. I like their taste / flavour 
2. They are less harmful to me than smoking 
3. They are less harmful to others around me than smoking 
4. To help me with cravings for cigarettes 
5. To help me quit smoking 
6. To help me to smoke fewer cigarettes 
7. They cost less 
8. They were recommended by a health professional 
9. They were recommended by a family/friend 
10. I can use them in places where smoking is not allowed 
11. Due to boredom 
12. To reduce stress 
13. To control body weight 
14. Other reason – please specify: ___________ [open-ended] 
77. Don’t know 
88. Refused 
V2.ecig.selfaddict Do you consider yourself addicted to e-cigarettes? 
1. Not at all 
2. Somewhat addicted 
3. Very addicted 
77. Don’t know 
88. Refused 
 
V2.cig.easy.quit Do you think using e-cigarettes would make it easier to quit smoking cigarettes? 
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1. Not at all 
2. A little 
3. A lot 





Please answer the following questions based on your thoughts and behaviours today. 
Select the number that indicates how well the following statements describe you:                                           




































































































































































The following are some situations in which certain people might be tempted to use e-cigarettes.                              
Please indicate whether you are sure that you could go without using e-cigarettes in each situation. 
25. When I feel nervous   
1 














26. When I feel depressed   
1 














27. When I am angry 
1 














28. When I feel very anxious 
1 














29. When I want to think about a difficult problem   
1 
































31. When having a drink with friends   
1 














32. When celebrating something   
1 














33. When drinking beer, wine, or other spirits   
1 














34. When I am with e-cigarette users   
1 














35. After a meal 
1 














36. When having coffee or tea 
1 















SMOKING BEHAVIOURS (NOT PERMITTED) 
V2.cig.use Over the past 7 days, we asked you to NOT smoke cigarettes. We know this may have been a very 
difficult thing to ask of you. It’s really, really important that we know about any cigarettes you may 
have smoked. 
 
Over the past 7 days (since your last visit to the lab), did you smoke any cigarettes? 
1. Yes 
2. No 
77. Don’t know 
88. Refused 
 
V2.cig.report Programmer Note: Ask only if V2.cig.use=1. 
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Thank you for letting us know. Did you report all the cigarettes you smoked in the past 7 days in 
the online daily diaries? 
1. Yes 
2. No 





Programmer Note: Ask only if V2.cig.report=2. 
Please tell us how many cigarettes you smoked on each day in the past 7 days. Please include ALL 
the cigarettes you smoked, even if you already reported them in the online daily diaries. 
Day 1 (night after your last visit to the lab): ___ 
Day 2: ___ 
Day 3: ___ 
Day 4: ___ 
Day 5: ___  
Day 6: ___ 
Day 7 (today, before your visit to the lab): ___ 
77. Don’t know 
88. Refused 
 
V2.cig.brand Programmer Note: Ask only if V2.cig.use=1. 
Please specify the brand of cigarettes you smoked in the past 7 days (include any specific flavours 
or varieties):  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
V2.cig.where Programmer Note: Ask only if V2.cig.use=1. 
Please specify where you smoked cigarettes in the past 7 days. 
[Please check all that apply] 
1. At home       
2. At school or work      
3. At a restaurant or bar      
4. In a vehicle       
5. While walking on the street     
6. In a park or other outdoor venue   
7. Other: ___  [open-ended text] 
77. Don’t know 
88. Refused 
 
V2.cig.home Programmer Note: Ask only if V2.cig.use=1 AND V2.cig.where=1. 




3. Both indoors and outdoors 
77. Don’t know 
88. Refused   
 
V2.cig.work Programmer Note: Ask only if V2.cig.use=1 AND V2.cig.where=2. 






3. Both indoors and outdoors 
77. Don’t know 
88. Refused  
 
V2.cig.restbar Programmer Note: Ask only if V2.cig.use=1 AND V2.cig.where=3. 




3. Both indoors and outdoors 
77. Don’t know 
88. Refused 
 
V2.cig.selfaddict Do you consider yourself addicted to regular tobacco cigarettes? 
1. Not at all 
2. Somewhat addicted 
3. Very addicted 





Please answer the following questions based on your thoughts and behaviours today. 
Select the number that indicates how well the following statements describe you:                                           




































































































































































The following are some situations in which certain people might be tempted to smoke cigarettes.                              
Please indicate whether you are sure that you could go without smoking cigarettes in each situation. 
37. When I feel nervous   
1 














38. When I feel depressed   
1 














39. When I am angry 
1 2 3 4 5 
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40. When I feel very anxious 
1 














41. When I want to think about a difficult problem   
1 














42. When I feel the urge to smoke cigarettes 
1 














43. When having a drink with friends   
1 














44. When celebrating something   
1 














45. When drinking beer, wine, or other spirits   
1 














46. When I am with cigarette smokers   
1 














47. After a meal 
1 














48. When having coffee or tea 
1 


















Next, we would like to ask you some questions about other behaviours – you might recognize some of these questions from our 
previous telephone conversation. 
V2.ATP In the past 7 days, have you used any other tobacco products, such as kreteks, bidis, cigars, pipe 
tobacco, smokeless tobacco or hookah/waterpipe? 




4. Pipe tobacco 
5. Smokeless tobacco 
6. Hookah/waterpipe 
7. Other: ___  [open-ended text] 
8. I have not used any other tobacco product in the past 7 days 
77. Don’t know 
88. Refused 
 
V2.ATP.cheat Programmer Note: Ask only if V2.ATP= not equal to 8. 
Please tell us how many times you used an other tobacco product (such as kreteks, bidis, cigars, pipe 
tobacco, smokeless tobacco or hookah/waterpipe), in the past 7 days. 
Day 1 (night after your last visit to the lab): ___ 
Day 2: ___ 
Day 3: ___ 
Day 4: ___ 
Day 5: ___  
Day 6: ___ 
Day 7 (today, before your visit to the lab): ___ 
 
V2.NRT In the past 7 days, have you used any nicotine replacement therapy products, such as the patch, gum, 
inhaler, or lozenges? 
1. Yes 
2. No 
3. Don’t know 
88. Refused 
 
V2.NRT.cheat Programmer Note: Ask only if V2.NRT=1. 
Please tell us how many times you used a nicotine replacement therapy product (such as the patch, 
gum, inhaler, or lozenges), in the past 7 days. 
in the last 7 days. 
Day 1 (night after your last visit to the lab): ___ 
Day 2: ___ 
Day 3: ___ 
Day 4: ___ 
Day 5: ___  
Day 6: ___ 
Day 7 (today, before your visit to the lab): ___ 
 
V2.NRT.terminate Programmer Note: If V2.NRT=1 
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Unfortunately, because you have used nicotine replacement therapy products within the study 
period, we can no longer have you participate in the study.  
Please return the iPad to the Research Assistant. Thank you. 
 
V2.SSM In the past 7 days, have you used any medications, such as “Zyban”, “Wellbutrin”, or “Champix”, to 
help you quit smoking? 
1. Yes 
2. No 
3. Don’t know 
88. Refused 
 
V2.SSM.terminate Programmer Note: If V2.SSM=1: 
Unfortunately, because you have used stop-smoking medications within the study period, we can no 
longer have you participate in the study.  
Please return the iPad to the Research Assistant. Thank you. 
 




3. Don’t know 
88. Refused 
 
V2.counselling.terminate Programmer Note: If V2.counselling=1: 
Unfortunately, because you have participated in smoking cessation counselling programs within the 
study period, we can no longer have you participate in the study.  




PERCEPTIONS OF E-CIGARETTES 
 
We would like to ask you some questions about your opinion regarding e-cigarettes. There is no right or wrong answer – we are 
simply interested in your thoughts. 
V2.ecig.accept Compared to smoking regular tobacco cigarettes, using e-cigarettes is…  
1. Using e-cigarettes is … a lot less socially acceptable  
2. … a little less socially acceptable 
3. … equally as socially acceptable 
4. … a little more socially acceptable  
5. Using e-cigarettes is … a lot more socially acceptable 
77. Don’t know 
88. Refused 
V2.ecig.satisf Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less satisfying 
2. … a little less satisfying  
3. … equally as satisfying  
4. … a little more satisfying  
5. Using e-cigarettes is … a lot more satisfying  
77. Don’t know 
88. Refused 
V2.ecig.pleasure Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
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1. Using e-cigarettes is … a lot less pleasurable  
2. … a little less pleasurable 
3. … equally as pleasurable 
4. … a little more pleasurable  
5. Using e-cigarettes is … a lot more pleasurable  
77. Don’t know 
88. Refused 
V2.ecig.harm Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less harmful  
2. … a little less harmful  
3. … equally as harmful  
4. … a little more harmful  
5. Using e-cigarettes is … a lot more harmful 
77. Don’t know 
88. Refused 
V2.ecig.cost Compared to smoking regular tobacco cigarettes, using e-cigarettes is… 
1. Using e-cigarettes is … a lot less expensive 
2. … a little less expensive 
3. … equally as expensive 
4. … a little more expensive  
5. Using e-cigarettes is … a lot more expensive 






We would like to ask you about your lung function and breathing. Please note, the following questions specifically ask about 
changes in the past 7 days. For example, many smokers experience shortness of breath; if this has not changed for you in the 
past week, please respond “no difference”. 
 
V2.HC.short.breath In the past 7 days, have you noticed any change in experiencing shortness of breath? 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V2.HC.cough.freq In the past 7 days, have you noticed any change in how often you cough? 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V2.HC. phlegm In the past 7 days, have you noticed any change in how often you cough up phlegm? 
1. Worse than usual 
2. No difference 
3. Better than usual 





V2.HC.chest.sound In the past 7 days, have you noticed any change in how your chest sounds, such as wheezing or 
whistling?  
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V2.HC.overall.lung Overall, in the past 7 days, would you describe your lung function as: 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V2.HC.gh.cig1* In the past 7 days, have you noticed any change in your overall health status as a result of not 
smoking cigarettes? 
1. Worse than usual 
2. No difference 
3. Better than usual 
77. Don’t know 
88. Refused 
 
V2.HC.gh.cig2* Programmer Note: Ask only if V2.HC.gh.cig1=1. 
You’ve indicated that your overall health status in the past 7 days has been worse than usual as a 
result of not smoking cigarettes. Please briefly explain any negative effects you have experienced in 
the past week: 
___  [open-ended text] 
 
V2.HC.gh.cig3* Programmer Note: Ask only if V2.HC.gh.cig1=3. 
You’ve indicated that your overall health status in the past 7 days has been better than usual as a 
result of not smoking cigarettes. Please briefly explain any positive effects you have experienced in 
the past 7 days: 
___  [open-ended text] 
 
 
EXPERIENCES OVER THE PAST WEEK 
V2.cig.difficulty* Over the past 7 days, how easy or difficult was it to go without smoking cigarettes? 
1. Very easy 
2. Somewhat easy 
3. Neither easy nor difficult 
4. Somewhat difficult 
5. Very difficult 
77. Don’t know 
88. Refused 
 
V2.cig.reflect* Did your experience over the past 7 days change how you think about your cigarette smoking? 
[Please write a response below] 
___  [open-ended text] 
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77. Don’t know 
88. Refused 
 
V2.ecig.reflect* Did your experience over the past 7 days change how you think about your use of e-cigarettes? 
[Please write a response below] 
___  [open-ended text] 











Daily diaries  
Daily diaries were completed by participants for each day (Days 1-7) in each of the three seven-
day study periods (Weeks 1-3), corresponding to participants’ condition order (Group A or 
Group B). A sample daily diary is included below for participants assigned to Group A for Week 
1 (equivalent to that for participants assigned to Group B for Week 2).  
 
Daily diaries for participants assigned to Group B for Week 1 and for participants assigned to 
Group A for Week 2 were similarly structured to the sample below, with the only difference 
being that questions regarding smoking behaviours (permitted) and the QSU were presented 
before questions regarding vaping behaviours (not permitted) and the E-QSU.  
 
Daily diaries for all participants for Week 3 were similarly structured to the sample below, with 





Please complete the daily diary at the end of each day (after 9pm). 
Please enter your participant ID: ______________ [insert] 
Please enter your email address: ______________ [insert] 
 
Programmer Note: If Daily Diary=1: 
We would like to ask you some questions about your behavior and experiences since your last visit to the lab (do not include 
anything from before your visit). 
 
Programmer Note: If Daily Diary=2-7: 
We would like to ask you some questions about your behavior and experiences today.  
 
 
VAPING BEHAVIOURS (PERMITTED) 
DD.ecig.times How many times did you use an e-cigarette today?  
___ [open-ended text] 





DD.ecig.puffs Progammer note: If DD.ecig.times>0, ask: 
On average, for each time you used an e-cigarette today, how many puffs did you take? 
___ Puffs 





Progammer note: If DD.ecig.times>0, ask: 
On average, for each time you used an e-cigarette today, how long did you use it for? 
___ Minutes 
77. Don’t know 
88. Refused 
 
DD.ecig.wake Progammer note: If DD.ecig.times>0, ask: 
How soon after waking today did you use your first e-cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
4. After 60 minutes 
77. Don’t know 
88. Refused 
 
DD.ecig.lastecig How long has it been since you last used an e-cigarette? 
___ minutes OR ___ hours OR ___ days 





Programmer Note: Ask only if Daily Diary=2. 
Please answer the following questions based on your thoughts and behaviours today. 
Select the number that indicates how well the following statements describe you:                                           



































































































































































SMOKING BEHAVIOURS (NOT PERMITTED) 
DD.cig.CPD How many cigarettes did you smoke today?  
___ [open-ended text] 
77. Don’t know 
88. Refused 
 
DD.cig.wake Progammer note: If DD.cig.CPD>0, ask: 
How soon after waking today did you smoke your first cigarette? 
1. Within 5 minutes 
2. 6-30 minutes 
3. 31-60 minutes 
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4. After 60 minutes 
77. Don’t know 
88. Refused 
 
DD.cig.lastcig How long has it been since you last smoked a cigarette? 
___ minutes OR ___ hours OR ___ days 





Programmer Note: Ask only if Daily Diary=2. 
Please answer the following questions based on your thoughts and behaviours today. 
Select the number that indicates how well the following statements describe you:                                           



































































































































































EXIT 1 (Day 1-6) 
DD.exit1 Programmer note: If Daily Diary=Day 1-6. 
 
Thank you for completing the daily diary.  
 
Please remember to complete the daily diary tomorrow night, at the end of the day.  
 
If you have any questions, please let us know. You can reach us at smokingstudy@uwaterloo.ca or 
519-888-4567 ext. 38549. 
 
 
EXIT 2 (Day 7) 
DD.exit2 Programmer note: If Daily Diary=Day 7. 
 
Thank you for completing the daily diary. We look forward to seeing you for your visit tomorrow.  
 
If you have any questions, please let us know. You can reach us at smokingstudy@uwaterloo.ca or 






Appendix D: Participant recruitment statistics  
Table A1: Methods used for participant recruitment 
Method of recruitment 





















24 Hours - - 77 16 77 16 
Metro - - 40 8 40 8 
The Record 10 4 - - 10 4 
Subtotal  10 4 117 24 127 28 
Online 
advertisement 
Facebook 46 6 36 6 82 12 
Kijiji 12 1 9 5 21 6 
Other 0 0 3 3 3 3 
Subtotal 58 7 48 14 106 21 
Print flyers  11 1 - - 11 1 
Vape shops  6 1 4 1 10 2 
Unspecified referral  18 3 21 5 39 8 
Total  103 16 190 44 293 60 
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Appendix E: Products used by dual users  
Table A2: Tobacco cigarette brands smoked by dual users (n=48) 
Brand* % (n) 
Belmont 25.0% (12) 
Next 20.8% (10) 
First Nations 10.4% (5) 
Canadian 6.3% (3) 
du Maurier 6.3% (3) 
Pall Mall 4.2% (2) 
Phillip Morris 4.2% (2) 
Players 4.2% (2) 
Other1 18.8% (9) 
Not stated 4.2% (2) 
Notes:  
* Proportions may not sum to 100% due to the fact that participants could report smoking multiple tobacco cigarette brands. 





Table A3: E-cigarette device and e-liquid brands used by dual users (n=48) 
Brand* % (n) 
Device   Vapor 2.1% 1 
 180 smoke 2.1% 1 
 E-got 2.1% 1 
 Dune 2.1% 1 
 Joy tec 2.1% 1 
E-liquid  Walk of shame 2.1% 1 
 Mylk 2.1% 1 
 Vape north 2.1% 1 
 The vapoist 2.1% 1 
 Pony Boy 2.1% 1 
 Vjuice 2.1% 1 
 Ego-t 2.1% 1 
 Cosmic fog 2.1% 1 
 Filmore 2.1% 1 
 Mothers earth 2.1% 1 
 360 brand 2.1% 1 
 Maven 2.1% 1 
 Badlands 2.1% 1 
 12 monkeys 2.1% 1 
 Sweet water liquids 2.1% 1 
 Kilo 2.1% 1 
 Rocochette 2.1% 1 
 Moshi 2.1% 1 
 VaporNorth.com 2.1% 1 
 Cloud Panda 2.1% 1 
 416 Vapes 2.1% 1 
 Liquidtronic 2.1% 1 
 Blu 2.1% 1 
 Candy 2.1% 1 
 Turkish tobacco 2.1% 1 
 Dune 2.1% 1 
 Self-made liquid 2.1% 1 
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 Liquid made by friend 2.1% 1 
Notes:  




Appendix F: Patterns of product use across study conditions  
Table A4: Daily patterns of use of tobacco cigarettes and e-cigarettes across study conditions (n=48)  
Condition: Exclusive use of tobacco cigarettes  
Product Variable Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
% (n) or mean (SD) 
Tobacco 
cigarette 
Times used (bouts) per daya, 
among all participants 
8.3 (6.0) 11.6 (6.6) 12.2 (7.1) 12.6 (6.6) 12.9 (6.1) 12.7 (7.2) 12.4 (7.3) 





26.3% (10) 36.4% (16) 37.8% (17) 40.4% (19) 43.8% (21) 29.8% (14) 38.6% (17) 
6-30 min 31.6% (12) 36.4% (16) 40.0% (18) 34.0% (16) 33.3% (16) 44.7% (21) 36.4% (16) 
31-60 min 15.8% (6) 13.6% (6) 11.1% (5) 19.1% (9) 16.7% (8) 17.0% (8) 20.5% (9) 
After 60 
min 
26.3% (10) 13.6% (6) 11.1% (5) 6.4% (3) 6.3% (3) 8.5% (4) 4.5% (2) 
Time since last use [hours], 
among all participants 
12.6 (42.9) 11.6 (41.9) 6.4 (34.5) 0.66 (0.9) 3.7 (17.6) 4.4 (17.9) 2.6 (7.5) 
         
E-
cigarette 
Times used (bouts) per daya, 
among all participants  
0.6 (1.4) 0.5 (1.7) 0.3 (1.1) 0.4 (1.7) 0.4 (0.9) 0.5 (1.6) 0.5 (1.2) 
Times used (bouts) per daya, 
among those who used e-
cigarettes 
3.0 (1.9) 3.6 (3.2) 2.8 (1.9) 4.0 (3.7) 2.1 (1.0) 3.1 (2.8) 2.5 (1.6) 
Number of puffs per bout, among 
those who used e-cigarettes 
3.6 (2.1) 6.1 (6.3) 3.8 (1.0) 7.0 (7.3) 6.1 (6.0) 5.8 (5.8) 5.0 (6.3) 
Duration of bout [minutes], 
among those who used e-
cigarettes 
6.7 (9.2) 3.1 (2.2) 2.6 (1.5) 3.6 (1.3) 2.8 (3.1) 2.8 (1.7) 1.6 (1.5) 
Time to first use, 




0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 
6-30 min 50.0% (4) 16.7% (1) 20.0% (1) 20.0% (1) 12.5% (1) 12.5% (1) 16.7% (1) 
31-60 min 12.5% (1) 0.0% (0) 0.0% (0) 0.0% (0) 0.0% (0) 12.5% (1) 0.0% (0) 
After 60 
min 
37.5% (3) 83.3% (5) 80.0% (4) 80.0% (4) 87.5% (7) 75.0% (6) 83.3% (5) 
Time since last use [hours], 
among all participants 
14.7 (12.9) 34.2 (21.9) 54.9 (29.5) 73.1 (36.8) 88.5 (47.2) 103.7 (55.8) 120.0 (65.7) 
Notes: 
1 Summary statistics collected for Day 1 do not reflect a full 24-hour period.  
2 Times used per day=cigarettes per day, in the past 7 days, for tobacco cigarettes; ‘bouts’ per day (defined as an instance of at least one puff) for e-cigarettes.  
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Condition: Exclusive use of e-cigarettes  
Product Variable Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
% (n) or mean (SD) 
Tobacco 
cigarette 
Times used (bouts) per daya, 
among all participants 
0.7 (1.4) 0.5 (1.4) 0.3 (0.7) 0.3 (0.7) 0.7 (3.0) 0.8 (1.9) 0.8 (1.7) 
Times used (bouts) per daya, 
among those who used tobacco 
cigarettes 
2.2 (1.8) 2.5 (2.1) 1.3 (1.0) 1.5 (1.0) 4.3 (6.7) 2.7 (2.8) 2.4 (2.1) 







42.9% (6) 10.0% (1) 0.0% (0) 11.1% (1) 14.3% (1) 7.7% (1) 12.5% (2) 
6-30 min 14.3% (2) 0.0% (0) 0.0% (0) 0.0% (0) 14.3% (1) 7.7% (1) 0.0% (0) 
31-60 min 21.4% (3) 10.0% (1) 0.0% (0) 11.1% (1) 14.3% (1) 7.7% (1) 6.3% (1) 
After 60 min 21.4% (3) 80.0% (8) 100.0% (9) 77.8% (7) 57.1% (4) 76.9% (10) 81.3% (13) 
Time since last use [hours], 
among all participants  




Times used (bouts) per daya, 
among all participants 
11.9 (15.8) 16.1 (16.7) 18.2 (16.9) 16.5 (17.4) 16.9 (16.6) 17.9 (18.1) 17.4 (15.4) 
 Number of puffs per bout, 
among all participants 
10.3 (12.0) 7.5 (4.6) 8.3 (6.2) 7.8 (5.3) 7.8 (4.6) 7.6 (4.8) 8.2 (5.4) 
Duration of bout [minutes], 
among all participants 
7.0 (7.0) 6.7 (6.2) 5.8 (4.2) 6.2 (4.3) 6.4 (4.4) 5.8 (4.1) 6.6 (6.5) 





19.0% (8) 29.8% (14) 21.3% (10) 33.3% (16) 30.4% (14) 25.5% (12) 33.3% (16) 
6-30 min 19.0% (8) 40.4% (19) 53.2% (25) 31.3% (15) 43.5% (20) 38.3% (18) 37.5% (18) 
31-60 min 11.9% (5) 23.4% (11) 19.1% (9) 29.2% (14) 15.2% (7) 31.9% (15) 12.5% (6) 
After 60 min 50.0% (21) 6.4% (3) 6.4% (3) 6.3% (3) 10.9% (5) 4.3% (2) 16.7% (8) 
Time since last use [hours], 
among all participants  
5.3 (31.1) 1.1 (2.7) 0.8 (1.9) 1.4 (3.8) 2.0 (5.1) 2.2 (7.4) 1.9 (4.1) 
Notes:  
1 Summary statistics collected for Day 1 do not reflect a full 24-hour period.  





Condition: No product use  
Product Variable Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
% (n) or mean (SD) 
Tobacco 
cigarette 
Times used (bouts) per daya, among 
all participants 
1.0 (2.1) 0.6 (1.2) 0.7 (1.3) 0.6 (1.3) 1.0 (2.5) 1.2 (2.1) 2.1 (2.9) 
Times used (bouts) per daya, among 
those who used tobacco cigarettes 
2.8 (2.7) 2.0 (1.3) 2.7 (1.2) 2.4 (1.4) 3.1 (3.5) 3.1 (2.3) 4.0 (2.9) 
Time to first use, 
among those who 
used tobacco 
cigarettes 
Within 5 min 25.0% (4) 0.0% (0) 16.7% (2) 15.4% (2) 12.5% (2) 16.7% (3) 4.2% (1) 
6-30 min 25.0% (4) 21.4% (3) 8.3% (1) 7.7% (1) 0.0% (0) 11.1% (2) 12.5% (3) 
31-60 min 0.0% (0) 7.1% (1) 0.0% (0) 0.0% (0) 12.5% (2) 5.6% (1) 8.3% (2) 
After 60 min 50.0% (8) 71.4% (10) 75.0% (9) 76.9% (10) 75.0% (12) 66.7% (12) 75.0% (18) 
Time since last use [hours], among 
all participants  




         
E-
cigarette 
Times used (bouts) per daya, among 
all participants 
0.4 (0.9) 0.5 (1.6) 0.5 (1.1) 0.6 (1.8) 0.8 (2.3) 0.6 (1.8) 0.6 (1.6) 
 Times used (bouts) per daya, among 
those who used e-cigarettes 
2.1 (0.9) 3.6 (2.6) 2.3 (1.3) 3.4 (2.8) 4.3 (3.7) 4.1 (3.1) 4.0 (1.8) 
 Number of puffs per bout, among 
those who used e-cigarettes 
3.0 (1.6) 4.3 (1.8) 3.7 (2.1) 3.0 (1.4) 2.6 (1.3) 3.1 (1.8) 4.1 (1.2) 
Duration of bout [minutes], among 
those who used e-cigarettes 
2.0 (1.5) 2.4 (1.8) 3.0 (2.8) 2.8 (3.0) 2.8 (3.0) 6.9 (10.7) 6.7 (10.4) 
Time to first use, 
among those who 
used e-cigarettes 
Within 5 min 20.0% (2) 14.3% (1) 0.0% (0) 11.1% (1) 0.0% (0) 0.0% (0) 0.0% (0) 
6-30 min 30.0% (3) 0.0% (0) 10.0% (1) 0.0% (0) 11.1% (1) 0.0% (0) 0.0% (0) 
31-60 min 0.0% (0) 0.0% (0) 0.0% (0) 22.2% (2) 11.1% (1) 14.3% (1) 14.3% (1) 
After 60 min 50.0% (5) 85.7% (6) 90.0% (9) 66.7% (6) 77.8% (7) 85.7% (6) 85.7% (6) 
Time since last use [hours], among 
all participants  
70.2 (80.9) 77.3 (78.0) 101.8 
(87.0) 





1 Summary statistics collected for Day 1 do not reflect a full 24-hour period.  





Appendix G: Key outcomes across study conditions 







Exclusive use of 
tobacco cigarettes 
Exclusive use of e-
cigarettes 
No product use 
Mean (95% CI) 





















































































































































E-SEQ 35.6  35.0  35.5  38.3  F=1.867 
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(32.2, 38.9) (31.9, 38.1) (32.5, 38.4) (35.0, 41.5) (p=0.150) 
 
























Abbreviations: CI=confidence interval; 1-HOP=1-hydroxypyrene; NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; QSU=Questionnaire of Smoking Urges; SEQ=Self-Efficacy Questionnaire;  
E-=measure adapted to use of e-cigarettes.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
1 Arithmetic mean. 












Exclusive use of 
tobacco cigarettes 
Exclusive use of 
e-cigarettes 
No product use 
% (n) 
Change in experiencing shortness of breath 
 Worse than usual or no difference 97.9% (47) 97.9% (47) 58.3% (28) 70.2% (33) F=6.952 
(p<0.001)  Better than usual 2.1% (1)a 2.1% (1)a 41.7% (20)b 29.8% (14)b 
Change in frequency of cough 
 Worse than usual or no difference 97.9% (46) 97.9% (47) 60.4% (29) 70.2% (33) F=6.816 
(p<0.001)  Better than usual 2.1% (1)a 2.1% (1)a 39.6% (19)b 29.5% (14)b 
Change in frequency of cough with phlegm 
 Worse than usual or no difference 93.6% (44) 95.8% (46) 59.6% (28) 68.1% (32) F=7.561 
(p<0.001)  Better than usual 6.4% (3)a 4.2% (2)a 40.4% (19)b 31.9% (15)b 
Change in chest sounds, such as wheezing or whistling 
 Worse than usual or no difference 93.6% (44) 95.8% (46) 59.6% (28) 68.8% (33) F=6.799 
(p<0.001)  Better than usual 6.4% (3)a 4.2% (2)a 40.4% (19)b 31.3% (15)b 
Change in overall lung function 
 Worse than usual or no difference 93.6% (44) 97.9% (47) 59.6% (28) 62.5% (30) F=6.778 
(p<0.001)  Better than usual 6.4% (3)a 2.1% (1)a 40.4% (19)b 37.5% (18)b 
Notes:  






Appendix H: Interaction effects of key outcomes across study conditions 
Stratified analyses were conducted to examine exhaled carbon monoxide across study conditions 
by assigned condition order (see Figure A3). Repeated measures models were conducted to 
examine exhaled carbon monoxide across study conditions, with baseline nicotine dependence 
(FTCD score), e-cigarette product type (tank system, other), and e-cigarette nicotine content 
(nicotine present, nicotine absent) as covariates, and an unstructured variance-covariance 
structure, separately for participants assigned to each condition order (Group A, Group B).  
Figure A3: Exhaled carbon monoxide across study conditions, by group (n=48)  
 
Notes:  
Abbreviations: ppm=parts per million.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
The repeated measures model examining exhaled carbon monoxide for Group A participants 
yielded a significant effect of condition (F=9.383, p<0.001): exhaled carbon monoxide was 
significantly higher in the condition of Exclusive use of tobacco cigarettes compared to the 
conditions of Dual use (mean difference=9.1, 95% CI: 4.0 to 14.3, p=0.002), of Exclusive use of 
e-cigarettes (mean difference=15.8, 95% CI: 9.2 to 22.4, p<0.001), and of No product use (mean 
difference=11.5, 95% CI: 6.4 to 16.7, p<0.001). In addition, carbon monoxide was significantly 
higher in the condition of Dual use compared to the condition of Exclusive use of e-cigarettes 
(mean difference=6.7, 95% CI: 2.6 to 10.8, p=0.003). However, exhaled carbon monoxide was 
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not significantly different between the conditions of Dual use and No product use (mean 
difference=2.4, 95% CI: -1.3 to 6.1, p=0.190).  
The repeated measures model examining exhaled carbon monoxide for Group B participants also 
yielded a significant effect of condition (F=3.788, p=0.028): exhaled carbon monoxide was 
significantly higher in the condition of Exclusive use of tobacco cigarettes compared to the 
conditions of Exclusive use of e-cigarettes (mean difference=6.8, 95% CI: 1.9 to 11.7, p=0.009), 
and of No product use (mean difference=5.8, 95% CI: 0.6 to 11.1, p=0.032). In addition, carbon 
monoxide was significantly higher in the condition of Dual use compared to the conditions of 
Exclusive use of e-cigarettes (mean difference=7.6, 95% CI: 2.7 to 12.6, p=0.004), and of No 
product use (mean difference=6.6, 95% CI: 1.7 to 11.5, p=0.011). However, exhaled carbon 
monoxide was not significantly different between the conditions of Exclusive use of tobacco 




Appendix I: Sensitivity analyses  
Sensitivity analyses were conducted in an attempt to examine the effect of non-compliance with respect to use of tobacco cigarettes. 
The first approach involved excluding participants with exhaled carbon monoxide levels greater than 5 ppm in the condition of No 
product use (n=37). A summary of biomarkers of exposure across study conditions among this sub-sample is presented in Table A7.  
Table A7: Biomarkers of exposure across study conditions, among participants with exhaled carbon monoxide levels less than 
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Urinary NNAL2  












Abbreviations: CI=confidence interval; 1-HOP=1-hydroxypyrene; NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Asterisks (*) denote significant differences in biomarker levels compared to the condition of Dual use, p<0.05.  
1 Arithmetic mean. 






A repeated measures model was conducted to examine urinary cotinine across study conditions, 
with assigned condition order (Group A, Group B) and baseline nicotine dependence (FTCD 
score), and an unstructured variance-covariance structure. Measures of urinary cotinine were 
adjusted for creatinine and log-transformed for analyses to ensure approximate normality; 
geometric means in original units are presented below (see Figure A4).  
Figure A4: Urinary cotinine1 across study conditions (n=11) 
 
Notes:  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
The repeated measures model yielded a significant effect of condition (F=9.350, p=0.004): 
urinary cotinine was significantly higher in the condition of Dual use compared to the conditions 
of Exclusive use of e-cigarettes (mean difference=2.7, 95% CI: 1.7 to 4.4, p=0.001), and of No 
product use (mean difference=14.0, 95% CI: 2.8 to 70.8, p=0.005). In addition, urinary cotinine 
was significantly higher in the condition of Exclusive use of tobacco cigarettes compared to the 
conditions of Exclusive use of e-cigarettes (mean difference=2.0, 95% CI: 0.5 to 4.5, p=0.075), 
and of No product use (mean difference=10.4, 95% CI: 2.4 to 45.7, p=0.006). Finally, urinary 
cotinine was significantly higher in the condition of Exclusive use of e-cigarettes compared to 
the condition of No product use (mean difference=5.1, 95% CI: 1.1 to 23.0, p=0.037). No 
177 
 
significant effect was detected for the interaction of condition and assigned condition order 
(F=0.875, p=0.462). 
Exhaled carbon monoxide 
Levels of exhaled carbon monoxide across study conditions are presented in Figure A5. A 
repeated measures model was conducted to examine exhaled carbon monoxide across study 
conditions, with assigned condition order (Group A, Group B) and baseline nicotine dependence 
(FTCD score) as covariates, and an unstructured variance-covariance structure.  
Figure A5: Exhaled carbon monoxide across study conditions (n=11) 
 
Notes:  
Abbreviations: ppm=parts per million.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
The repeated measures model yielded a significant effect of condition (F=7.769, p=0.007): 
exhaled carbon monoxide was significantly higher in the condition of Exclusive use of tobacco 
cigarettes compared to the conditions of Exclusive use of e-cigarettes (mean difference=10.0, 
95% CI: 3.6 to 16.4, p=0.007), and of No product use (mean difference=11.5, 95% CI: 4.9 to 
18.0, p=0.003). In addition, carbon monoxide was significantly higher in the condition of Dual 
use compared to the conditions of Exclusive use of e-cigarettes (mean difference=9.6, 95% CI: 
3.6 to 15.5, p=0.007), and of No product use (mean difference=11.0, 95% CI: 5.4 to 16.6, 
p=0.002). No significant effect was detected for the interaction of condition and assigned 




A repeated measures model was conducted to examine urinary 1-HOP across study conditions, 
with assigned condition order (Group A, Group B) and baseline nicotine dependence (FTCD 
score), and an unstructured variance-covariance structure. Measures of urinary 1-HOP were 
adjusted for creatinine and log-transformed for analyses to ensure approximate normality; 
geometric means in original units are presented below (see Figure A6).  




Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
The repeated measures model indicated no significant differences in urinary 1-HOP across study 
conditions (F=1.485, p=0.283). However, a significant effect was detected for assigned condition 
order (F=21.281, p=0.002), with Group A participants exhibiting greater levels of 1-HOP 
compared to Group B participants (β=2.1, 95% CI: 1.4 to 3.1, p=0.002). In addition, baseline 
nicotine dependence was significantly associated with urinary 1-HOP (F=8.776, p=0.021), with 
higher levels of baseline nicotine dependence associated with higher levels of urinary 1-HOP 
(β=1.1, 95% CI: 1.0 to 1.2, p=0.021). No significant effect was detected for the interaction of 





A repeated measures model was conducted to examine urinary NNAL across study conditions, 
with assigned condition order (Group A, Group B) and baseline nicotine dependence (FTCD 
score), and an unstructured variance-covariance structure. Measures of urinary NNAL were 
adjusted for creatinine and log-transformed for analyses to ensure approximate normality; 
geometric means in original units are presented below (see Figure A7).  
Figure A7: Urinary NNAL1 across study conditions (n=11) 
 
Notes:  
Abbreviations: NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
The repeated measures model yielded a significant effect of condition (F=4.529, p=0.034): 
urinary NNAL was significantly higher in the condition of Exclusive use of tobacco cigarettes 
compared to the conditions of Exclusive use of e-cigarettes (mean difference=2.8, 95% CI: 1.3 to 
6.1, p=0.016), and of No product use (mean difference=3.3, 95% CI: 1.6 to 7.0, p=0.006). In 
addition, urinary NNAL was significantly higher in the condition of Dual use compared to the 
conditions of Exclusive use of e-cigarettes (mean difference=2.4, 95% CI: 1.2 to 4.9, p=0.017), 
and of No product use (mean difference=2.9, 95% CI: 1.4 to 6.0, p=0.009). A significant effect 
was detected for assigned condition order (F=45.343, p<0.001), with Group A participants 
exhibiting greater levels of NNAL compared to Group B participants (β=4.9, 95% CI: 2.8 to 8.5, 
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p<0.001). Baseline nicotine dependence was also significantly associated with urinary NNAL 
(F=60.357, p<0.001), with higher levels of baseline nicotine dependence associated with higher 
levels of urinary NNAL (β=1.5, 95% CI: 1.4 to 1.8, p<0.001).  
A significant effect was detected for the interaction of condition and assigned condition order 
(F=4.783, p=0.034). Stratified analyses indicated that the main effect of condition held for Group 
B participants (F=8.541, p=0.021): urinary NNAL was significantly higher in the condition of 
Exclusive use of tobacco cigarettes compared to the conditions of Exclusive use of e-cigarettes 
(mean difference=4.5, 95% CI: 1.9 to 10.5, p=0.006), and of No product use (mean 
difference=5.0, 95% CI: 2.0 to 13.0, p=0.007). In addition, urinary NNAL was significantly 
higher in the condition of Dual use compared to the conditions of Exclusive use of e-cigarettes 
(mean difference=4.4, 95% CI: 2.0 to 9.6, p=0.005), and of No product use (mean 
difference=4.9, 95% CI: 2.0 to 11.9, p=0.006). In addition, baseline nicotine dependence was 
significantly associated with urinary NNAL (F=32.684, p=0.005), with higher levels of baseline 
nicotine dependence associated with higher levels of urinary NNAL (β=1.6, 95% CI: 1.3 to 2.0, 
p=0.005) (see Figure A8).  
In contrast, no significant differences in urinary NNAL were detected across study conditions for 
Group A participants (F=0.212, p=0.883). However, baseline nicotine dependence was 
significantly associated with urinary NNAL (F=1.993, p=0.001), with higher levels of baseline 
nicotine dependence associated with higher levels of urinary NNAL (β=1.5, 95% CI: 1.5 to 1.6, 
p=0.001) (see Figure A8). 
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Figure A8: Urinary NNAL1 across study conditions, by group 
 
Notes:  
Abbreviations: NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  






The second approach involved excluding participants who self-reported smoking tobacco cigarettes in the condition of No product use 
(n=28). A summary of biomarkers of exposure across study conditions among this sub-sample is presented in Table A8. 
Table A8: Biomarkers of exposure across study conditions, among participants who did not report smoking tobacco cigarettes 
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Urinary NNAL2  












Abbreviations: CI=confidence interval; 1-HOP=1-hydroxypyrene; NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Asterisks (*) denote significant differences in biomarker levels compared to the condition of Dual use, p<0.05.  
1 Arithmetic mean. 






A repeated measures model was conducted to examine urinary cotinine across study conditions, 
with assigned condition order (Group A, Group B) and baseline nicotine dependence (FTCD 
score), and an unstructured variance-covariance structure. Measures of urinary cotinine were 
adjusted for creatinine and log-transformed for analyses to ensure approximate normality; 
geometric means in original units are presented below (see Figure A9).   
Figure A9: Urinary cotinine1 across study conditions (n=20)  
 
Notes:  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
The repeated measures model yielded a significant effect of condition (F=3.413, p=0.041): 
urinary cotinine was significantly higher in the condition of Dual use compared to the conditions 
of Exclusive use of e-cigarettes (mean difference=2.1, 95% CI: 1.1 to 4.3, p=0.034), and of No 
product use (mean difference=5.3, 95% CI: 1.6 to 17.2, p=0.009). In addition, urinary cotinine 
was significantly higher in the condition of Exclusive use of tobacco cigarettes compared to the 
condition of No product use (mean difference=4.7, 95% CI: 1.7 to 13.5, p=0.006); the contrast 
between the condition of Exclusive use of tobacco cigarettes and the condition of Exclusive use 
of e-cigarettes was borderline significant (mean difference=1.9, 95% CI: 1.0 to 3.8, p=0.058). 
Similarly, the contrast between the condition of Exclusive use of e-cigarettes and the condition of 
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No product use was borderline significant (mean difference=2.5, 95% CI: 1.0 to 6.3, p=0.055). In 
addition, baseline nicotine dependence was significantly associated with urinary cotinine 
(F=5.401, p=0.035), with higher levels of baseline nicotine dependence associated with higher 
levels of urinary cotinine (β=1.6, 95% CI: 1.0 to 2.4, p=0.035). No significant effect was 





Exhaled carbon monoxide 
Levels of exhaled carbon monoxide across study conditions are presented in Figure A10. A 
repeated measures model was conducted to examine exhaled carbon monoxide across study 
conditions, with assigned condition order (Group A, Group B) and baseline nicotine dependence 
(FTCD score) as covariates, and an unstructured variance-covariance structure.  
Figure A10: Exhaled carbon monoxide across study conditions (n=20) 
 
Notes:  
Abbreviations: ppm=parts per million.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
The repeated measures model yielded a significant effect of condition (F=3.558, p=0.042): 
exhaled carbon monoxide was significantly higher in the condition of Exclusive use of tobacco 
cigarettes compared to the conditions of Exclusive use of e-cigarettes (mean difference=6.9, 95% 
CI: 2.3 to 11.6, p=0.006), and of No product use (mean difference=6.8, 95% CI: 1.2 to 12.5, 
p=0.021). In addition, carbon monoxide was significantly higher in the condition of Dual use 
compared to the conditions of Exclusive use of e-cigarettes (mean difference=6.9, 95% CI: 0.7 to 
13.1, p=0.032), and of No product use (mean difference=6.8, 95% CI: 1.8 to 11.9, p=0.011). No 






A repeated measures model was conducted to examine urinary 1-HOP across study conditions, 
with assigned condition order (Group A, Group B) and baseline nicotine dependence (FTCD 
score), and an unstructured variance-covariance structure. Measures of urinary 1-HOP were 
adjusted for creatinine and log-transformed for analyses to ensure approximate normality; 
geometric means in original units are presented below (see Figure A11). 




Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
The repeated measures model indicated no significant differences in urinary 1-HOP across study 
conditions (F=2.462, p=0.098). However, a significant effect was detected for assigned condition 
order (F=5.366, p=0.035), with Group A participants exhibiting greater levels of 1-HOP 
compared to Group B participants (β=1.9, 95% CI: 1.1 to 3.3, p=0.035). In addition, baseline 
nicotine dependence was significantly associated with urinary 1-HOP (F=10.283, p=0.006), with 
higher levels of baseline nicotine dependence associated with higher levels of urinary 1-HOP 
(β=1.3, 95% CI: 1.1 to 1.5, p=0.006). No significant effect was detected for the interaction of 





A repeated measures model was conducted to examine urinary NNAL across study conditions, 
with assigned condition order (Group A, Group B) and baseline nicotine dependence (FTCD 
score), and an unstructured variance-covariance structure. Measures of urinary NNAL were 
adjusted for creatinine and log-transformed for analyses to ensure approximate normality; 
geometric means in original units are presented below (see Figure A12).  
Figure A12: Urinary NNAL1 across study conditions (n=20) 
  
Notes:  
Abbreviations: NNAL=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.  
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
1 Geometric means, expressed in original units.  
 
The repeated measures model yielded a significant effect of condition (F=3.476, p=0.039): 
urinary NNAL was significantly higher in the condition of Exclusive use of tobacco cigarettes 
compared to the conditions of Exclusive use of e-cigarettes (mean difference=1.6, 95% CI: 1.0 to 
2.6, p=0.038), and of No product use (mean difference=1.8, 95% CI: 1.1 to 3.0, p=0.015). In 
addition, urinary NNAL was significantly higher in the condition of Dual use compared to the 
conditions of Exclusive use of e-cigarettes (mean difference=1.8, 95% CI: 1.1 to 2.7, p=0.013), 
and of No product use (mean difference=2.0, 95% CI: 1.3 to 3.1, p=0.006). No significant effect 




Appendix J: Additional findings: Nicotine withdrawal  
Measures of nicotine withdrawal for tobacco cigarettes across study conditions are presented in 
Figure A13.  




Abbreviations: QSU=Questionnaire of Smoking Urges. 
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
QSU-Factor 1 
Scores for the QSU Factor 1, which reflect expectations of positive outcomes from smoking 
tobacco cigarettes (e.g., a cigarette would taste good right now), were also examined across study 
conditions. The repeated measures model yielded a significant effect of condition (F=6.229, 
p=0.001): participants reported significantly greater expectations of positive outcomes from 
smoking tobacco cigarettes in the condition of Exclusive use of e-cigarettes as compared to 
conditions of Dual use (mean difference=0.7, 95% CI: 0.2 to 1.2, p=0.008), and of Exclusive use 
of tobacco cigarettes (mean difference=1.2, 95% CI: 0.6 to 1.7, p<0.001). In addition, 
participants reported significantly greater expectations of positive outcomes from smoking 
tobacco cigarettes in the condition of No product use as compared to the condition of Exclusive 
use of tobacco cigarettes (mean difference=1.0, 95% CI: 0.4 to 1.6, p=0.001), as well as in the 
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condition of Dual use as compared to the condition of Exclusive use of tobacco cigarettes (mean 
difference=0.5, 95% CI: 0.0 to 0.9, p=0.039) (see Figure A13).  
QSU-Factor 2 
Scores for the QSU Factor 2, which reflect expectations of relief from the negative effect of 
smoking tobacco cigarettes (e.g., I would do almost anything to be able to smoke a cigarette right 
now), were also examined across study conditions. The repeated measures model yielded a 
significant effect of condition (F=6.658, p=0.001): participants reported significantly greater 
expectations of relief from the negative effect of smoking tobacco cigarettes in the condition of 
Exclusive use of e-cigarettes as compared to conditions of Dual use (mean difference=0.8, 95% 
CI: 0.3 to 1.3, p=0.001), and of Exclusive use of tobacco cigarettes (mean difference=0.8, 95% 
CI: 0.4 to 1.3, p=0.001). In addition, participants reported significantly greater expectations of 
relief from the negative effect of smoking tobacco cigarettes in the condition of No product use 
as compared to conditions of Dual use (mean difference=0.8, 95% CI: 0.3 to 1.3, p=0.002), and 
of Exclusive use of tobacco cigarettes (mean difference=0.8, 95% CI: 0.3 to 1.2, p=0.002) (see 
Figure A4). Baseline nicotine dependence was also significantly associated with QSU Factor 2 
scores (F=5.664, p=0.022), with higher levels of baseline nicotine dependence associated with 
greater expectations of relief from the negative effect of smoking tobacco cigarettes (β=0.2, 95% 




Measures of nicotine withdrawal for e-cigarettes across study conditions are presented in  
Figure A14.  




Abbreviations: E-QSU=Questionnaire of Smoking Urges, adapted for e-cigarettes. 
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
E-QSU-Factor 1  
Scores for the E-QSU Factor 1, which reflect expectations of positive outcomes from using e-
cigarettes (e.g., an e-cigarette would taste good right now), were also examined across study 
conditions. The repeated measures model indicated no statistically significant differences in 
expectations of positive outcomes from using e-cigarettes across study conditions (F=1.615, 
p=0.200) (see Figure A14).   
E-QSU-Factor 2  
Scores for the E-QSU Factor 2, which reflect expectations of relief from the negative effect of 
using e-cigarettes (e.g., I would do almost anything to be able to use an e-cigarette right now), 
were also examined across study conditions. The repeated measures model indicated no 
statistically significant differences in expectations of relief from the negative effect of using e-
cigarettes across study conditions (F=0.474, p=0.702) (see Figure A14). However, assigned 
condition order showed an overall significant effect (F=5.531, p=0.024): Group A participants 
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expressed significantly greater expectations of relief from the negative effect of using e-
cigarettes as compared to Group B participants (β=0.8, 95% CI: 0.1 to 1.5, p=0.024). Baseline 
nicotine dependence was also significantly associated with E-QSU Factor 2 scores (F=5.207, 
p=0.028), with higher levels of baseline nicotine dependence associated with greater 





Appendix K: Additional findings: Self-efficacy  
Measures of self-efficacy for abstaining from tobacco cigarettes across study conditions are 
presented in Figure A15.  
Figure A15: Measures of self-efficacy for abstaining from tobacco cigarettes across study 
conditions (n=48)  
 
Notes:  
Abbreviations: SEQ=Self-Efficacy Questionnaire. 
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
SEQ-Factor 1 
Scores for the SEQ Factor 1, which reflect participants’ confidence in their ability to abstain 
from smoking when facing internal stimuli (e.g., feeling depressed), were also examined across 
study conditions. The repeated measures model indicated no statistically significant differences 
in participants’ confidence in their ability to abstain from smoking tobacco cigarettes when 
facing internal stimuli across study conditions (F=1.708, p=0.180) (see Figure A15). 
SEQ-Factor 2 
Scores for the SEQ Factor 2, which reflect participants’ confidence in their ability to abstain 
from smoking when facing external stimuli (e.g., when having a drink with friends), were also 
examined across study conditions. The repeated measures model yielded a significant effect of 
condition (F=4.145, p=0.012): participants reported significantly greater confidence in their 
ability to abstain from smoking tobacco cigarettes when facing external stimuli in the condition 
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of No product use as compared to conditions of Exclusive use of tobacco cigarettes (mean 
difference=2.4, 95% CI: 0.9 to 3.9, p=0.003), and of Exclusive use of e-cigarettes (mean 




Measures of self-efficacy for abstaining from e-cigarettes across study conditions are presented 
in Figure A16.  
Figure A16: Measures of self-efficacy for abstaining from e-cigarettes across study 
conditions (n=48)  
 
Notes:  
Abbreviations: E-SEQ=Self-Efficacy Questionnaire, adapted for e-cigarettes. 
Conditions with different superscript letters were significantly different from one another, p<0.05.  
Error bars indicate upper limits of 95% confidence intervals.  
 
E-SEQ-Factor 1 
Scores for the E-SEQ Factor 1, which reflect participants’ confidence in their ability to abstain 
from vaping when facing internal stimuli (e.g., feeling depressed), were also examined across 
study conditions. The repeated measures model indicated no statistically significant differences 
in participants’ confidence in their ability to abstain from vaping when facing internal stimuli 
across study conditions (F=2.352, p=0.086) (see Figure A16). 
E-SEQ-Factor 2 
Scores for the E-SEQ Factor 2, which reflect participants’ confidence in their ability to abstain 
from vaping when facing external stimuli (e.g., being with other vapers), were also examined 
across study conditions. The repeated measures model indicated no statistically significant 
differences in participants’ confidence in their ability to abstain from vaping when facing 
external stimuli across study conditions (F=2.192, p=0.103) (see Figure A16). 
